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ABSTRACT 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by 
memory loss and cognitive dysfunctions including language problems, 
disorientation, loss of organization and planning skills and other neuropsychiatric 
symptoms that drive towards a final stage of total incapability of managing self-
care. The main pathological features are brain atrophy, neuronal and synaptic loss, 
β-amyloid accumulation, plaques deposition and neurofibrillary tangles formation. 
Nowadays there is no treatment able to cure this disease, but several drugs are 
administered to patients to ease the symptoms and slow the disease progression. 
Since β-amyloid plaques are one of the main hallmarks of AD, multiple efforts 
have been addressed in order to test new therapies targeting and decreasing this 
burden. However, it is still not clear if this is the origin or just a consequence of 
AD. Thus, many classical and new pathological mechanisms are under study to 
decipher the real mechanism and progression of the disease. 
So far, several transgenic animal models have been developed to study the 
pathogenesis of AD (see Table 1.1). Among these, the 3xTg-AD mouse is the 
unique animal model which develops both Aβ plaques and neurofibrillary tangles 
with a spatio-temporal pattern that closely mimics human AD. Indeed, 3xTg-AD 
mice start to intracellularly accumulate β-amyloid around 3-6 months of age with 
a subsequent increased extracellular secretion from 9 months and deposition of 
neuritic plaques from 12 months of age, at this time these mice start to show also 
a clear increase in tau hyperphosphorylation with formation of neurofibrillary 
tangles. 
The research work conducted for this PhD thesis has had the aim to study distinct 
aspects of AD pathology within the hippocampus and entorhinal cortex, key areas 
attaint by the AD pathology and responsible of the memory loss and behavioural 
impairments, in the 3xTg-AD mouse model by using a detailed and distinct 
immunohistochemical approach. 
Therefore, in the Results section, starting by, chapter 3, the immunoreactivity 
changes of the Calcium sensing receptor (CaSR) were analysed in the 
hippocampus of the 3xTg-AD mice. CaSR role in AD has recently started to be a 
main centre of attention, since Aβ peptides were shown to bind and activate CaSR 
which through this interaction is able to induce the hyperproduction and secretion 
of Aβ itself. In addition, following the activation of this pathological mechanism, 
CaSR is hyperexpressed. Experiments performed on human cortical astrocytic 
cultures treated with toxic exogenous Aβ have demonstrated that the inhibition of 
the CaSR through an allosteric antagonist, such as NPS 2143, result in the total 
block of this detrimental pathological mechanism. CaSR immunoreactivity 
measurement in the hippocampus of the 3xTg-AD mice showed an increase of its 
expression in specific areas involved also by early Aβ accumulation and plaques 
depositions such as the Cornu Ammonis 1 (CA1) and the dentate gyrus with 
major expression in the projection neurons. 
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In chapter 4, following the Calcium changes hypothesis appearing in AD and its 
progression, the alteration of calcium binding proteins such as parvalbumin and 
calretinin has been studied in the hippocampus of 3xTg-AD mice 18 months old, 
when the presence of -amyloid and tangles is evident. These proteins are an 
extremely relevant marker for different subpopulations of GABAergic inhibitory 
interneurons, which surprisingly are usually considered less vulnerable in AD 
pathology. In this study, a decrease in the numerical density (Nv) of parvalbumin 
and calretinin neurons was identified in the CA1 region of hippocampus, which is 
the hippocampal subfield showing the highest level of Aβ plaques burden in this 
model. This work is of major relevance since it characterizes and indicates a 
specific neuronal vulnerability underestimated in AD, which could be key to 
better elucidate the neuronal circuits that are affected during the pathology 
progression. 
Finally, in chapter 5 is reported the study of the alterations of a trophic factor that 
has shown to be of major importance not only in AD but also in physiological 
aging: S100.  In this project I have contributed to the characterisation of S100β-
positive astrocytes in the 3xTg-AD mouse model to study another possible aspect 
of AD pathology that is considered to be the potential astrocytic dysfunction 
hypothesis. For this purpose, the Nv and a complete morphological analysis 
(including the surface and volume analysis of total cell, processes and somata) 
was performed in the S100β-positive cells within the entorhinal cortex of 
transgenic animals and their non-transgenic counterpart from 1 month until 18 
months of age. Whilst the Nv was not altered, an increase in the S100β-positive 
profiles was identified at 18 months of age both in aged and 3xTg-AD mice 
compared to younger mice and a significant increase was found also between the 
3xTg-AD and non-transgenic animals at 18 months of age (an increase in the 
3xTg-AD mice of 69.74% and 76.73% in the surface area and volume, 
respectively, comparing to age-matched control animals).  
Altogether these three, seemingly, independent and disconnected studies 
demonstrate how complicated and variable is the aetiology and progress of AD 
and highlight the need to deeply investigate more targets other than neuronal 
pathology to further understand the pathologic mechanisms of this disease and its 
progression. Furthermore, a deep characterization in animal models such as the 
3xTg-AD mice (centre of this work) is necessary to have a strong background 
knowledge of the pathological features and alterations present in them in order to 
achieve a better understanding and interpretation of the potential and possible 
outcomes which could direct us for the always important and key aspects of drug 
testing. Hopefully, this could be later on reproduced in human material providing 
new insights to a combined therapy targeting all neuronal cells: neurons and glia. 
Thus implying a global nervous cell understanding and treatment strategy. 
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RIASSUNTO 
 
Il morbo di Alzheimer è una malattia neurodegenerativa caratterizzata da perdita 
di memoria e disfunzioni cognitive che includono problemi nel linguaggio, 
disorientamento, perdita delle capacità di organizzazione e pianificazione ed altri 
sintomi neuropsichiatrici fino al raggiungimento di uno stadio finale in cui il 
paziente necessita una assistenza totale. Le principali caratteristiche patologiche 
sono l’atrofia corticale, la perdita di neuroni e sinapsi, l’accumulo di proteina β-
amiloide, la deposizione di placche neuritiche e la formazione di grovigli 
neurofibrillari composti dalla proteina tau iperfosforilata. 
Al giorno d’oggi ancora non esiste una terapia in grado di curare questa malattia, 
sebbene diverse tipologie di farmaci siano somministrate ai pazienti per diminuire 
i sintomi e rallentare la progressione della malattia. Un approccio terapeutico 
molto studiato negli ultimi anni consiste nel cercare di eliminare le placche di β-
amiloide che costituiscono uno degli elementi patologici più importanti 
nonostante non sia ancora ben chiaro se siano la causa o la conseguenza dello 
sviluppo di questa malattia. Lo studio dei meccanismi patologici che causano e 
fanno progredire la malattia di Alzheimer è ancora aperto e un’ampia attività di 
ricerca si sta effettuando per far luce il più possibile su questa patologia 
complessa. 
Diversi modelli animali transgenici sono stati finora sviluppati per lo studio della 
malattia di Alzheimer (vedi Tabella 1.1). Fra questi, il topo triplo transgenico 
(3xTg-AD) è l’unico modello animale che sviluppa placche di β-amiloide e 
grovigli neurofibrillari con un andamento spazio-temporale più simile alla 
malattia di Alzheimer nell’uomo. Infatti i topi 3xTg-AD iniziano ad accumulare 
proteina β-amiloide a livello intracellulare intorno ai 3-6 mesi d’età con 
conseguente aumento della sua secrezione a 9 mesi, ed infine a partire dai 12 mesi 
d’età la deposizione di placche senili accompagnata da un’aumentata 
iperfosforilazione di tau con formazione di grovigli neurofibrillari.  
Il lavoro di ricerca condotto durante il mio dottorato ha avuto lo scopo di studiare, 
mediante l’impiego di un dettagliato approccio immunoistologico, diversi tipi di 
alterazioni nell’ippocampo e nella corteccia entorinale nei topi 3xTg-AD, le quali 
risultano essere le aree della corteccia cerebrale maggiormente colpite sin dalla 
fase pre-sintomatica della malattia.  
Nel Capitolo 3 di questa tesi viene descritta una alterazione nell’espressione del 
“Calcium sensing receptor” (CaSR) nell’ippocampo dei topi 3xTg-AD. Il ruolo 
del CaSR nell’Alzheimer è recentemente diventato oggetto di attenzione grazie a 
degli studi che hanno dimostrato la capacità dei peptidi di β-amiloide di interagire 
ed attivare il CaSR, il quale in seguito a questa interazione induce 
l’iperproduzione e secrezione della stessa β-amiloide. Successivamente 
all’innesco di questo meccanismo patogenetico, il CaSR risulta anche 
iperespresso. Esperimenti condotti su colture primarie di astrociti umani hanno 
dimostrato che questo meccanismo è completamente inibito utilizzando un 
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antagonista allosterico del CaSR come il composto NPS2143. L’analisi 
dell’espressione del CaSR nell’ippocampo dei topi 3xTg-AD ha dimostrato un suo 
aumento in specifiche aree coinvolte nell’accumulo iniziale di β-amiloide e nella 
successiva deposizione di placche, quali il Cornu Ammonis 1 (CA1) e il giro 
dentato (DG). 
Nel capitolo 4, le “calcium binding proteins” quali parvalbumina e calretinina 
sono state studiate nell’ippocampo dei topi 3xTg-AD a 18 mesi di età seguendo 
l’ipotesi riguardante la disomeostasi del calcio nella patogenesi e progressione del 
morbo di Alzheimer. Queste proteine sono oltretutto un marker molto utilizzato 
per differenti sottopopolazioni di interneuroni inibitori GABAergici. In questo 
studio è stata identificata una diminuzione nella densità numerica (Nv) dei 
neuroni positivi per parvalbumina e calretinina nella regione CA1 
dell’ippocampo, la quale corrisponde all’area con maggior carico di placche di β-
amiloide in questo modello animale. Questo lavoro ha permesso di caratterizzare 
una specifica vulnerabilità neuronale sottostimata nella malattia di Alzheimer, la 
quale rende maggior chiarezza sui circuiti neurali affetti nella progressione di 
questa patologia. 
Infine, nel capitolo 5 è riportato lo studio delle alterazioni del fattore trofico 
S100β la cui importanza è stata dimostrata non solo nell’Alzheimer, ma anche 
nell’invecchiamento fisiologico. In questo progetto ho contribuito alla 
caratterizzazione di astrociti positivi per S100β nei topi 3xTg-AD al fine di 
studiare un’ulteriore ipotesi per la malattia di Alzheimer che consiste nella 
“disfunzione astrocitaria”. A questo scopo, sono state analizzate la Nv e le 
caratteristiche morfologiche (superficie e volume dell’intera cellula, dei processi e 
del soma) delle cellule positive per S100β nella corteccia entorinale di topi da 1 a 
18 mesi di età. Mentre la Nv è risultata inalterata, è stato rilevato un generale 
aumento dei profili positivi per S100β ai 18 mesi di età sia nei topi 3xTg-AD, sia 
in quelli non transgenici. Un aumento ancor più significativo è stato però misurato 
nei topi 3xTg-AD quando paragonati ai non transgenici (69,74% e 76,73% in area 
della superficie e volume rispettivamente). 
In conclusione, questi tre apparentemente indipendenti e disconnessi studi 
dimostrano quanto complicata e variabile sia l’eziologia e la progressione della 
malattia di Alzheimer e mettono in luce la necessità di studiare più a fondo anche 
ulteriori meccanismi patogenetici che esulano dalla semplice patologia neuronale. 
Inoltre, la caratterizzazione dettagliata di modelli animali come i topi 3xTg-AD 
utilizzati in questo lavoro è necessaria per poter avere una profonda conoscenza di 
base delle caratteristiche patologiche presenti in essi, in modo tale da avere una 
miglior pianificazione e comprensione degli esiti che possono derivare dal loro 
utilizzo nel test di nuovi farmaci. 
La riproduzione in futuro di questi studi su materiale umano potrebbe fornire un 
punto di partenza per un approccio terapeutico combinato che riguardi un corretto 
ripristino funzionale sia dei neuroni che della glia nonché una strategia differente 
e più mirata per il blocco della produzione anomala della proteina β-amiloide. 
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Chapter 1 
 
General Introduction 
 
1.1. ALZHEIMER’S DISEASE: CLINICAL AND 
HISTOPATHOLOGICAL FEATURES 
1.1.1. The discovery of Alzheimer’s Disease 
Alzheimer’s Disease (AD) was described for the first time by the German 
psychiatric and neuropathologist Aloysius “Alois” Alzheimer who presented the 
case of his patient, Auguste D, at the 37th Assembly of the Southwest German 
Psychiatrists in Tubingen in 1906. When Professor Alois Alzheimer met and 
assessed Auguste D, she was only 51 years old and she was admitted for her 
weakness of memory, persecution mania, sleeplessness, and restlessness 
(Toodayan, 2016). She died 5 years later and Alzheimer obtained her brain for the 
corresponding neuropathological study and assessment in order to determine the 
anatomical alterations and relate them with the behavioral symptoms. Using the 
Bielschovsky silver method on sections of her cerebral cortex, Alzheimer 
observed advanced changes in the neurofibrils which formed tangled bundles of 
fibrils where neurons were disintegrated. Moreover, he also described the 
presence of senile plaques (as later named), as small miliary foci containing 
deposits of a peculiar material (Alzheimer, 1907). Few years later, his former 
boss, Emil Kraepelin, inaugurated the term Alzheimer’s Disease in the new 
edition of her Handbook of Psychiatry (Kraepelin, 1910); changing the original 
description of Alois Alzheimer in his manuscript of 1907 where he named it as 
“dementia praecox” (Alzheimer, 1907; Stelzmann et al., 1995). 
1.1.2. Clinical features 
Alzheimer’s Disease is the main cause of dementia in the elderly and represent a 
significant health burden. Dementia is generally described as an acquired 
syndrome of cognitive impairment determined by brain dysfunction.  
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A recent report estimated that there were 46.8 million people worldwide living 
with dementia in 2015 and this number is expected to increase to 74.7 million in 
2030 and 131.5 million in 2050. Much of the increase will be in developing 
countries since in these countries the standard of living is becoming higher (Prince 
et al., 2015). 
The clinical diagnosis of Alzheimer’s disease is conducted following the National 
Institute on Neurological and Communicative Disorders and Stroke and the 
Alzheimer Disease and Related Disorder Association (NINCDS/ADRDA) criteria 
which was established in 1984 and recently reviewed (McKhann et al., 1984, 
2011; Dubois et al., 2007). The NINCDS/ADRDA criteria define AD as a gradual 
and progressive decline in two or more cognitive domains confirmed by clinical 
neuropsychological testing and associated with impairment in social and 
occupational functions. These criteria allow the clinical classification of AD into 
“probable” and “possible”, the diagnosis is confirmed as “definitive” by means of 
a histopathological exam of the brain after the death of the patient. The criteria 
established by the Diagnostic and Statistical Manual of Mental Disorders, whose 
Fifth Edition has become recently available (DSM-5) are equally applicable as the 
NINCDS/ADRDA criteria (Tarawneh and Holtzman, 2012; American Psychiatric 
Association, 2013). 
Several tests are commonly used to evaluate patients suspected of dementia. 
Among the cognitive screening tests, the most used is the Mini-Mental Status 
Examination (MMSE) which consist of nineteen items measuring orientation, 
memory, concentration, language and praxis (Folstein et al., 1975). The most 
widely applied instrument of clinical staging which measures the severity of 
dementia is the Clinical Dementia Rating (CDR). The CDR is a 5-point scale 
obtained by the evaluation of the subject through a structured interview which 
covers six domains of cognitive and functional performance: memory, orientation, 
judgement and problem solving, community affairs, home and hobbies and 
personal care (Morris, 1997). Another frequently used scale for measuring 
cognition, especially in clinical trials, is the Alzheimer’s Disease Assessment 
Scale-Cognitive (ADAS-Cog), which consist of 11 parts evaluating cognitive 
functions (Mohs et al., 1997). 
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The testing of biomarkers such as the level of Aβ42 in the CSF is used by far only 
for research purposes and permit to describe the individuals as “probable or 
possible AD dementia with evidence of the AD pathophysiological process” 
(McKhann et al., 2011; Tarawneh and Holtzman, 2012). The existing dichotomy 
between the neurobiology of AD and the clinical manifestations has stimulated a 
strong debate since the asymptomatic pathological manifestation of the disease 
and the early appearance of symptoms related to pathophysiological and/or 
topological markers might be considered for the more recent therapeutic 
approaches that could prevent or definitely block the disorder. New research 
criteria have been proposed by the International Working Group for New 
Research Criteria for the Diagnosis of AD permitting the diagnosis of AD with a 
high level of accuracy even at a prodromal stage. According to this new 
algorithm, the diagnosis of AD is made when concur both clinical evidence of the 
disease and in vivo presence of biological markers (Dubois et al., 2007, 2010). 
Cognitive symptoms in AD appear over a decade after the beginning of the 
pathology and they progress very slowly in the early stages of mild AD. At the 
beginning, most individuals present short-term memory impairment with 
difficulty in learning and recalling new information, in addition, aphasia, 
disturbances of visuospatial skills may occasionally arise. Slight environmental 
disorientation and language impairment start to appear. Early AD affected people 
usually experience difficulties with executive functions, such as planning and 
organizational tasks, insight, judgement and problem solving. In this stage some 
cases exhibit also behavioral changes as apathy and reduced motivation and 
depressive symptoms. The patients are typically unaware of their illness 
(Tarawneh and Holtzman, 2012; Cummings, 2016). All these symptoms become 
more severe with the progression of pathology. Patients with moderate to severe 
AD show serious memory deficit in retaining new information, marked 
disorientation problems also in familiar environments, inability to recognize 
relatives and aggravated decline of executive functions. In addition, at advanced 
stages patients manifest neuropsychiatric symptoms, which include agitation, 
hallucinations, delusions, disruption of sleep-wake cycles, anxiety and depression. 
All cognitive functions are compromised at late stages of the disease, patients 
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totally depend on others and need a full time nursing care (Tarawneh and 
Holtzman, 2012; Cummings, 2016). 
An intermediate stage between normal aging and dementia has been defined as 
“mild cognitive impairment” (MCI; Petersen et al., 2011). The main criteria to 
define MCI is the memory impairment confirmed by a cognitive test, but revisions 
introduced also the evaluation of executive functions in the diagnosis, generally 
daily living activities are preserved in MCI patients. The MCI criteria might be 
useful for the identification of cases at high risk of AD even if some individuals 
diagnosed of MCI never develop AD, but they later show to have other kinds of 
non-AD dementia, some patients remain stable and others regress probably 
because of a misdiagnosed depression (Tarawneh and Holtzman, 2012).  
The most important risk factor for AD is age, since the clinical symptoms onset is 
usually after the age of 50. With regards to the age of appearance of the 
symptoms, there is a distinction between an early-onset (AD) that affects people 
younger than 60 years and a late-onset Alzheimer’s Disease which is 
characterized by the manifestation of the syndrome after the age of 60. Patients 
with early-onset AD frequently have a familial history that might be associated 
also with genetic mutations involving the genes encoding for amyloid precursor 
protein (APP), presenilin-1 (PS1) and presenilin 2 (PS2).  Nevertheless, AD is 
mostly a sporadic, age-dependent, late-onset disease. Moreover, AD is more 
frequent among women than men and in individuals that bear the Apolipoprotein 
E4 allele form (Rebeck et al., 1993). Comorbidities that might contribute to AD 
development are hypothyroidism, vitamin B12 deficiency and depression 
(Tarawneh and Holtzman, 2012; Cummings, 2016). 
1.1.3. Pathogenic hallmarks 
Alzheimer’s Disease is neuropathologically characterized by the extracellular 
deposition of β-amyloid (Aβ) proteins with the formation of neuritic plaques, and 
the intraneuronal presence of aggregated hyperphosphorilated tau proteins, which 
generate neurofibrillary tangles and neuropil threads. The distribution pattern of 
these typical hallmarks in the human AD brain was well described and classified 
in sequential stages by Braak and Braak in 1991 (Braak and Braak, 1991). This 
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Figure 1.1 The pathogenic hallmarks of AD. (A-D) Drawings of A. Alzheimer: (A) Example of 
neurofibrillary changes at early stages of AD. (B) Fibrillary changes in neurons at a progressed 
stage of AD. (C) Neurofibrillary changes at terminal stages of AD. (D) β-amyloid plaque (P1) 
surrounded by reactive astrocytes (glz). Adapted from Alzheimer, 1910. (E) Intracellular and 
extracellular accumulation of Aβ in the pyramidal layer of hippocampal CA1. (F) Intracellular 
accumulation of hyperphosphorylated tau in the pyramidal layer of hippocampus of the 3xTg-AD 
mouse model (picture from personal unpublished material of Rodríguez J.J.). 
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histopathological classification is routinely used in the post-mortem biopsy 
examination to confirm the AD diagnosis. These features are followed by 
alterations of neuroglia such as astrogliosis and atrophia of astrocytes and 
microglial cell activation, neuronal and synapse loss and synaptic dysfunction, the 
latter usually parallel tangle formation (Olabarria et al., 2010, 2011, Rodríguez et 
al., 2010, 2013; Serrano-Pozo et al., 2011; Yeh et al., 2011; Fig. 1.1 A-D).  
Macroscopically, a typical cortical atrophy can be observed by means of MRI 
scan. This atrophy affects symmetrically mainly the medial temporal lobes and 
with a lesser severity the primary motor, sensory and visual cortices and result in 
cortical thinning and lateral ventricles dilatation (Serrano-Pozo et al., 2011). 
1.1.4. Braak stages 
The cerebral cortex, mainly the isocortex, is the main site of amyloid deposition. 
Cases with severe neurofibrillary (NF) changes consistently show high densities 
of amyloid deposits, while those rich in amyloid are not always affected by NF 
changes. Moreover, a few cases with moderate NF changes do not reveal the 
presence of amyloid (Braak and Braak, 1991). Braak and Braak described two 
different classifications: one on the basis of amyloid pathology (stages A, B and 
C) and another one on the basis of tau pathology progression (stages from I to VI). 
The distribution pattern of amyloid deposits permits to identify three stages (Fig. 
1.2 A). In stage A, few amyloid deposits are found in the basal portion of frontal, 
temporal and occipital isocortex, the hippocampal formation is devoid of amyloid, 
while the presubiculum and the entorhinal cortex are weakly stained. In stage B 
almost all isocortical association areas present amyloid deposits, the basal portion 
of frontal, temporal and occipital isocortex show a typical laminar distribution of 
the deposits, the hippocampal formation is only mildly involved in subiculum and 
CA1; bands of amyloid may also be present in the entorhinal cortex (EC). The 
stage C is characterized by the presence of densely packed amyloid deposits in 
virtually all isocortical areas with a laminar distribution. Also primary isocortical 
areas (sensory and motor core fields) show depositions. The hippocampal 
formation shows the same pattern for stage B (Braak and Braak, 1991). 
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Two kinds of neurofibrillary changes can be distinguished in AD brains: 
neurofibrillary tangles (NFTs) and neuropil threads (NTs). NFTs develop within 
the nerve cell soma from where they may extend into the dendrites; when the 
parent cell deteriorates, the NFT converts into an extracellular structure (“ghost 
tangle”). NTs consist of argyrophilic processes of nerve cells loosely scattered 
throughout the neuropil. NFT and NT show a regular distribution pattern, hence 
their observation made possible the distinction of six stages grouped in the 
transentorhinal, limbic and isocortical stages (Fig. 1.2 B; Braak and Braak, 
1991). In the first two stages (I and II), the transentorhinal stages, the 
neurofibrillary changes are confined to the transentorhinal region, a transition 
zone between the proper entorhinal cortex and the temporal isocortex. In the 
limbic stages, the stages III and IV, both transentorhinal and entorhinal cortex are 
severely affected, but in stage III “ghost tangles” can be observed only in the 
transentorhinal region, while in stage IV they are extended also to the entorhinal 
region. The hippocampal formation in stage III is mildly involved in the CA1 
region and subiculum. Some changes are exhibited in the basal portion of frontal, 
temporal and occipital association areas. Most cases display mild changes of 
magnocellular forebrain nuclei, anterodorsal nucleus of the thalamus, and 
amygdala. This latter changes are all more severe in stage IV. In the isocortical 
stages V and VI all the previous changes are more aggravated and extended 
virtually all components of the hippocampal formation are involved as well as all 
isocortical association areas are affected. In stage VI there is a consistent loss of 
neuronal cells, accompanied by numerous ghost tangles in the EC and 
hippocampal CA1. NTs are present also in the primary sensory areas, alterations 
are now extended to the reticular nucleus of the thalamus and the lateral tuberal 
nucleus of the hypothalamus. Besides, the extrapyramidal system and substantia 
nigra are also involved in this stage (Braak and Braak, 1991). 
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Figure 1.2 The Braak staging of Aβ and tau pathology in AD brains. (A) The three stages of 
amyloid pathology in AD brains (stages A, B, C from left to right). (B) A simulation that 
summarize the distribution of the six stages of diffusion of the NFTs in the AD brains (trans-
entorhinal stages, I and II; limbic stages, III and IV; isocortical stages, V and VI). Adapted from 
Braak and Braak, 1991. 
1.1.5. APP function and processing 
Normal brains physiologically produce Aβ40/Aβ42 peptides from the amyloid 
precursor protein (APP) cleavage and among these two variants, Aβ40 is the most 
abundant, while Aβ42 is the most prone to aggregate (Masters and Selkoe, 2012). 
During the development of AD, the ratio of Aβ40/Aβ42 changes, Aβ42 
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concentration initially increases in the CSF, next it falls and Aβ42 begin to rise in 
the brain (Steinerman et al., 2008; Shaw et al., 2009). Aβ can aggregate into 
several forms that coexist in the AD brain, the most studied forms are oligomers, 
composed by 2 to 6 peptides, and fibrils which fold into β-pleated sheets forming 
insoluble fibres. Neuritic plaques, one of the two main lesions present in AD 
brains, are formed by extracellular deposits of filamentous Aβ protein, mostly the 
Aβ42 longer form, but also Aβ40 (Selkoe, 2001). Such plaques are associated with 
axonal and dendritic injuries, dystrophic neurites, activated microglia and reactive 
astrocytes. Preamyloid deposits or diffuse plaques are considered to be precursors 
of neuritic plaques, they have an amorphous, non-fibrillar appearance and they are 
composed exclusively by Aβ42 peptides (Selkoe, 2001). Several studies have 
demonstrated that extracellular Aβ depositions are preceded by an increased 
accumulation of intracellular Aβ42 proteins which contribute to AD progression 
before amyloid plaques appear (Gouras et al., 2000; Oddo et al., 2003a; Casas et 
al., 2004; LaFerla et al., 2007; Wirths et al., 2009). Moreover soluble Aβ 
oligomers and pre-fibrillar deposits are the most deleterious forms of Aβ (Walsh 
and Selkoe, 2007; Shankar et al., 2008). Aβ peptides not only form senile plaques 
in the brain parenchyma, but they also accumulate in the vessel walls giving rise 
to the cerebral amyloid (or congophilic) angiopathy which is the cause of lobar 
hemorrhages in AD. Interestingly, the more soluble Aβ40 peptide is the major 
constituent of cerebral amyloid angiopathy and it accumulates in the intersitium 
between the smooth muscle cells of the tunica media of leptomeningeal arteries 
and cortical capillaries, small and medium size arteries (Serrano-Pozo et al., 
2011). 
The APP is a single-pass transmembrane protein, type I oriented, with the amino 
terminus in the lumen/extracellular space and the carboxyl terminus within the 
cytosol (Kang et al., 1987; O’Brien and Wong, 2010). The specific physiological 
role of APP in the CNS is still unknown, several studies have demonstrated that 
during development it could modulate cell growth, motility, neurite outgrowth and 
synaptic pruning (Young-Pearse et al., 2007), while in the adult brain it could 
regulate the proliferation, survival and maturation of neurons in the two neuronal 
stem niches, the subventricular zone (SVZ) and the subgranular zone (SGZ). This 
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influence has been shown to be positive or negative depending on the area and the 
neuronal subtype (Wang et al., 2016). 
 
Figure 1.3 The pathways of APP processing. The anti-amyloidogenic pathway is mediated by α-
secretase and γ-secretase and determine the extracellular release of APPsα and p3 fragments and 
the intracellular release of the AICD. The anti-amyloidogenic pathway is initiated by β-secretase 
(BACE1) with the extracellular release of APPsβ fragment, later the transmembrane fragment 
βAPP CTF is cleaved by γ-secretase producing Aβ peptides, which will be released in extracellular 
environment, and the cytosolic fragment AICD (Gardenal, E. personal drawing). 
APP can undergo two principal proteolytic pathways: the amyloidogenic pathway, 
which leads to the production of the A peptide, and the anti-amyloidogenic 
pathway, which does not generate A (O’Brien and Wong, 2010). Through 
clathrin-associated vesicles, APP can be transported from the Trans-Golgi 
network (TGN) to the cell surface or to an endosomal compartment (O’Brien and 
Wong, 2010). The amyloidogenic pathway occurs in the endosome where APP is 
first cleaved by the -secretase enzyme (BACE1, -site APP cleaving enzyme-1) 
generating two fragments: the APPs, which is shedded in the lumen, and the 
carboxy terminal -CTF or C99 which is subsequently cleaved by the -secretase 
enzyme. Hence, -secretase proteolysis of  -CTF produces the A peptide that is 
then released in the extracellular space through vesicle recycling or degraded in 
lysosomes and the amyloid intracellular domain (AICD) which is released into the 
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cytosol and is targeted to the nucleus where it may activate signaling transcription 
(Fig. 1.3). In the anti-amyloidogenic pathway, APP is processed at the cell surface 
and is proteolysed in the middle of A region by the -secretase enzyme. This 
cleavage produces the APPs ectodomain fragment, that is released in the 
extracellular space, and the -CTF or C83 carboxy terminal fragment. C83 is then 
digested by -secretase with the release of the extracellular p3 peptide and the 
AICD (Fig. 1.3 O’Brien and Wong, 2010). 
1.1.5.1. -secretase 
The -secretase enzyme, also called BACE1, is a type-I transmembrane aspartyl 
protease, it presents its active site in the lumen/extracellular space and it is highly 
expressed in the brain. It is the enzyme that initiates the amyloidogenic pathway 
by cleaving APP at the +1 or +11 sites of A. Although a homologous protease, 
BACE2, was identified, BACE1 is the principal -secretase in the brain, indeed 
knock-out mice for BACE1 don’t produce A (Cai et al., 2001). For this reason, 
BACE1 is considered as an important therapeutic target and its inhibition allow to 
reduce also the production of CTF fragments which include the A domain and 
whom accumulation seem to contribute to toxic effects (Citron, 2004; Schenk et 
al., 2012). The physiological role of this secretase is still under study, in the 
peripheral nervous system BACE1 contribute in the myelination process after 
birth, but this function hasn’t been confirmed for the CNS yet. A loss of function 
of BACE1 is related to memory impairment and changes in spontaneous activity, 
moreover it has also been demonstrated its involvement in the regulation of 
voltage-dependent sodium channels (Haass et al., 2012a). 
1.1.5.2. γ-secretase 
The γ-secretase enzyme is a protease complex formed by four essential subunits: 
presenilin (PS) 1 or 2, nicastrin (NCT), anterior pharynx defective (APH)-1a or 
APH-1b and the PS enhancer (PEN)-2. PS is a polytopic protein composed by 9 
transmembrane domains (TMD) with the two catalytic aspartyl residues localized 
within TMD 6 and TMD 7; its endoproteolitical cleavage occurs in the same just 
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mentioned TMDs and it is likely to stabilize the conformation of the active-site 
aspartates (Steiner et al., 2008). The biological function of the other essential 
subunits is still not clear. NCT is a type I membrane glycoprotein and it seems to 
be a selective substrate receptor for the γ-secretase; PEN-2 is required for the 
endoproteolysis of PS and its stabilization in the protease complex; so far, APH-1 
role is poorly understood (Steiner et al., 2008; Zhang et al., 2014). γ-secretase 
substrates are cleaved several times within their TMDs. The final γ-cleavage of 
APP is not precise and can generate Aβ peptides of 40 or 42 aminoacids. Aβ42 
peptides aggregate more easily and are believed to have a toxic role in the AD 
brain (Haass et al., 2012b).  
1.1.5.3. α-secretase 
The α-secretase activity is attributed to several zinc metalloproteinases that belong 
to the “a disintegrin and metalloprotease” (ADAM) family.  
The α-secretase digest APP within the Aβ portion, at the residue +17, resulting in 
the anti-amyloidogenic APP processing. In the brain the main α-secretase activity 
is due to ADAM10, increased expression of ADAM10 results in a decrease of Aβ 
deposition, this make ADAM10 a potential therapeutic target for AD (Postina et 
al., 2004). 
1.1.6. Tau structure and function 
The protein tau is one of the first microtubule associated proteins (MAPs) to be 
characterized (Weingarten et al., 1975). Its hyperphosphorylated, aggregated and 
insoluble form is the principal component of the neurofibrillary tangles (NFTs), 
which are one of the main hallmarks of Alzheimer’s disease. Many 
neurodegenerative disorders have been linked to tau gene mutations and protein 
alterations, for this reason they are called “tauopathies” (Morris et al., 2011; 
Arendt et al., 2016). 
In the CNS, tau is mostly expressed in neurons, where it is found mainly in the 
axons (Kempf et al., 1996), but it locates also in the somatodendritic 
compartments (Tashiro et al., 1997); in addition, it is expressed in 
oligodendrocytes and astrocytes (Arendt et al., 2016). 
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Tau protein is formed by four regions: an N-terminal “projection domain”, that 
projects away from the microtubules, a “proline-rich domain”, a “microtubule-
binding domain” (MBD) and a C-terminal domain (Mandelkow and Mandelkow, 
2011). 
Alternative splicing of exons 2, 3 and 10 can generate six isoforms of tau proteins 
that differ by the number of microtubule binding repeat sequences expressed and 
by which N-terminal exons are included (Mandelkow and Mandelkow, 2011). 
Tau is physiologically unfolded and has a disordered structure due to its 
hydrophilic character, which confers to the protein a high flexibility and mobility. 
The most known function of tau is to stabilize microtubules, probably acting as a 
spacer through the N-terminal projection domain that is negatively charged and 
keep microtubules apart via electrostatic repulsion. However, several other 
functions of tau are under study, since it can interact with many other binding 
partners. The proline-rich domain is supposed to have a role in cell signaling 
through the binding and modulation of Src family kinases as Fyn, Fgr and Lck. 
Tau can also bind to and bundle actin filaments, moreover it interacts with a 
numerous set of kinases as for instance GSK3β, cdk5, MAP kinase and with other 
proteins. Also DNA, RNA and lipids have been demonstrated to be tau binding 
partners (Morris et al., 2011). 
Tau is subjected to several post-translational modifications that regulate its 
function and localization. Phosphorylation is the most studied modification of tau 
since it is strictly related to the pathogenesis of several neurodegenerative 
disorders. Most of the phosphorylated sites are localized in the regions flanking 
the microtubule-binding repeats, the phosphorylation of tau was found to decrease 
its affinity for microtubules and to regulate its subcellular localization and the 
interaction with molecules involved in the regulation of axonal transport, cargo 
delivery to dendritic spines, its association with plasma membrane, apolipoprotein 
E, Src kinases and other proteins (Arendt et al., 2016). Tau is physiologically 
highly phosphorylated during fetal brain development (Yu et al., 2009), 
hibernation (Arendt et al., 2003) and in response of stressor events like head 
trauma, hypothermia and experimental insulin-dependent diabetes (Planel et al., 
2007). In cell cultures, the exposure of neurons to Aβ oligomers or toxic 
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treatments as hypoxia, glucose, serum deprivation and hydrogen peroxide 
increased the hyperphosphorylation of tau which in turn detach from microtubules 
and membranes (Morris et al., 2011). 
Hyperphosphorylation of tau is likely the result of an altered activity of tau 
kinases and phosphatases. When hyperphosphorylated, tau proteins detach from 
microtubules and deposit in pre-tangles, subsequently this non fibrillary form of 
tau changes conformation and forms β-sheet aggregates. However, despite being 
NFTs a typical hallmark of AD, there is evidence that tau is more deleterious in its 
soluble prefibrillar oligomeric state than in the aggregated form (Arendt et al., 
2016). 
 
1.1.7. Amyloid hypothesis and tau hypothesis 
The most supported hypothesis of AD pathogenesis sustains that the accumulation 
of the amyloidogenic protein Aβ is the cause of AD (Glenner & Wong, 1984). 
Although there is still a strong skepticism about this hypothesis, many studies 
have been conducted on the basis of this pathogenic mechanism. Indeed, the 
transgenic animal models of AD developed by far are characterized by the 
expression of mutant forms of amyloid precursor protein that give rise to an 
increased production of toxic Aβ, hence most of the recent therapeutic efforts aim 
to reduce the overproduction of Aβ in the brain. 
The first evidence of Aβ dyshomeostasis role in giving rise to AD was the finding 
that mutations causing familial AD affect the APP gene and Presenilin 1 and 2 
genes which encode for the catalytic subunit of γ-secretase and cause an increase 
in the production of Aβ42 peptides (Scheuner et al., 1996). Moreover, individuals 
with Down’s syndrome, the trisomy of chromosome 21, bear three copies of APP 
gene, produce more Aβ and develop AD (Hof et al., 1995). Interestingly, some 
subjects who have a micro-duplication of chromosome 21 only in the region of 
APP gene do not develop Down’s syndrome but develop AD in their mid-50s 
(Rovelet-Lecrux et al., 2006). Conversely, protective mutations that decrease the 
APP cleavage by β-secretase are associated with a lower risk of cognitive decline 
and AD (Jonsson et al., 2012). Some other genes related to an increased risk of 
AD are linked to Aβ dyshomeostasis. For instance, Apolipoprotein E4 (ApoE4) 
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isoform has been shown to decrease Aβ clearance respect the other 
Apolipoprotein isoforms (Castellano et al., 2012). The risk genes CR1, CD33 and 
TREM2, which are component of innate immunity, are probably implicated in 
maintaining the microglia ability of phagocyte Aβ in AD (Jones et al., 2010). 
Lastly, after the identification of the AD correlation with genes involved in 
endosomal vesicle recycling, it has been demonstrated that some of these genes, 
like SORL1 and PICALM are directly involved in the processing of APP. 
Moreover, PICALM was also demonstrated to regulate the transport of Aβ across 
the blood brain barrier (Jones et al., 2010; Selkoe and Hardy, 2016; Zhao et al., 
2016). 
The causality of Aβ in AD is supported also by studies demonstrating that Aβ 
oligomers damage synaptic structure and function and impair LTP. What is 
generally considered the “Achilles heel” in the amyloid hypothesis is the fact that 
many people who have Aβ plaques don’t develop AD. A study has isolated 
soluble Aβ42 oligomers and amyloid plaques from AD brains and demonstrated 
that the diffusible Aβ oligomers impair long term potentiation (LTP) and reduce 
dendritic spine density in normal rodent hippocampus, while insoluble Aβ plaques 
do not, unless they are previously solubilized to release Aβ dimers (Shankar et al., 
2008). Thus the presence of amyloid plaques in normal brains might not cause AD 
because the more toxic Aβ dimers are not released. The amyloid hypothesis is 
endorsed also by the in vivo temporal appearance of the AD biomarkers before 
any other pathological feature. In fact, the Aβ42 levels in CSF and the deposition 
of Aβ in the brain cortex seem to appear respectively 25 and 15 years before the 
symptom onset (Bateman, 2012). 
The real validity of the amyloid hypothesis will probably be proved or rejected 
after the current clinical trials targeting Aβ production will be concluded (Selkoe 
and Hardy, 2016).  
Nevertheless, as previously described, Aβ depositions are not the unique 
characteristics of AD, since tau pathology has an important role in the 
pathogenesis of this form of dementia (Braak and Del Tredici, 2013). An 
interesting debate has recently emerged about moving the causality of AD into a 
“tau hypothesis”. This hypothesis has arisen by observations that despite being 
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Aβ42 present in the CSF several years before the onset of clinical symptoms,  
intraneuronal tau accumulations appear decades before the deposition of amyloid 
plaques in the brain (Braak et al., 2013). Moreover, several studies have recently 
demonstrated that tau alterations start to appear in subcortical regions such as the 
nucleus basalis of Meynert, the locus coeruleus and the raphe nuclei in early 
pathology (Braak stages 0 or I). The study of brains from different ages showed 
that tau lesions are present also in the midbrain of 30 years of age subjects 
bringing attention to the possibility that tau pathology may begin even much 
earlier than previously thought (Braak et al., 2011; Attems et al., 2012; Arendt et 
al., 2016). 
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1.2. THE HIPPOCAMPAL FORMATION: BRAIN AREAS INVOLVED IN 
MEMORY FORMATION 
 
1.2.1. Memory formation 
One of the first symptoms to be reported by patients affected by Alzheimer’s 
disease is the loss of memory (Jahn, 2013). Memory can be classified into short-
term memory vs. long-term memory and the latter is commonly distinguished into 
implicit memory vs. declarative memory. These different categories have also 
neuroanatomical and neurophysiological characteristics. The short-term memory 
lasts only seconds or minutes and the brain areas mainly related to it are situated 
in the frontal and parietal lobes. On the contrary, long-term memory could 
hypothetically have unlimited duration since it determines a de novo synthesis of 
proteins in the cortical areas involved in the specific types of memory. Declarative 
memory, which is a long-term conscious memory, can be subdivided into episodic 
and semantic memory. Episodic memory refers to the storage of information 
related to a specific context of time and place, in other words autobiographical 
events. Semantic memory corresponds to the storage of information not related to 
a context, but to general knowledge accumulated during life (Jahn, 2013). In AD, 
the first impairment involves the semantic memory, mainly affecting verbal 
fluency and naming (Verma and Howard, 2012). Different regions of the medial 
temporal lobe have been demonstrated to contribute to the formation and storage 
of long-term declarative memory, these structures are the hippocampal formation 
and the entorhinal, perirhinal and parahippocampal cortices (Scoville and Milner, 
1957; Suzuki and Eichenbaum, 2000; Suzuki and Amaral, 2004). In addition, the 
hippocampus and the entorhinal cortex have been demonstrated to be critically 
involved in spatial navigation and memory, explaining the orientation difficulties 
of AD patients (Witter and Moser, 2006; Strange et al., 2014). Furthermore, AD 
patients progressively show impairment in working memory, a kind of short-term 
memory characterized by the ability to remember information for a short period 
with the purpose of processing and manipulate them and by its importance for the 
formation of long-term memory. The pre-frontal cortex is the brain region usually 
associated to working memory functioning, even if other cortical areas are also 
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involved. Accordingly, the deterioration of pre-frontal cortex is related to deficits 
in attention, problem solving, decision making and behaviour (Jahn, 2013). 
1.2.2. Histological description of the memory-related regions early affected 
in AD 
The entorhinal cortex is commonly considered the first affected area in AD, 
followed by hippocampus and associative and executive cortical areas, but several 
studies have demonstrated that neurofibrillary tangles appear very early in the 
nucleus basalis of Meynert (nbM) even before the involvement of the entorhinal 
cortex (Arendt et al., 1983; Sassin et al., 2000; Mesulam et al., 2004).  
1.2.2.1. The nucleus basalis of Meynert 
The nucleus basalis of Meynert, which is located in the basal forebrain, is a 
cholinergic nucleus since 90% of the magnocellular neurons in the nbM are 
cholinergic and belong to the Ch4 group (Mesulam et al., 1983). The Ch4 neurons 
of nbM project to amigdala and to the entire cortex (Mesulam et al., 1983). In 
human, these Ch4 neurons permit to topographically divide the nbM into six 
different regions: the anteromedial, anterolateral, anterointermediate, 
intermediodorsal, intermedioventral and the posterior (Mesulam and Geula, 
1988). Each one of these sectors projects to a different area: the anteromedial 
projects to medial cortical regions including the cingulate cortex and the 
anterolateral projects to fronto- parietal opercular regions and amygdala; the 
anterointermediate part projects to the frontal cortex, the parietal cortex and the 
temporal cortex, and finally, the posterior region of the nbM sends cholinergic 
projections to the superior temporal cortex (Mesulam et al., 1983). Although the 
nbM projects to the entire cerebral cortex, it receives cortical projections only 
from limbic and paralimbic regions of the brain, including the amygdala. The 
hippocampus doesn’t receive cholinergic innervation from the nbM but from the 
medial septal nucleus and the vertical limb of the diagonal band nucleus 
(Mesulam et al., 1983). 
The early lesions and neuronal loss in the nbM support the cholinergic hypothesis, 
which proposes that a cortical cholinergic deficit cause cognitive decline in AD, 
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since the concentrations of acetylcholine and choline acetyltransferase are 
remarkably reduced in the cerebral neocortex and hippocampus of AD brains 
(Bartus et al., 1982; Liu et al., 2015). 
The present work is focused mainly in the study of alterations in the hippocampus 
and entorhinal cortices, which are histologically described more in detail in the 
next paragraph. 
The hippocampal formation is a C-shaped elongated structure localized in the 
medial temporal lobe composed by several adjacent cortical regions which are the 
dentate gyrus, the proper hippocampus, the subiculum, presubiculum, 
parasubiculum and the entorhinal cortex (Fig. 1.4A-D). Most of mammals have 
two hippocampal formations, one in each side of the brain (Amaral and Lavenex, 
2007). 
1.2.2.2. The Dentate Gyrus 
The Dentate Gyrus (DG) is formed by three layers: the molecular layer (ML), the 
granule cell layer (GCL) and the hilus (Fig. 1.4 B, C). This trilaminar structure is 
present in all the studied species. The molecular layer is mostly occupied by 
projections, while relatively few cells are present. The projections are composed 
by the axons that form the perforant pathway and arrive from the entorhinal 
cortex, and by the dendrites of the granule cells, pyramidal basket cells and hilar 
cells (Amaral et al., 2007). Two kinds of interneurons were described in the 
molecular layer: the MOPP cells (molecular layer perforant path-associated cells) 
(Han et al., 1993), which are multipolar aspiny cells that innervate the outer two 
thirds of the ML and a type of axo-axonic cells that are located in the inner 
molecular layer, next to the granule cells, and make synapses with the initial 
portion of granule cell axons (Soriano and Frotscher, 1989).  
The granule cell layer is occupied mainly by tightly packed granule cell bodies. 
The granule cells are excitatory cells and seem to use glutamate as principal 
neurotransmitter. They have a cone-shaped tree of spiny apical dendrite that 
extend through the entire molecular layer and stop at the hippocampal fissure or at 
the ventricular surface. The unmyelinated axons that originate from the granule 
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cells are called mossy fibres. The mossy fibres form synapses with the mossy 
cells, the pyramidal basket cells and other cells of the polymorphic layer and with 
the pyramidal cells of the hippocampal CA3 (Amaral et al., 2007). At the 
boundary of the granule cell layer and the hilus, the pyramidal basket cells are 
located. These cells are inhibitory interneurons, they have a pyramidal-shaped cell 
body that is larger than the granule cells, a single aspiny apical dendrite that 
extend to the molecular layer and several aspiny basal dendrites directed to the 
polymorphic cell layer. The pyramidal basket cells form inhibitory synapses 
mainly on the cell bodies and dendrites of the granule cells (Amaral et al., 2007). 
The hilus, or polymorphic layer, is occupied mainly by the mossy cells, which are 
innervated by the mossy fibres of the granule cells. The mossy cells have 
triangular or multipolar cell bodies as large as the basket cells and several thick 
spiny dendrites, which project distally to the granule cell layer and to the inner 
third of the molecular layer.  In addition to the mossy cells, more types of cells are 
present in the hilus, the most well described are the HIPP cells (hilar perforant 
path-associated cell, (Amaral, 1978; Han et al., 1993). HIPP cells are multipolar 
cells with long spines, their axons extend to the outer two-third of the molecular 
layer forming symmetrical inhibitory synapses on the dendrites of the granule 
cells thus being responsible for local inhibition. 
1.2.2.3. The Cornu Ammonis or proper hippocampus 
The Cornu Ammonis (CA), so called because the shape resembles the ram’s horn 
of the Egyptian God “Ammon”, is subdivided in three areas: the CA1, CA2 and 
CA3 (Fig.1.4). The CA is characterized by the presence of a single layer of 
pyramidal neurons, which terminates at the border with the hilus of dentate gyrus. 
The pyramidal cell layer (PCL) or stratum pyramidale is a compact accumulation 
of the somas of the pyramidal neurons, but also some interneurons are present 
such as basket, axo-axonic, bistratified and radial trilaminar cells. The basal 
dendrites of the pyramidal cells extend in the deep layer called stratum oriens (Str 
Or), while the apical dendrites protrude into the stratum radiatum (Str Rad) and 
terminate in the stratum lacunosum-moleculare (Str Lac Mol). The stratum oriens 
and radiatum are occupied also by horizontal trilaminar cells, basket and 
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bistratified cells (Witter and Amaral, 2004). In the CA3 region an extra layer is 
present, the stratum lucidum (Str Luc), which locates between the PCL and 
stratum radiatum and is formed by the mossy fibres arriving from the DG (Amaral 
and Witter, 1989). The stratum lucidum of CA3 receives the projections from 
granule cells of the DG and CA3 pyramidal neurons send their projections to CA1 
subfield through the Schaffer collaterals (Amaral and Witter, 1989). 
1.2.2.4. The Entorhinal Cortex 
The Entorhinal Cortex (EC) corresponds to the Brodman area 28 and it is so 
called for being bordered by the rhinal sulcus (Brodmann, 1909). It is part of the 
posterior temporal cortex and is strongly connected with the hippocampus. 
The EC is generally subdivided into two subfields: the lateral entorhinal cortex 
(LEC, Brodmann area 28a), which occupy a rostrolateral position in the EC and 
the medial entorhinal cortex (MEC, Brodmann area 28b) that occupy a 
caudiomedial position. The EC lamination is characterized by three superficial 
layers (I, II and III), the lamina dissecans and two deeper layers (V and VI). Layer 
I or the molecular layer is formed by a compact band of transversely oriented 
fibres and is almost devoid of neurons, indeed only two types of neurons were 
described in this layer, horizontal cells and multipolar neurons (MPNs), both of 
which are GABAergic. Layer II presents mainly principal neurons ad large stellate 
neurons, more distributed in the MEC, and pyramidal-like cells; but also several 
kind of interneurons are present. Layer III is a wide layer rich of pyramidal cells 
and less stellate cells and interneurons. Next to the superficial layers there is the 
lamina dissecans that is the cell-sparse fibre layer, it is occupied by occasional 
pyramidal-shaped neurons and it is better developed in the MEC. Layer V 
presents three sublayers, the Va layer with large to medium size pyramidal cells 
and layers Vb and Vc with small and less densely packed pyramidal cells. In this 
layer are found also horizontal cells and polymorphic MPNs. The last layer, layer 
VI, is delineated by the white matter and is occupied by pyramidal cells. LEC and 
MEC are occupied by different types of interneurons and in some layers the 
principal neurons differ in their morphology and electrophysiologically (Canto et 
al., 2008). 
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Figure 1.4 Representation of hippocampal anatomic structure and entorhinal connections. 
(A) Drawing of Cajal of a rabbit hippocampus. (B) Representation of the hippocampal loop and 
the connections between hippocampus and entorhinal cortex. (C) Toluidine stained section of the 
mouse hippocampus showing the hippocampal subfields and layers (personal picture of Rodríguez 
J.J.). (D) Toluidine stained section representative of the anatomical subdivisions of the human 
hippocampal formation (Gardenal E. personal unpublished image).  
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1.2.3. Hippocampal connectivity 
The connections between the different areas of the hippocampal formation are 
generally simplified and described as the “trisynaptic circuit” (Fig. 1.4B). The 
projections start from the entorhinal cortex and extend unidirectionally in a sort of 
circuit composed by three sets of subsequent links: the perforant pathway 
projections to the dentate gyrus and CA1, the mossy fibres projections from the 
dentate granule cells to the CA3 pyramidal cells and the Schaffer collaterals of 
CA3 pyramidal cells directed to the CA1 pyramidal cells. Subsequently to the 
trysinaptic circuit, the connections extend from the CA1 back to the subiculum 
and the EC. This description of the hippocampal connections is largely simplified 
and a complex intrinsic and extrinsic organization has emerged (Amaral, 1993; 
Witter et al., 2000). 
The EC projects to all hippocampal CA1, CA2, CA3 areas, the dentate gyrus and 
the subiculum. The connection between the entorhinal cortex and the 
hippocampus is called perforant pathway. Specifically, the projection of neurons 
from layer II of the EC innervate the outer two-thirds of the dentate molecular 
layer and the outer portions of stratum lacunosum-moleculare of CA3 and CA2 
(Witter, 2007). Neurons of layer III of the EC project to the stratum lacunosum-
moleculare of CA1 and to the molecular layer of the subiculum. The fibres from 
layer II and III distribute along the longitudinal axis in the same way, the cells of 
the lateral part of entorhinal cortex project to the rat septal hippocampus (caudal 
level for the monkey), while neurons of the medial part of the entorhinal cortex 
terminate in the rat temporal hippocampus (rostral level for the monkey) (Witter 
and Amaral, 1991; Amaral, 1993). The perforant pathways of the lateral 
entorhinal cortex and medial entorhinal cortex present a different distribution 
along the transversal axis of hippocampus. Neurons from layer II of the LEC 
project to the outer third of the dentate molecular layer and CA3 stratum 
lacunosum-moleculare, while axons originating from layer II of the MEC extend 
to the middle one third of these layers. Layer III cells from the LEC project to the 
distal part of the CA1 and the proximal part of the subiculum, whereas the cells 
from the MEC project to the proximal CA1 and the distal subiculum (Amaral, 
1993; Witter et al., 2000; van Groen et al., 2003). 
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The superficial layers II and III of perirhinal and postrhinal cortices also project to 
specific areas of the hippocampal formation, which are the molecular layer of 
CA1 and the subiculum. These connections have a different distribution in the 
transversal axis of CA1 and subiculum similarly to the LEC and MEC 
topographical organization (Suzuki and Amaral, 1990; Witter et al., 2000; Naber 
et al., 2001).  
The return projections from the CA1 to the parahippocampal region show a 
transverse topographical organization similar to the connections from the 
parahippocampus to the CA1 and subiculum. Axons coming from a specific point 
of CA1 target approximally one third of the transverse extent of the subiculum, 
moreover neurons from the proximal CA1 project to the distal subiculum and 
vice-versa the distal part of CA1 extend to the proximal part of subiculum.  
Projections from CA1 terminate in the pyramidal cell layer and in the molecular 
layer. 
Projections from the CA1 and the subiculum to the EC terminate in the lamina 
dissecans and in layer V over the full transverse extent of the EC. The same 
projections reach also the superficial layers, mainly layer III. The connections to 
the EC are organized in a similar way to the perforant pathway, but they are also 
divergent, since the return projection from the CA1 and subiculum to the EC 
rarely terminate in the originating part of the EC (Witter et al., 2000). 
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1.3. ANIMAL MODELS 
 
So far, several animal models have been used and created through different 
approaches to study dementia and cognitive decline (Neha et al., 2014). Being 
memory loss one of the most important features of old age, spontaneous aged 
models were the first used to study memory deficits and dementia. Aging animals 
are good models for general cognitive research since they have no central 
neurochemical manipulations. They exhibit not only neurochemical and 
morphological alterations, but also cholinergic hypofunction similarly to the 
pathogenesis of AD (Sherman and Friedman, 1990; Neha et al., 2014). 
1.3.1. Chemically induced animal models for AD 
Memory loss and pathophysiological alterations typical of AD can be induced by 
manipulating neuronal and neurotransmitter pathways with several different 
chemical compounds. 
Scopolamine is an anti-cholinergic drug which can induce aspects of dementia 
like memory loss and disorientation (Riedel et al., 2009). Colchicine, a 
microtubule-disrupting agent, causes the loss of cholinergic neurons and pathways 
determining memory loss and behavioural changes (Kumar et al., 2007). A 
phenotype similar to dementia can be induced also by increasing L-methionine, 
which produces endothelial dysfunction as homocysteine level is increased 
(Koladiya et al., 2009), or by administering sodium azide, which inhibits the 
mitochondrial respiratory chain, produces free radicals and causes excitotoxicity 
followed by neurodegeneration and altered processing of APP (Henriques et al., 
2005; Luques et al., 2007; Neha et al., 2014). In addition, infusion of Aβ peptides 
in the brain induces memory loss, Aβ plaques formation and neurodegeneration 
(Yamada and Nabeshima, 2000).    
A valid model of lesion of nbM is the injection of ibotenic acid, which is an N-
methyl-D-aspartic acid (NMDA) receptor agonist that leads to neuronal toxicity 
by overloading calcium into the neurons (Zhang et al., 2013). Some similar 
neurotoxins and cholinotoxins causing lesions of the forebrain with memory loss 
are kainic acid (Park et al., 2012), quisqualic acid (Toledano and Bentura, 1994) 
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and quinolinic acid (Beninger et al., 1986; Yamada et al., 1991). Cholinergic 
neurons lesions are induced also by the administration of the specific cholinergic 
toxin AF64 and antibodies against neurotrophic factors (Toledano and Alvarez, 
2004). 
All the models illustrated above are very good to test drugs effect on memory 
impairment and cognitive deficits, but they don’t develop the two main 
pathological hallmarks of AD, that are the senile plaques and neurofibrillary 
tangles. Hence, transgenic mouse models have been generated to study the 
pathophysiology of AD typical lesions (Gotz et al., 2004). 
1.3.2. Transgenic animal models for AD 
1.3.2.1. Single and double transgenic mouse models of AD 
Transgenic animal models have been created to simulate amyloidogenesis and tau 
pathology on the basis of genetic mutations related to FAD (Table 1.1). The 
mouse is the specie commonly used to generate an AD model and several 
transgenic models have been created so far (Gotz et al., 2004; Cavanaugh et al., 
2014; Neha et al., 2014). 
Games et al. (1995) developed the first mouse model of amyloidosis by inserting 
the transgene of mutant APP V717F under the platelet-derived growth factor 
promoter (PDAPP). This model develops extracellular thioflavin-S-positive Aβ 
deposits, neuritic plaques, synaptic loss, astrocytosis and microgliosis (Games et 
al., 1995). Other single transgenic mouse models of amyloidosis developed later 
and commonly used are the Tg2576 and the APP23 mouse models. The Tg2576 
mice express the human APP695 containing the Swedish double mutation 
K670N/M671L and exhibit an impairment in spatial memory and learning from 9 
months of age accompanied by an increased production of Aβ40 and Aβ42/43 and 
deposition of Aβ plaques, in addition gliosis and neuritic dystrophy (Hsiao et al., 
1996). The APP23 mice bear the Swedish mutation in the APP751 isoform under 
the control of the Thy-1 promoter and show a reduced number of neurons in the 
CA1 region of hippocampus, amyloid plaques, inflammatory processes, neuritic 
and synaptic degeneration and tau hyperphosphorylation (Sturchler-Pierrat and 
Staufenbiel, 2000). Other APP mutant mice model bearing the Swedish mutation 
41 
 
are the C3-3 mice (Borchelt et al., 1997) and TgCRND8 mice, the latter is a 
double mutant for APP since it carries also the V717F mutation (Chishti et al., 
2001). Single transgenic mice were generated also with familial mutations of the 
Presenilin 1 (PS1) gene. The knock-in mouse model bearing a mutated PS1 gene 
which substitute the endogenous gene shows increased levels of Aβ42/43 peptides 
(Nakano et al., 1999).   
Double transgenic mice were obtained by crossing APPSwe transgenic animals 
with the mutant presenilin 1 M146L animals to obtain the PSAPP mice 
(McGowan et al., 1999) or with the PSEN1 A246E (Borchelt et al., 1997). These 
double mutant APP/PSEN1 mice develop more pronounced and diffuse fibrillary 
Aβ deposits at younger age (Holcomb et al., 1999) than single mutant and 
prominent gliosis (McGowan et al., 1999), but they don’t show any tau pathology. 
A mouse model obtained by crossing the APPSL mice, which carry the Swedish 
and the London (V717I) mutations, with the PS1 knock-in mice bearing the 
M233T and L235P mutations, show a massive neuronal loss in the CA1/CA2 
pyramidal neurons, accompanied with a high amount of intracellular Aβ 
accumulation, but no extracellular Aβ plaques (Casas et al., 2004). All these 
single and double transgenic mice are good models to study the amyloidogenic 
pathogenesis but they don’t have tau pathology and they don’t develop AD 
pathogenesis. 
Several animal models have been developed to create tau pathology so far. The 
first transgenic mouse model for tau was created by expressing the longest human 
tau isoform under the control of the Thy1 promoter. These mice exhibit 
somatodendritic localization and hyperphosphorylation of tau, but they don’t have 
NFTs (Götz et al., 1995). The establishment of a mouse model bearing the 
mutated tau P301L, typical of frontotemporal dementia, under the Th1.2 promoter 
showed a stronger pathologic phenotype with accumulation of 
hyperphosphorylated tau, which is translocated to the somatodendritic 
compartments and is accompanied by astrocitosis, neurodegeneration and 
formation of tau abnormal filaments (Götz et al., 2001). 
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A quintuple transgenic mouse model carries 5 familial AD mutations in APP and 
PS1/2 genes with the result of a rapid early intracellular Aβ accumulation and 
extracellular amyloid deposition inducing the death of many pyramidal cortical 
and subiculum neurons and memory impairment (Oakley et al., 2006). 
So far, the only transgenic mouse model exhibiting both amyloid pathology and 
NFTs similarly to human AD is the triple transgenic mouse model (Oddo et al., 
2003a, 2003b). 
1.3.2.2. The 3xTg-AD mouse model 
The triple transgenic mouse model of AD was generated by co-injecting the 
human APPSwe and tauP301L transgenes into single-cell embryos derived from 
homozygous mutant PS1M146V knocked in (PS1-KI mice). The APP and tau 
transgenes co-integrated at the same site and the M146V mutation was knocked in 
to the endogenous PS1 locus, for this reason these mice breed as a “single” 
transgenic line and it is unlikely that APP and tau transgenes assort independently 
in the subsequent breeding. The hemizygous mice were also crossed and 
homozygous mice for all three transgenes were obtained (Oddo et al., 2003b). The 
penetrance of the phenotype is 100% and the pathology evolve equally in both 
male and female. 
The 3xTg-AD mice exhibit a regional dependent Aβ deposition related with age 
progression. These mice start to show intraneuronal Aβ immunoreactivity 
between 3 and 4 months of age in neocortical regions and at 6 months of age in 
the CA1 area of hippocampus. In 6 months old mice, Aβ proteins begin to 
accumulate also extracellularly in the frontal cortex and by 12 months of age Aβ 
extracellular deposits are present also in other cortical areas and in the 
hippocampus (Oddo et al., 2003a, 2003b).  
Tau changes start to appear in the hippocampus of the 3xTg-AD mice around 12 
months of age when an intense immunoreactivity for human tau can be detected in 
the CA1 pyramidal neurons, especially in the somatodendritic compartments. 
Later, the tau pathology expands to the cortical regions. The 3xTg-AD mice show 
also immunoreactivity for the antibodies specific for the conformational changes 
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of tau, as MC1 antibody, and its phosphorylated form, such as AT180, AT8 and 
PHF1 antibodies. 
The 3xTg-AD mice show the same temporal and regional pattern of distribution 
of Aβ and tau alterations in human AD, moreover the early accumulation of Aβ 
prior to tangle formation is consistent with the amyloid cascade hypothesis (Oddo 
et al., 2003a, 2003b). 
As in the human AD pathogenesis, this mouse model exhibits an impairment in 
the basal synaptic transmission and in long-term potentiation (LTP) which is 
detectable already at 6 months of age when intraneuronal Aβ appears in the CA1 
pyramidal neurons suggesting a direct correlation between Aβ intracellular 
accumulation and synaptic dysfunction (Oddo et al., 2003b). Moreover 
behavioural tests with the Morris water maze (MWM) showed that this animal 
model exhibit long-term memory retention starting in parallel with intracellular 
Aβ accumulation and prior to amyloid plaques and tau pathology (Billings et al., 
2005). 
The 3xTg-AD mice show also an age-dependent reduction of neurogenesis in the 
dentate gyrus and in the subventricular zone. This impaired cell proliferation 
parallels the rise in the number of Aβ positive neurons in the hippocampus and the 
deposition of amyloid plaques (Rodríguez et al., 2008, 2009b). Changes in 
astrocytic and microglial morphology were detected in this mouse model. 
Astrogliosis was observed mainly around amyloid plaques while in general 
astroglial activation or atrophy were observed with a specific regional pattern in 
hippocampus and cortical regions (Oddo et al., 2003a; Mastrangelo and Bowers, 
2008; Rodríguez et al., 2008). Furthermore, increased microglia activation was 
detected in the hippocampus parallel with Aβ plaques deposition and increased 
density of resting microglia was found even before extracellular amyloid 
deposition (Mastrangelo and Bowers, 2008; Rodríguez et al., 2010, 2013). 
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Transgenic animal model Neuropathology Reference 
PDAPP Aβ deposits (Games et al., 1995) 
APPSwe Plaques (Hsiao et al., 1996) 
APPSwe x PS1A246E Plaques (Borchelt et al., 1997) 
APP23 Plaques 
(Sturchler-Pierrat et al., 
1997) 
PSAPP Plaques (Holcomb et al., 1998) 
Tg-CRND8 (APPSwe/APPV717) Plaques (Chishti et al., 2001) 
PS1M146L Diffused plaques (Blanchard et al., 2003) 
BACE x APPSwe Plaques (Mohajeri et al., 2004) 
APPSLPS1ki Plaques (Casas et al., 2004) 
APPSwe/PS1dE9 Plaques (Savonenko et al., 2005) 
Alz7 (4R tau) Hyperphopshorylated tau (Götz et al., 1995) 
TauP301L Tangles (Lewis et al., 2000) 
P301L Tangles (Götz et al., 2001) 
JNPL3 (4R+P301L) Tangles 
(Lewis et al., 2000; 
Arendash et al., 2004) 
rTg4510 (P301L; Tet-off) Tangles (Ramsden et al., 2005) 
Tg2576 x JNPL3 Plaques + Tangles (Lewis et al., 2001) 
Tg2576 x VLW (tauvlw) Plaques + Tangles (Ribé et al., 2005) 
3xTg-AD (APPSwe + 
PS1M146V+P301L) 
Plaques + Tangles (Oddo et al., 2003a, 2003b) 
5xFAD Plaques (Oakley et al., 2006) 
 
Table 1.1 Summary of the most used transgenic mouse models of AD. 
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1.4. CALCIUM SENSING RECEPTOR IN AD 
 
1.4.1. Calcium Sensing Receptor structure and dimerization in the brain 
The calcium sensing receptor (CaSR) is a G protein-coupled receptor (GPCR) and 
more specifically it belongs to the subfamily C, which is formed by three distinct 
groups of receptors. Group I includes the metabotropic glutamate receptors, 
mGluRs 1–8, which are receptors for the excitatory neurotransmitter glutamate 
and are widely expressed in the brain. Group II consists of several types of 
receptors including the CaSRs and the VRs (vomeronasal receptors). The latter 
are expressed in neurons of the vomeronasal organ of the rat and are pheromones 
receptors. Group III contains a subfamily of receptors, the γ-aminobutyric acid 
(GABA)B receptors, that bind and are activated by the inhibitory neurotransmitter 
GABA (Brown and MacLeod, 2001).  
The CaSR consists of a large NH2-terminal extracellular domain (ECD), a 
transmembrane domain (TMD) and a COOH-terminal intracellular domain (ICD). 
The ECD is also called the VFT domain because its bilobed structure resembles a 
Venus Flytrap. Its proper glycosylation is necessary for its expression in the 
plasma membrane, moreover it is important for the protein folding and 
dimerization. The VFT domain is responsible for the binding of Ca2+, the CaSR’s 
primary agonist, even if also the TMD might bind Ca2+. Other molecules can bind 
and activate the CaSR through the ECD and TMD such as divalent and trivalent 
cations (Mg2+, Gd3+), cationic compounds (neomycin) and organic polycation 
compounds (spermine, polyamine, amyloid--peptide, poly-L-arginine). The 
TMD is formed by 7 transmembrane -helices, it is essential for the protein 
processing, expression in the plasma membrane and stability and it permits the 
signal transmission along the receptor. It is the binding domain for the 
“calcimimetics” (NPS R-568, NPS R-467), which are molecules that interact 
allosterically with the receptor and increase the CaSR affinity for Ca2+. The ICD 
is required for the interaction with G-proteins and the activation of the 
intracellular cascade of signal transduction, it is also involved in the dimerization 
of the CaSR (Fig. 1.5) (Msaouel et al., 2004).  
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The CaSR can be found intracellularly in its immature form or in the plasma 
membrane after its glycosylation and processing. It is constitutively present in the 
membrane as a dimer, probably because its dimerization confers more stability, 
but it can be functional also when expressed as a monomer (Brown and MacLeod, 
2001; Gama et al., 2001).  
 
 
 
Figure 1.5 Representation of the CaSR domains and their ligands specificity. Adapted from 
Dal Prà et al., 2014. 
 
 
Interestingly, the CaSR can form heterodimers with Group I metabotropic 
glutamate receptors (mGluR1a) in hippocampal and cerebellar neurons, but they 
are expressed differently in other brain regions. The CaSR, when present as 
heterodimers with mGluR1a, become sensitive to glutamate-mediated 
internalization, suggesting a role in the regulation of the neuronal function (Gama 
et al., 2001). The CaSR was demonstrated to co-localize with GABAB receptors 
(R1 and R2) in cultured mouse hippocampal neurones and also co-
immunoprecipitate with GABABR1 from brain lysates. The expression of CaSR is 
increased in GABABR1 knock-out mouse brains and it is suppressed when the 
GABABR1 was overexpressed in HEK 293 cell culture with a consequent 
inhibition of phospholipase C activation in response to high extracellular [Ca2+] 
(Chang et al., 2007). On the contrary, co-expression of CaSR with GABABR2 in 
HEK 293 causes CaSR hyperexpression (Chang et al., 2007). These studies have 
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pointed out a very complex mechanism of functioning of CaSRs related to their 
ability of forming homodimers and heterodimers with other GPCRs that seems to 
be very important for their trafficking to the membrane, their ligand binding 
sensitivity and thus the regulation of signalling responses (Chang et al., 2007). 
1.4.2. Regional and cellular distribution of the CaSR in the brain 
The CaSR is widely expressed in the body, especially in the parathyroid cells, C 
cells, kidney cells, intestine, placenta and bone cells (Msaouel et al., 2004).  
The study of CaSR expression in rat showed that it is widely distributed 
throughout the CNS and the regions with highest CaSR cells density are those 
implicated in fluid and mineral homeostasis, hence CaSR could be important for 
maintaining such homeostasis. The subfornical organ is the brain region with 
highest expression of CaSR, which could have an important role in sensing the 
systemic fluid Ca2+, owing to the absence of blood brain barrier in this region. 
CaSR is also abundantly expressed in the hippocampus, where its distribution is 
similar to that of mGluRs and iGluRs. It is also present in the olfactory bulb, 
striatum, cingulate cortex, cerebellum, ependymal zones of the cerebral ventricles 
and perivascular nerves around cerebral arteries, some CaSR expressing cells 
were found also in rat dorsal root ganglia (Ruat et al., 1995; Yano et al., 2004). 
The CaSR has been found abundantly expressed in neurones (mostly in 
projections and terminals) and in oligodendrocytes in vivo (Ruat et al., 1995; 
Chattopadhyay et al., 1998; Ferry et al., 2000); in vitro studies demonstrated its 
expression also in human primary astrocytes and in rat microglia (Chattopadhyay 
et al., 1999a; Dal Pra et al., 2005). 
1.4.3. Functions of CaSR in the nervous system 
CaSR is known to be involved in the systemic [Ca2+] homeostasis in organs like 
parathyroid glands, kidneys, bone and gut where it is abundantly expressed. 
However, its function in the brain is still not totally understood. Local small 
changes of extracellular ionized [Ca2+] occur also in the brain during 
physiological activities like synaptic transmission, development and sleep. These 
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fluctuations in extracellular [Ca2+] are detected by CaSR which can activate 
specific responses (Ruat and Traiffort, 2013). 
Numerous functions have been assigned to CaSR expressed by neurons in the 
CNS from regulation of neuronal growth and migration, to the role in 
neurotransmission and synaptic plasticity.  
The study of CaSR transcripts expression in mouse sympathetic neurons of the 
superior cervical ganglion (SCG) demonstrated a role of CaSR in enhancing axon 
growth and branching to distal targets, but not in the early axonal outgrowth. 
Indeed, the sympathetic axons ramify to their distal targets and broadly branch in 
the immediate perinatal period when also CaSR mRNAs noticeably increase. This 
finding was proved both using calcimimetic and calcilytic modulators of CaSR 
and expressing wild-type and dominant-negative CaSR protein in SCG neurons. 
Also the comparison of sympathetic neurons from wild-type and CaSR-deficient 
mice confirmed the direct involvement of CaSR in neurite growth in this specific 
developmental window (Vizard et al., 2008). CaSR expression level has been 
demonstrated to increase also in rat hippocampal pyramidal neurons several days 
after birth. In detail, CaSR proteins rise markedly at 10 days postnatally and last 
until 30 days, when their expression begins to diminish to reach the lower adult 
levels. In this time frame, long-term potentiation is first induced and the 
development of hippocampus proceeds most rapidly supporting the idea that the 
CaSR may have a role in the functional maturation of hippocampus and other 
brain regions (Chattopadhyay et al., 1997). Furthermore, Vizard et al. found that 
the CaSR takes part also in the regulation of dendritic growth in hippocampal 
pyramidal neurons in postnatal mice, therefore it may contribute to the 
mechanisms of learning and memory formation (Vizard et al., 2008).  
The involvement of CaSR in cell migration has been proposed in a study on 
neurons synthesizing gonadotropin-releasing hormone (GnRH). Elevated 
extracellular [Ca2+] stimulated chemotaxis of GnRH neurons from the basal 
forebrain to the preoptic area of anterior hypothalamus, this mechanism was 
mediated by CaSR with a partial contribution of the monocyte chemoattractant 
protein-1 (MCP-1) (Chattopadhyay et al., 2007). The hypothesis that CaSR might 
be involved in neurotransmission and synaptic plasticity was first advanced after 
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the finding of CaSR expression in nerve terminals (Ruat et al., 1995). 
Extracellular Ca2+ is necessary for synaptic transmission. When an action 
potential invades a nerve terminal, Ca2+ channels in the presynaptic terminal open 
and allow the transient entrance and increase of intracellular Ca2+. Ca2+ triggers 
synaptic vesicle exocytosis, thereby releasing the neurotransmitters contained in 
the vesicles and initiating synaptic transmission (Katz and Miledi, 1967).  
Several studies have demonstrated that CaSR can activate Nonselective Cation 
Channels (NSCC) when stimulated by its polycationic agonists or after falls in 
extracellular [Ca2+] (Chen et al., 2010). It has been proposed that the decrease in 
[Ca2+]o in the synaptic cleft may act as feedback to presynaptic CaSR and the 
associated increased activity of NSCCs may increase action potential duration; in 
this way CaSR may influence synaptic transmission through a homeostatic 
pathway to prevent synaptic failure when [Ca2+]o falls (Ye et al., 1996).  
Activation of CaSR was demonstrated to induce also a distinct form of 
spontaneous glutamate release independent on Ca2+ influx, that could be important 
for the formation of new synaptic connections (Vyleta and Smith, 2011).  
In vitro studies conducted in the human astrocytoma cell line U87, and primary 
cultures of rat microglia and oligodendroglia showed that CaSR stimulates Ca2+-
activated K+ channels, contributing to local ionic homeostasis following the 
lowering of [Ca2+]o due to increased neuronal activity; it has been hypothesized 
that CaSR could play a role in microglia activation, but this hasn’t been 
demonstrated yet (Chattopadhyay et al., 1998, 1999a, 1999b). The CaSR 
expression was found at high levels in oligodendrocyte progenitor cells (OPCs) 
until the pre-myelinating stage and decreased by several folds in the mature 
oligodendrocytes (Chattopadhyay et al., 2008). High [Ca2+]o acting via CaSR  
promoted the proliferation of oligodendrocyte progenitor cells and stimulated the 
increase of the mRNA levels of myelin basic protein in preoligodendrocytes. In 
addition, myelin basic protein levels were significantly reduced in the cerebellum 
of CaSR-null mice during development. The study of a case of neonatal 
hyperparathyroidism due to homozygous inactivating mutations of the CaSR 
showed a decrease in white matter associated with delayed myelination (Ward et 
al., 2004). Finally, the analysis of CaSR mRNA revealed that it co-localizes with 
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the myelin basic protein in rat brains during the first weeks after birth and also in 
mature oligodendrocytes (Ferry et al., 2000). This confirms that the CaSR is 
probably involved in the development and function of oligodendrocytes (Ruat and 
Traiffort, 2013).  
1.4.4. CaSR role in the pathogenesis of AD 
The first evidence of CaSR correlation with AD was given by a study that 
reported the direct activation of CaSR by β-amyloid in rat hippocampal neurons 
(Ye et al., 1997). It was demonstrated that the exposure of neurons to Aβ produces 
a CaSR mediated activation of NSCC, indeed these channels are not activated by 
Aβ in neurons from mice with disrupted CaSR-/- (Ye et al., 1997). Nevertheless, 
the molecular mechanism of Aβ interaction with CaSR is not clear. Some 
hypothesis sustain that it is possible that either β-amyloid fibrils or variously sized 
oligomers, having regular positive charges, mimic CaSR agonists, or hydrophobic 
interactions between β-amyloid and CaSR may take place (Ye et al., 1997). 
Furthermore, a genotyping study demonstrated a direct correlation between CaSR 
and AD, and confirmed that the CaSR can be activated by Aβ as well as by apoE 
(isoforms 3 and 4) (Conley et al., 2009). The direct interaction of CaSR with Aβ42 
and the formation of AβCaSR complexes was demonstrated in normal human 
cultured astrocytes by the utilization of in situ Proximity Ligation Assay 
(Söderberg et al., 2006; Dal Prà et al., 2014). 
Several studies conducted on human cortical primary astrocytes demonstrated, for 
the first time, the real pathogenic involvement of CaSR in AD. The first 
experiments on the CaSR in normal adult human astrocytes showed that it has a 
role in the activation of NOS (Nitrix Oxide Synthase)-2 enzyme. Astrocytes, 
when activated by pro-inflammatory cytokines, present increased expression and 
activation of NOS-2. This enzyme is responsible for NO production, which 
contributes to the killing of neurons in several neuropathology. It has been shown 
that treating activated astrocytes with a calcilytic stops their production of NO 
(Dal Pra et al., 2005). This interesting finding was further studied combining the 
treatments of astrocytes with soluble A-peptide and myelin basic protein (MBP). 
All these substances were able to induce a higher release of NO thus to enhance 
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the effect caused by pro-inflammatory cytokines (Chiarini et al., 2005). These 
studies pointed out the possibility to use CaSR antagonist to prevent the death of 
neurons in inflammatory conditions. 
But the most important finding related to CaSR was the discovery that its altered 
activation is related with the increased production and spread of Aβ peptides. 
First, it was found that the treatment of cortical astrocytes with an A42 surrogate 
induces the production of VEGF-A mediated by the nuclear translocation of the 
hypoxia-inducible factor (HIF)-1 and  complexes (Chiarini et al., 2010). The 
same mechanism induces also a rise in the expression and activity of -secretase 
in the first place and then of -secretase activity with the result of an increased 
production and secretion of A peptides (Dal Prà et al., 2011). Interestingly, the 
treatment of neurons with A is toxic and triggers their progressive death, while 
astrocytes don’t die but start to produce A, promoting the death of the 
surrounding neurons. Finally, it was proven that the administration of the CaSR 
antagonist NPS2143 to astrocytes treated with A can block this mechanism of 
A self-induction and prevent the neuronal death (Armato et al., 2013). The 
research work described in this thesis demonstrates an increased expression of the 
CaSR in the hippocampus of the 3xTg-AD animal model, this hyperexpression is 
specific of the subfields first affected by Aβ-plaques deposition. Hence, an 
alteration of CaSR related to AD hallmarks is demonstrated also in vivo (Chapter 
3, Gardenal et al., 2017).  
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1.5. CALCIUM BINDING PROTEINS IN AD 
 
Calcium binding proteins (CaBPs) like calmodulin, calretinin (CR), parvalbumin 
(PV) and calbindin-D28K are small intracellular proteins diffused in the central 
nervous system and expressed by specific subtypes of neurons. These CaBPs are 
able to sense intracellular Ca2+ and are supposed to play an important role in 
buffering excess of cytosolic Ca2+ (Baimbridge et al., 1992). Calcium 
dyshomeostasis is considered a valid hypothesis of AD pathogenesis and for this 
reason the study of CaBPs changes in AD could reveal important information on 
this subject. CaBPs are considered neuroprotective and their reduction in the 
neurons seem to render them more vulnerable. In particular, PV-positive 
interneurons are responsible for gamma oscillatory activity, which is reduced 
during epileptiform discharges, a cognitive dysfunction typical of AD. The restore 
of the normal function of PV-interneurons demonstrated to be effective in 
increase gamma activity, decrease epileptiform activity and reduce learning and 
memory deficits in a mouse model of AD (Verret et al., 2012). An impairment of 
PV-cells has been demonstrated also in other disorders associated with altered 
network activity like schizophrenia and autism (Sohal et al., 2009; Fazzari et al., 
2010). 
Furthermore, the immunolabelling of different CaBPs in the brain is used to 
distinguish different populations of GABAergic inhibitory interneurons since they 
are expressed in specific subtypes of interneurons without overlapping each other 
(Del Río and DeFelipe, 1996; Jinno and Kosaka, 2002, 2006; Maccaferri et al., 
2003). Hence, the labelling of interneurons with CaBPs immunoreactivity is 
considered an extremely reliable biomarker to evaluate possible distinct 
vulnerability of different GABAergic interneurons subpopulations in specific 
brain regions. Neuronal network dysfunction and excitability is thought to play an 
important role in AD pathogenesis, the specific dysfunction of inhibitory 
interneurons may be the cause of neuronal hyperexcitability which is deleterious 
for neuronal survival. 
The present work specifically focuses only on PV and CR since we have observed 
significant alterations of these proteins in the hippocampus of the 3xTg-AD mice 
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(Chapter 4, Zallo et al. in preparation). Here is reported a summary of the 
alterations in PV and CR expression and cell density in AD human brains and in 
AD animal models. 
1.5.1. Hippocampal features and distribution of parvalbumin neurons 
The cell bodies of PV interneurons are generally larger than those of other 
interneurons and they localise mainly in the stratum pyramidale and oriens of the 
cornu ammonis and in the stratum granulare and the hilus of the dentate gyrus. 
About 20-24% of the GABAergic neurons contain parvalbumin in the 
hippocampus. Interestingly, the PV neurons present a weaker staining of GABA 
than the others GABAergic cell bodies lacking this calcium binding protein 
(Kosaka et al., 1987; Freund and Buzsáki, 1996; Jinno and Kosaka, 2006). The 
dendrites of the PV cells spread in all layers and are radially oriented in parallel 
with the principal cells dendrites, their staining of their arborisation become 
weaker in the stratum lacunosum moleculare of cornu ammonis and in the 
molecular layer of dentate gyrus. The majority of PV dendrites present 
varicosites, but they normally don’t have spines. All PV-positive neurons can be 
classified as basket cells or chandelier cells (also called axo-axonic cells), even if 
the opposite is not true (Freund and Buzsáki, 1996; Jinno and Kosaka, 2006) and 
they are responsible for perisomatic inhibition (soma, axon initial segment, 
proximal dendrites) of principal cells (Freund and Buzsáki, 1996). 
1.5.2. Hippocampal features and distribution of calretinin neurons 
CR-positive neurons are distributed in all layers of hippocampus and they can be 
differentiated in two main categories on the basis of dendritic morphology and 
distribution: the spiny CR-immunoreactive neurons and the spine-free CR-
immunoreactive neurons. 
The spiny CR interneurons are mainly distributed in the hilus and in the stratum 
lucidum of CA3, the regions rich of mossy fibres. Both somata and dendrites are 
full of long hairlike spines that form synapses with the mossy fibres, while the 
axons are not visible with immunostaining being strongly myelinated. The 
dendrites never enter the stratum granulare or pyramidale. These interneurons 
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receive inputs from mossy fibres and innervate principal cells dendrites. It is still 
not clear whether or not they are GABAergic neurons (Freund and Buzsáki, 
1996).  
The spine-free CR interneurons represent a large group of GABAergic cells which 
form multiple synapses with other interneurons, in particular they strongly 
innervate calbindin D28K interneurons, VIP-basket cells and other CR-positive 
cells, but they don’t converge into PV basket and axo-axonic cells (Gulyás et al., 
1996). Thus, the spine-free CR neurons are interneurons specialized to innervate 
other interneurons and because of these peculiar connections they have probably a 
role as disinhibitory interneurons and they might be involved in the generation of 
synchronous, rhythmic hippocampal activity (Freund and Buzsáki, 1996; Gulyás 
et al., 1996). These interneurons are widely distributed in all hippocampal areas 
and layers and they are usually characterised by axons with numerous varicosities 
in stratum radiatum and axons that form a horizontal plexus at the border between 
the stratum oriens and the alveus (Gulyás et al., 1996).   
Finally, other CR interneurons are horizontal neurons localized near the 
hippocampal fissure, their soma is located on either side of the fissure and they 
seem to be Cajal-Retzius cells (Freund and Buzsáki, 1996). 
1.5.3. Parvalbumin alterations in Alzheimer’s disease 
1.5.3.1. PV alterations in the hippocampus: 
The hippocampal PV-positive neurons were studied in both AD mouse models 
and in human Alzheimer’s disease brains.  
In the APPSL/PS1KI double mutant mouse model a regional specific age-related 
loss of PV-positive neurons were found within the hippocampus. The number of 
PV neurons was significantly decreased in the stratum pyramidale of CA1 and 
CA2 in the mice 10 months old respect to the mice 2 months old (Takahashi et al., 
2010). This loss in the PV-immunoreactive neurons was explained by the 
presence of the mutated PS1 gene, since PS1KI mice presented the same 
alterations, while the APPSL mice displayed no differences in the number of PV-
positive neurons. The same authors found no differences in the density of PV-
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positive neurons in the dentate gyrus of post-mortem human brains (Takahashi et 
al., 2010).  
A study of calcium binding proteins reactivity in the dentate gyrus of the 
APPSwe/PS1A246E mouse model found a decrease in the immunoreactivity of PV 
which was extended in both the granular cell layer and hilus (Popovi et al., 2008).  
The analysis of parvalbumin-positive neurons in the TgCRND8 mouse model of 
AD at 6 months of age revealed a significant decrease only in the stratum oriens 
of CA1 and CA3 hippocampal areas (Albuquerque et al., 2015). This apparent 
resistance of PV cells in this AD model could be due to the age of the mice 
investigated, which are younger than in other studies (Takahashi et al., 2010) or it 
may be related to the different genetic characteristics of this mouse model. Indeed, 
these mice bear a mutation in the Aβ precursor gene and Takahashi et al. pointed 
out that in their work PV vulnerability may be due mainly to PS1 mutation. 
Conversely, the study of calcium binding proteins in the APPSwe/PS1dE9 mouse 
model exhibited no neuronal loss in transgenic mice 12 months old respect to their 
controls at the same age and to the 3 months old mice. In addition, the PV 
immunoreactivity resulted increased in the CA1 and CA3 at 3 months of age and 
in CA1, CA3 and DG at 12 months of age (Verdaguer et al., 2015). While the 
increase at 3 months occurred in all sublayers of CA1 and CA3 respect to the 
control mice, the increase at 12 months was apparent especially in the dendritic 
projections layers of stratum oriens and radiatum, of hilar and granular cells and 
of the Inner Molecular Layer (Verdaguer et al., 2015). 
In the hippocampal formation of human AD brains a significant reduction of 
approximately 60% of PV interneurons was observed in both dentate gyrus and 
Cornu Ammonis areas, while the subiculum and presubiculum didn’t show any 
vulnerability. In the dentate gyrus the alteration affected all layers and was 
accompanied also by a decreased immunoreactivity of the neuropils. In the Cornu 
Ammonis the neuronal loss was detected in CA1 and CA2, while CA3 showed 
only a modest decrease in the density of PV-stained processes (Brady and 
Mufson, 1997).  
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1.5.3.2. PV alterations in the entorhinal cortex: 
The analysis of the entorhinal PV-containing neurons in human Azlheimer’s 
disease brains revealed a dramatic alteration in layer II where there was a clear 
reduction in the immunostaining of both soma and dendrites and in the number of 
PV neurons. In some cases, also layer IIIb was affected with a decrease in the 
immunoreactivity and in its width, while the cell density was not altered. 
Interestingly, the layers II and IIIb didn’t exhibit any neurons containing both 
neurofibrillary tangles and PV (Solodkin et al., 1996; Mikkonen et al., 1999). 
1.5.3.3. PV alterations in other cortical areas: 
Studies on cortical areas different from the hippocampal formation and the 
entorhinal cortex pointed out a different reaction of PV neurons to AD. In the 
frontal cortex of the double mutant APPSL/PS1KI no alteration of PV-positive 
neurons was found, while the PV cell density resulted increased in the APP and 
PS1KIho mice (Lemmens et al., 2011). The study of frontal cortex in human AD 
cases by Arai et al. revealed a vulnerability in PV positive cells that were reduced 
in number and size (Arai et al., 1987). However other authors found no alterations 
in PV neurons in the frontal lobe (Ferrer et al., 1993). 
A decrease in the levels of PV was found also in the olfactory cortex and olfactory 
bulb of APPSwe/PSEN1De9 mice (Saiz-Sanchez et al., 2012, 2013), while in the 
piriform cortex of human brains with AD PV-positive cells were found to be 
increased (Saiz-Sanchez et al., 2014). 
A relatively resistance of PV interneurons to degeneration in AD was 
demonstrated in human neocortex by studies on temporal cortex where only 
chandelier cells presented dystrophic neurites and sprouting (Ferrer et al., 1991; 
Fonseca et al., 1993), prefrontal cortex (Hof et al., 1991), superior frontal gyrus 
(Sampson et al., 1997) and visual cortex (Leuba et al., 1998). Finally, a study on 
human parahippocampal gyrus demonstrated a reduction in the expression of PV 
in the AD brains (Inaguma et al., 1992). 
 
57 
 
1.5.4. Calretinin alterations in Alzheimer’s disease 
1.5.4.1. CR alterations in the hippocampus: 
CR-positive neurons were numerically reduced in the stratum granulare and hilus 
of the dentate gyrus in the APPSL/PS1KI mouse model of AD and also in the 
PS1KIho mice at 10 months of age respect to 1 month old mice, supporting the 
assumption that the neuronal loss in the double mutant mouse model may be due 
mainly to the presence of the mutated PS1 gene (Takahashi et al., 2010). It should 
be considered that this study only compares transgenic mice of 10 and 1 months 
of age without considering the wild-type mice, which should be included in the 
study in order to understand if any alteration at older age may be due to an age 
effect instead of a pathogenic process. Despite this consideration, Takahashi et al. 
found the same differences of CR-immunoreactive neurons in the dentate gyrus of 
Alzheimer’s disease patients compared to control subjects (Takahashi et al., 
2010). 
The study of CR interneurons in the APPSwe/PS1A246E mice described a trend 
similar to the model used by Takahashi. Indeed, the numerical density of the CR 
cells was found decreased in the hilus and in the inner molecular layer of the 
dentate gyrus (Popovi et al., 2008). 
As for the PV analysis, the APPSwe/PS1dE9 exhibited a different trend in CR 
expression respect to the other double mutant mouse model mentioned above. The 
number of CR-positive cells in the subgranular zone of the dentate gyrus 
decreased at 12 months of age respect to 3 months of age mice, but this reduction 
occurred in both mutant and wild-type mice. Interestingly, the numerical density 
at 3 months of age showed a significant difference in the subgranular zone 
between the mutant and wild type mice. On the contrary, at 12 months an increase 
in the CR neurons in the hilus was detected. No differences were found at any age 
analysed in the CA1 (Verdaguer et al., 2015). 
1.5.4.2. CR alterations in the entorhinal cortex: 
In the human brains of severely affected cases of Alzheimer’s disease the radial 
organization of the multipolar and bipolar neurons was disappeared in many 
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subfields and the dendrites in layers II and III were curled and reduced in length. 
The clustered fibre staining normally visible around cell islands of layer II was 
not apparent. In the most severe cases the CR cell density seems to be affected 
also in layer V compared to control tissues (Mikkonen et al., 1999). In the study 
of Brion and Résibois in human entorhinal cortex, the CR-positive neurons had a 
reduced dendritic tree (Brion and Résibois, 1994). 
1.5.4.3. CR alterations in the other cortical areas: 
In the frontal cortex of the APPSL/PS1KI mouse model of AD no changes were 
found in the calretinin positive neurons (Lemmens et al., 2011) as previously 
observed in human AD brains where both prefrontal cortex and temporal cortex 
didn’t exhibited any changes in CR neurons density and characteristics (Hof et al., 
1993; Fonseca and Soriano, 1995). 
CR-positive neurons were reduced in the olfactory cortex, olfactory bulb, anterior 
olfactory nucleus and tubercle of APPSwe/PS1dE9 mice (Saiz-Sanchez et al., 2012, 
2013) and in the piriform cortex of AD cases (Saiz-Sanchez et al., 2014). 
CR cell density was found increased in the superior frontal gyrus (Sampson et al., 
1997), while no alterations in the CR number were found in the visual cortex 
(Leuba et al., 1998). 
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1.6. ASTROCYTES AND THEIR INVOLVEMENT IN ALZHEIMER’S 
DISEASE 
 
The functional role of astroglia in the brain and its involvement in the 
pathogenesis of Alzheimer’s disease are described in details in several reviews 
and books (Heneka et al., 2010; Verkhratsky et al., 2010; Kettenmann and 
Ransom, 2013; Verkhratsky and Butt, 2013; Rodríguez-Arellano et al., 2015; 
Filous and Silver, 2016). Here there is a brief description of both healthy function 
and pathologic dysfunction of astrocytes in AD. 
1.6.1. Physiological functions of astrocytes 
For a long time, astrocytes were considered as mere supportive cells for neurons, 
but nowadays we know that they have several different functional roles in the 
nervous system. 
Astrocytes constitute a metabolic link between neurons and blood vessels. 
Astrocyte endfeet, which were first discovered by Camillo Golgi (Golgi, 1903), 
embrace brain vasculature and induce the formation of tight junctions in the 
endothelial cells of the BBB. The tight junctions are important to limit the passive 
diffusion of substances between the blood and the CNS thus to maintain a strict 
control of what can enter in the CNS. Following the alterations of the neural 
activity, astrocytes are able to modulate blood flow by using their perivascular 
processes to induce vasoconstriction or vasodilatation (Zonta et al., 2002). 
Neurons seem to achieve metabolic support from astrocytes through a mechanism 
called “astrocyte-neuron lactate shuttle”. In this model, the glutamate released 
because of synaptic activity is re-uptaken by the astrocytes by means of a sodium-
coupled mechanism of transport. The so caused increase of sodium inside the 
astrocytes activates the recruitment of glucose and its glycolytic processing, 
which results in the synthesis and release of lactate to fuel neurons during 
synaptic transmission (Magistretti, 2006). 
The recovery of the glutamate released during the synaptic transmission is carried 
out mainly by astrocytes via the “glutamate-glutamine shuttle” mechanism, which 
is of noteworthy importance. Indeed, if glutamate remain in the extracellular fluid 
too long it will trigger excitotoxic neuronal death. Glutamine synthetase, an 
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enzyme expressed almost exclusively by astrocytes (Martinez-Hernandez et al., 
1977), converts the glutamate into the non-toxic glutamine. The latter is then 
transported back to neurons through the extracellular space (Danbolt, 2001). 
Astrocytes accomplish the control of the extracellular ionic homeostasis necessary 
for the maintenance of neuronal excitability. This activity requires the transport of 
ions and a parallel coordinated movement of water that occurs through aquaporins 
channels present in the perisynaptic and perivascular astrocytic processes. 
Synaptic transmission is regulated also by astrocytes which, together with pre- 
and post-synaptic neuronal terminal, form the tripartite synapse (Araque et al., 
1999). Astrocytes express neurotransmitter receptors that can sense the 
transmitters released by neurons in the synaptic cleft and induce astrocytic 
excitability. This signaling stimulate the astrocytic release of neurotransmitters 
such as glutamate, GABA, ATP and D-serine that can modify the synaptic 
strength and function. Astrocytes can virtually express every kind of 
neurotransmitter receptor, however different brain regions are endowed with 
distinct receptors (Lalo et al., 2006, 2008; Jabs et al., 2007; Verkhratsky and 
Kirchhoff, 2007). 
Finally, astrocytes participate also in synaptogenesis, in synaptic maturation and 
maintenance, moreover they secret factors like thrombospondin that promote post-
lesion synaptic plasticity and recovery (Christopherson et al., 2005). 
1.6.2. Astrocytic physiological alterations in Alzheimer’s disease animal 
models and cell cultures 
Glia has started to be considered as an active participant of Alzheimer’s disease 
only recently, but the first evidence of its involvement in AD was already 
described by A. Alzheimer who reported also glial cells alterations in the brain of 
his patient (Alzheimer, 1907; Stelzmann et al., 1995). 
More recently, several studies have showed that rat astrocytes specifically react to 
A exposure changing their morphology and activity with dramatic consequences 
on the functioning of the other cells and the worsening of the disease. Astrocytes 
were demonstrated to reduce the clearance of A by preventing its phagocytosis 
by microglial cells (Dewitt et al., 1998). However, human astrocytes also 
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exhibited a modest activity of A42 phagocytosis and accumulation by themselves 
that often result in their lysis with eventual deposition of small plaques throughout 
the entorhinal cortex of AD patients (Nagele et al., 2003). On the contrary, in situ 
experiments with cultured adult mouse astrocytes incubated on APP mouse brain 
sections showed that astrocytes can reduce overall A levels in these slices. The 
endogenous astrocytes incapability of removing A may suggest the hypothesis 
that a dysregulation of A clearance by astrocytes may cause the accumulation of 
A in AD (Wyss-Coray et al., 2003). 
Some studies have shown impairment in the glutamate-glutamine shuttle activity 
of astrocytes. Treatment of rat cultured astrocytes with A1-40 induced a reduction 
in the uptake of glutamate through GLT-1 due to its activity inhibition mediated 
by oxidative stress and the altered activity of MAP kinases (Matos et al., 2008). 
The expression analysis of GLT-1 in the triple transgenic mouse model of AD 
showed that its level is unchanged in the mPFC during the pathogenesis of AD, 
while glutamine synthetase level is significantly reduced. In addition, the 
numerical density of GS positive astrocytes appear to be decreased respect to the 
non-transgenic mice in their early age. This disruption may affect glutamate 
homeostasis resulting in the failure of synaptic connectivity therefore to cognitive 
decline (Kulijewicz-Nawrot et al., 2013). 
Both in vitro and in vivo amyloidosis models demonstrated alterations also in 
astrocytic calcium homeostasis (Vincent et al., 2010). The treatment of co-culture 
of rat astrocytes and neurons with A seems to stimulate an increase in the 
intracellular Ca2+ signal in astrocytes, but not in neurons. The Ca2+ signal 
disruption induces a transient depolarization in mitochondria accompanied by a 
slow collapse of potential that leads to oxidative damage due to the activation of 
NADPH oxidase and the depletion of glutathione. Neurons depend on astrocytes 
for antioxidant support, thus this mechanism brings to neuronal death (Abramov 
et al., 2003, 2004). A study on cultured rat astrocytes demonstrated that the 
transient rise of intracellular [Ca2+], stimulated by A, probably derive from 
intracellular Ca2+ stores and it is intensified by a reduced extracellular [Ca2+], 
which bring to the hypothesis of involvement of receptors that sense extracellular 
Ca2+ (Stix and Reiser, 1998). On the other side, Aβ reversibly interrupts 
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intracellular [Ca2+] oscillations induced by P2 receptors (Stix, 1998). In vitro rat 
astrocytes exposure to A alters also intercellular calcium waves, which travel 
faster, further and with a higher amplitude, furthermore, the astrocytic 
propagation of intercellular calcium signals specifically induced by A apparently 
requires the opening of gap junctions between astrocytes and the release of ATP 
(Haughey and Mattson, 2003). In vivo multiphoton imaging analysis on mice 
expressing mutated APP and PS1 proteins showed a global increase of resting 
calcium waves and more frequent and synchronized calcium transients in 
astrocytes, also rare intercellular calcium waves between astrocytes were observed 
(Kuchibhotla et al., 2009). Finally, a two-photon imaging study on different 
mouse models of AD revealed an increase in spontaneous astrocytic Ca2+ 
signaling in reactive astrocytes associated with instability of the vasculature tone 
in the early stages of disease (Takano et al., 2007). 
The rapid effect of A in the induction of calcium signaling alterations support 
the hypothesis that astrocytes may be involved in the early stages of pathogenesis 
of AD. 
1.6.3. Astrocytic morphological and numerical alterations in ageing and 
Alzheimer’s disease mouse models 
During the last decade several morphometric studies have tried to elucidate the 
astrocytic modifications related with normal ageing and Alzheimer’s disease. 
These studies revealed a complex morphological reaction of astrocytes to age-
dependent cognitive decline and AD pathogenesis that appears as concomitant 
gliosis and atrophy with a specific regional pattern. 
Astrocytic morphological analyses have been performed by labelling the cells 
with specific astrocytic markers, which are the glial fibrillary acidic protein 
(GFAP), glutamine synthetase (GS) and S100β.  
GFAP is a type III intermediate filament protein and it is mainly expressed in 
reactive astrocyte (Eng et al., 1971, 2000). Glutamine synthetase is an enzyme 
that catalyzes the condensation of glutamate and ammonia into glutamine 
allowing neurotransmitter recycling and ammonia detoxification (Albrecht et al., 
2010; Rose et al., 2013). S100β is a calcium-binding protein with neurotrophic 
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functions at low nanomolar concentrations and inflammatory and neurotoxic 
effects at higher micromolar concentrations (Yardan et al., 2011). 
The characterization of these markers in SV129/C57BL6 mice 24 months old 
demonstrated a structural atrophy of the EC, where the surface area, cell volume 
and body volume of GFAP-positive cells are reduced respect to 3 months old 
mice, even though GS-positive cells don’t show any change while the profiles of 
S100β consistently increase. Conversely, the hippocampus showed different 
alterations, GFAP-positive astrocytes appear hypertrophic, whereas GS profiles 
decrease in both DG and CA1. S100β-positive cells showed a moderate increase 
in DG and no differences in CA1 (Rodríguez et al., 2014).  
GFAP- and GS-positive profiles were analyzed in the EC, hippocampal formation 
and mPFC of 3xTg-AD mice and their correspondent non-transgenic mice 
(Olabarria et al., 2010, 2011, Yeh et al., 2011, 2013, Kulijewicz-Nawrot et al., 
2012, 2013). 
In the EC, GFAP-IR astrocytes of 3xTg-AD animals showed a morphological 
atrophy with a significant decrease in the total surface and volume and in the 
somata volume from 1 months of age, this reduction was sustained through all 
ages analyzed, however, from 9 months of age onwards the difference between 
the transgenic animals and their control became almost null because of the parallel 
age effect in the normal mice. The early changes were more pronounced in the 
superficial layers, while the alterations at 12 months were evident only in the 
deeper layer VI. Post-mortem studies revealed astrocytic gliosis only in the 
intralaminar astrocytes, while the interlaminar astrocytes appeared to be disrupted. 
In this AD mouse model neither A depositions and senile plaques triggered 
astrogliosis in any layer of the entorhinal cortex. This might be considered as an 
incapability of EC astrocytes to react to the pathogenesis and support the neurons, 
hence it may provide an explanation for the vulnerability of the EC. The GFAP-IR 
cells numerical density was unaltered in all layers at all ages investigated, neither 
ageing nor Alzheimer disease triggers cell loss (Yeh et al., 2011). The total 
expression of GS and the number of GS-IR positive cells were found to be 
constant between 3xTg-AD animals and their non-transgenic counterpart from 1 
to 12 months of age. GS/GFAP-IR morphologic analysis demonstrated that these 
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cells, despite having GFAP atrophy, are not affected in the intracellular 
distribution of GS (Yeh et al., 2013). 
In the mPFC, the analysis of GFAP-positive profiles of the 3xTg-AD mouse 
model showed a significant decrease in their cytoskeletal surface area and volume 
respect to the non-transgenic mice. This reduction was already evident at 3 
months of age in the pre-symptomatic and pre-pathological stage and was 
sustained until 18 months of age. A intracellular accumulation starts to occur in 
the mPFC of the 3xTg-AD mice at about 6 months of age and increases with 
disease progression, however extracellular plaques appear only at 18 month of 
age. These neuropathological alterations were not associated with the presence of 
GFAP positive astrocytes. 
The total number of GFAP-positive astrocytes was constant at every age and 
didn’t show any difference between the 3xTg-AD mice and the control group 
(Kulijewicz-Nawrot et al., 2012).  
GS-positive cells number as well as their cell bodies surface areas were decreased 
in the 3xTg-AD animals respect to their non-transgenic counterpart. The 
numerical density was significantly lower in the 3xTg-AD animals from already 1 
month until 12 months of age, when the GS-positive astrocytes number started to 
decrease also in the control animals, reaching the same level of the transgenic 
mice (Kulijewicz-Nawrot et al., 2013). 
In the hippocampus, GFAP-IR astrocytes of 3xTg-AD mice show both atrophic 
and gliotic morphology associated to different hippocampal subfields and to A 
plaques. In general, there is a significant reduction in the cell surface and volume 
and in somata volume in the DG at the early stage of the disease, beginning at 6 
months of age and persisting and worsening until 18 months, whereas in the CA1 
these atrophic profiles are evident only at 18 months of age. At 12 months of age, 
Aβ plaques start to accumulate in the hippocampus of the 3xTg-AD animals 
affecting mainly the CA1, the DG starts to exhibit A plaques at 18 months of 
age. These plaques are surrounded by hypertrophic GFAP-positive astrocytes 
which associate also with A loaded blood vessels. To sum up, while atrophic 
GFAP-IR astrocytes appear at early stages of the pathology, the astrogliotic 
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astrocytes are exclusively associated with the A plaques and are detectable only 
in the middle-late stages of the disease (from 12 months onwards, Fig. 1.6). 
The numerical density of the GFAP-IR astrocytes doesn’t change in both DG and 
CA1 of 3xTG-AD animals respect to the non-transgenic and it is constant at all 
ages (Rodríguez et al., 2009a; Olabarria et al., 2010).   
The hippocampus of 3xTg-AD mice showed alterations in the GS astrocytic 
expression and numerical density respect to the normal controls. The GS-IR 
astrocytes number started to decrease in the DG at 12 months and by 18 months 
both DG and CA1 showed a reduced numerical density. In parallel, GS expression 
showed a significant decrease with no regional differences at 18 months of age. 
GS-IR cells drop in CA1 area is more patent in the vicinity of neuritic plaques, 
demonstrating an association of GS-IR cell number with A deposit (Olabarria et 
al., 2011). 
66 
 
 
 
Fig. 1.6 Drawing representing the astrocytic hypothesis of AD. At early stages of AD, 
astrocytes are atrophic and unable to properly carry out their functions, inducing brain damage. At 
advanced stages of AD astrocytes associated to Aβ-plaques become reactive and hypertrophic, 
triggering an inflammatory condition in the brain (adapted from Verkhratsky et al., 2010; 
Rodríguez-Arellano et al., 2015).   
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Aim of the Thesis 
 
 
The aim of this PhD thesis has been to characterize, through an in vivo 
immunohistochemical approach, different aspects of AD pathology in the 
hippocampus and entorhinal cortex of the 3xTg-AD mouse model, which are the 
memory-related areas early affected in the onset and progression of AD.  
Considering the complexity of AD pathology and the enormous lack of 
knowledge that we still have regarding its cause and development it is necessary 
to perform extensive studies to characterize also the non-classical pathological 
mechanisms, which might have a key role for finding new and more efficient 
therapies. Therefore, in this work I have reported the immunohistochemical 
analysis of the hippocampal expression of the CaSR and the calcium binding 
proteins PV and CR, and the numerical density and morphometric profiles of 
S100β-positive astrocytes in the entorhinal cortex of 3xTg-AD mice.  
In chapter 3, I aimed to study the alterations of expression of the CaSR in the 
hippocampal subfields affected during the stages of onset and progression of AD 
main hallmarks which correspond to 9, 12 and 18 months of age in the 3xTg-AD 
mice. This part of the thesis was thought to demonstrate the involvement of CaSR 
in the increase of Aβ production and plaques deposition, since previous in vitro 
experiments have demonstrated that the CaSR is directly activated by Aβ 
oligomers with a consequent increase of Aβ peptides production and secretion and 
the rise of CaSR expression itself. 
The target of chapter 4 was to elucidate the involvement of PV- and CR-positive 
interneurons in AD by means of an analysis of their expression level and 
numerical density in the hippocampus of the 3xTg-AD mice. This is the first study 
of this kind in this mouse model, which is the animal model that better resemble 
the human pathological hallmarks of AD whose characterization is necessary to 
get a clear idea of its neuronal networks alterations to allow its application in the 
evaluation of new drugs.  
Lastly, in chapter 5, a numerical and morphometric characterization of astrocytes 
positive for S100β protein has been done with the aim of examining astrocytic 
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alterations in the onset and progression of AD. This part of the research had the 
purpose of clarifying how different subpopulations of astrocytes react and 
remodel during ageing and AD depending on the region affected and the stage of 
the disease. This research work had also the aim to demonstrate the correlation of 
an astroglial dysfunction with AD origin and development. 
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Chapter 2 
 
Materials and Methods 
 
2.1. Animal model 
Chapters 3, 4 and 5 
 
All animal procedures were carried out in accordance with the United Kingdom 
Animals (Scientific Procedures) Act of 1986 under the license of the Home 
Office. All efforts were made to reduce the number of animals by following the 
3R’s. 
The 3xTg-AD mice were generated at the Transgenic Mouse Facility at the 
University of California, Irvine and are derived from 129/C57/BL6 hybrid, with 
APPSwe, PS1M146V and TauP301L mutations (Oddo et al., 2003a, 2003b; Billings et 
al., 2005; Rodríguez et al., 2008, 2009b). The 3xTg-AD mice progressively 
develop Aβ plaques and neurofibrillary tangles, with a temporal and regional 
pattern that closely mimics their development in the human AD brain. In this AD 
model, Aβ pathology precedes typical indications of tau pathology such as 
conformational or hyperphosphorylation changes in the tau protein in accord with 
the amyloid cascade hypothesis.  
The non Tg mice were from the same strain with same genetic background. Mice 
were grouped by gender and genotype and housed under controlled temperature 
with a light–dark cycle of 12:12 h having ad libitum access to food and water. 
 
2.2. Animal perfusion 
Chapters 3, 4 and 5 
 
As described previously (Olabarria et al., 2010; Kulijewicz-Nawrot et al., 2012), 
3xTg-AD and non Tg control mice of different age groups were intraperitoneally 
anesthetized with sodium pentobarbital (50 mg/kg). Mice were trans-cardially 
perfused with 4 % paraformaldehyde (PFA, Sigma, UK) and 0.1 M phosphate 
buffer (PB) at pH 7.4. Brains were removed and post-fixed in 4% 
paraformaldehyde overnight, then they were transferred in 0.1 M PB and cut into 
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4 - 5 mm coronal slabs of tissue containing the entire rostro-caudal extent of the 
hippocampus and entorhinal cortex, according to the mouse brain atlas of Paxinos 
and Franklin (2001). The tissues were transferred in a cryo-protectant solution 
containing 25% sucrose and 3.5% glycerol in 0.05 M PB at pH 7.4 and stored at -
20°C. For the immunohistochemistry the tissues were further sectioned in 40-50 
µm-thick slices with a vibrating microtome (VT1000S, Leica, Milton Keynes, 
UK). Free floating sections were collected in 0.1 M PB and stored in the cryo-
protectant solution if not used immediately.  
 
2.3. Antibodies 
Chapters 3, 4 and 5 
 
A mouse monoclonal anti-Calcium Sensing Receptor antibody (anti-CaSR; 
Sigma-Aldrich, UK; C0493) was used for the determination of CaSR expression 
throughout the dorsal hippocampus. For the identification of intracellular β-
amyloid deposits and plaques it was used a monoclonal mouse antibody that 
reacts with abnormally processed isoforms, as well as precursor forms of Aβ, 
recognizing an epitope within amino acids 3–8 (EFRHDS; anti-Aβ 6E10 [SIG-
39320] Signet Laboratories, Dedham, MA), for hyperphosphorylated tau it was 
used the mouse monoclonal antibody anti-PHF tau AT8 (Innogenetics, Gent, 
Belgium). For double immunostaining of CaSR with GFAP and Aβ, a rabbit anti-
GFAP (Sigma-Aldrich, UK; G9269) and a mouse anti-Aβ Alexa 488 6E10 
conjugated antibody (Covance, USA) were used. 
For the OD measurement and cell counting of PV and CR neurons, a mouse 
monoclonal anti-parvalbumin antibody (Swant) and a rabbit polyclonal anti-
calretinin antibody (Swant) were used. 
For the astrocytes labelling in the entorhinal cortex a mouse monoclonal anti-GS 
antibody (clone GS6, Millipore), a rabbit polyclonal anti-GFAP antibody (Sigma-
Aldrich, UK; G9269) and a rabbit polyclonal anti-S100β antibody (DAKO, 
Z0311) were used. 
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Antigen Host Type Diluition Source Reference
CaSR mouse monoclonal 1:250 Sigma-Aldrich, UK; 
C0493
Aβ 6E10 mouse monoclonal 1:1000 Covance, USA; SIG-
39320
Oddo et al., 2003a
Aβ 6E10 
Alexa488
mouse monoclonal 1:1000 Covance, USA; SIG-
39347
Olabarria et al., 2011
PHF-tau mouse monoclonal 1:1000 Innogenetics; AT8 Oddo et al., 2003a 
Rodríguez et al., 2008
Parvalbumin mouse monoclonal 1:2000 Swant
Calretinin rabbit polyclonal 1:2000 Swant
GFAP rabbit polyclonal 1:20000 Sigma-Aldrich, UK; 
G9269
Olabarria et al., 2010 
Yeh et al., 2011
GS mouse monoclonal 1:2000 Millipore, MAB301 Olabarria et al., 2011 
Yeh et al., 2013
S100β rabbit polyclonal 1:5000 DAKO, Z0311 Rodríguez et al., 2014
 
Table 2.1 Summary of the primary antibodies used in this research work and their details. 
 
 
Secondary Antibody Diluition Source Reference
Biotinylated goat anti-mouse 1:400 Vector Laboratories
Olabarria et al., 2010      
Yeh et al., 2013
Biotinylated goat anti-rabbit 1:400 Vector Laboratories
Olabarria et al., 2010      
Yeh et al., 2011
Alexa595 goat anti-mouse 1:200 Invitrogen; A11005 Olabarria et al., 2010
Alexa488 goat anti-rabbit 1:200 Invitrogen; A11008 Noristani et al., 2011
 
 
Table 2.2 Summary of the secondary antibodies used in this research work and their details. 
 
 
2.4. Immunohistochemistry 
Chapters 3, 4 and 5 
 
A minimum of three coronal sections at levels -1.58 mm/-2.46 mm (dorsal 
hippocampus, chapters 3 and 4) or -2.92/-3.88 mm (lateral entorhinal cortex, 
chapter 5) posterior to Bregma, were selected from each animal for 
immunohistochemistry according to the mouse brain atlas of Paxinos and Franklin 
(2004). The immunohistochemistry was done following this procedure: 
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1st part: 
- To block endogenous peroxidase, the sections were incubated for 30 
minutes in 30% methanol in 0.1M PB with 3% H2O2. 
- Sections were rinsed with 0.1M PB for 5 minutes. 
- To block aldehydes coming from the fixative that could cause 
autofluorescence and to help antigen retrieval, the sections were placed in 
1% sodium borohydride in 0.1M phosphate buffer (PB) for 30 minutes, 
that was squirted over tissue during incubation.  
- Sections were rinsed copiously with PB until no bubbles remain. 
- Tissue was rinsed in 0.1M tris saline buffer (TS, 0.9% NaCl) 2 X 5 
minutes. 
- The sections were incubated in blocking solution (0.5% BSA and 0.25% 
Triton in 0.1M TS) for 30 min. 
- Primary antibody was diluted at the proper concentration in 0.1% BSA and 
0.25% Triton in 0.1M TS, for dual immunofluorescence a cocktail of the 
primary antibodies was prepared.  
- Slices were transferred with a brush from crucibles to vials and they were 
incubated capped and shaking for the necessary time (from 24 to 72 hours) 
at room temperature. 
 
2nd part: 
- Slices were transferred back to crucibles and rinsed in 0.1M TS 2 X 15 
minutes. 
 
Peroxidase reaction (chapters 3, 4) 
- Biotinylated secondary antibody was diluted in 0.1% BSA and 0.25% 
Triton in 0.1M TS in capped vials. Tissue was transferred to vials as 
previously and incubated shaking at room temperature for 1hr. 
- During incubation, avidin-biotin peroxidase complex (ABC) solution was 
prepared by adding 2 drops of solution A and 2 drops of solution B for 
every 10 ml of antibody diluent (0.1% BSA and 0.25% Triton in 0.1M TS) 
and immediately vortexed. Then the solution was allowed to stand for 30 
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minutes prior to use (VECTASTAIN Elite ABC HRP Kit, PK-6100, 
Vector Laboratories, USA). 
- Sections were rinsed in 0.1M TS 2 X 15 minutes. 
- The sections were transferred to new vials containing the ABC solution 
and incubated for 30 minutes. 
- The sections were transferred back to crucibles and rinsed in 0.1M TS 
twice for 15 minutes. 
- During the washes the DAB solution was prepared by adding 22 mg of 
3,3’ diaminobenzidine for every 100 millilitres of 0.1M TS whilst stirring. 
Just prior to use, 10 l of 30% H2O2 were added per every 100 millilitres.   
- Following rinses, tissues were incubated in DAB, time depending on 
reaction strength or previous experiment, squirting solution over the tissue. 
- Sections were rinsed in 0.1 M TS 3 times per 2 minutes to stop the 
reaction, then 3 times per 5 minutes in 0.1 M PB. 
- For light level examination of peroxidase reaction, the sections were 
mounted onto gelatinised slides and allowed to dry overnight. 
- Sections were dehydrated by using increasing concentrations of ethanol, 
from 50% to 100%, finally into xylene. 
- Coverslips were applied by using Entellan, air bubbles were removed and 
the slides were dried at least overnight. 
 
Immunofluorescence (chapters 3, 5) 
- Secondary antibodies for fluorescence were prepared in capped vials, 
diluted in 0.1% BSA and 0.25% Triton in 0.1M TS. Tissues were 
transferred to vials as previously and incubated shaking at room 
temperature for 1 hour. 
- Sections were transferred back to crucibles and rinsed in 0.1M TS twice 
per 15 minutes. 
- For dual immunofluorescence the sections were sequentially incubated in 
the 2nd secondary antibody shaking at room temperature for 1 hour. 
- Sections were washed in 0.1M TS twice per 15 minutes, then in 0.1M PB 
3 times per 5 minutes.  
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- Finally, they were mounted onto gelatinised slides, coverslipped using 
VECTASHIELD Antifade Mounting Medium (H-1000, Vector 
Laboratories, USA) and closed with nail polish. 
2.5. Optical density measurement 
Chapter 3 and 4 
 
To perform the optical density measurement all images needed to be taken using 
standardized settings. A Nikon Eclipse 80i microscope coupled with an 8001 
MicroFIRE camera was used equipped with the grey filters ND8 and ND32 and 
the blue filter NCB11. To exclude any experimental errors and/or bias, all images 
were taken at constant light intensity, with the same optical filters and at a 
magnification of 4X that permits to obtain a picture of the entire dorsal 
hippocampus. The software used for photomicrographs acquisitions is 
Neurolucida (MBF Bioscience).  
The expression of CaSR, PV and CR was analysed by measuring their OD, as 
described by (Cordero et al., 2005; Noristani et al., 2010, 2012) using a computer-
assisted imaging analysis software (ImageJ 2.0.0-rc-39/1.50b; NIH, USA).  
In more detail this procedure was followed: 
- Each picture was converted to 8-bit grayscale whose scale of intensity rank 
from 0 to 250, with a measurement of 250 corresponding to the area with very 
low expression of the target protein and 0 corresponding to the area with 
highest labelling. 
The commands are: Image > Type > 8-bit 
- Each layer of CA subfields (stratum pyramidale, stratum oriens, stratum 
radiatum, and stratum lacunosum-moleculare, including stratum lucidum for 
CA3) and of dentate gyrus (DG; granular cell layer, molecular layer, and 
hilus) was outlined using the polygon selection tool (Fig. 1.7), then area and 
mean grey values were measured through these commands: 
1. Analyse > Set Measurements > tick Area and Mean Grey Value 
2. Analyse > Measure > a windows opens with the measurements 
The measurements were selected and copied into an excel sheet. 
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- The changes in the target proteins immunoreactivity were analysed against a 
constant control region that was established to be the Corpus Callosum (CC). 
250 was divided by the intensity value of the control region and the obtained 
factor was multiplied by the region of interest in every given section. Inverse 
Optical Density (IOD) was obtained by subtracting the OD (after the control 
region normalisation) from 250. Values of IOD were taken and averaged in 
both the left and right hemisphere of each slice. The results are shown as 
Inverse Optical Density (IOD ⁄ pixel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1: Schematic representation of mouse dorsal hippocampus selection for OD analysis. 
(A) Representative drawing of the Bregma level of dorsal hippocampus used for analysis in 
chapter 3 and 4, adapted from Paxinos and Franklin, 2001. (B) Representative picture of a section 
of dorsal hippocampus stained with anti-CaSR antibody (Gardenal E. personal unpublished 
image). (C) Example of grayscale conversion and of the layers outlining conducted to analyse the 
OD in the immunolabelled sections in chapter 3 and 4. 
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2.6. Cell counting 
Chapters 4 and 5 
 
To determine the numerical density (Nv, number/mm3) of immunolabelled cells in 
the dorsal hippocampus of 3xTg-AD mice respect to non Tg mice, 2 
representative sections at the level -1.58/-2.46 mm posterior to Bregma were 
chosen and both hemispheres were used for the counting. To keep the counting 
bias to a minimum the counting was performed by two different observers and the 
mean of the two measurements was calculated. The counting was performed on 
each layer of the hippocampus in pictures taken at 4X magnification and using the 
software ImageJ with the following procedure: the area in mm2 of each layer 
(region of interest) was determined after having outlined the perimeter of each 
layer, the area was then multiplied by the thickness of the section to obtain the 
volume of the layer measured in every specific section. Finally, the counted cell 
number was divided by the volume of the region of interest providing the Nv of 
every hemisphere analysed, the final Nv value was given by calculating the mean 
of all the hemispheres that were measured.  
For the determination of the Nv of S100β-, GFAP- and GS-positive astrocytes in 
the entorhinal cortex, confocal z-stacks at 20X magnification were acquired in 
each hemisphere of three non-consecutive coronal sections at the level -2.92/-3.88 
mm posterior to Bregma (lateral entorhinal cortex). Next, through the Leica 
software “LAS AF Lite” the acquisitions were converted into tiff pictures and by 
means of the software ImageJ each tiff z-stack was condensed into one picture 
with the command “max projections”. Then the procedure to calculate the Nv was 
the same as the neuron counting in mouse hippocampus: the area of the region of 
interest was measured in mm2 and multiplied by the thickness of the section (20 
µm) the number of cells counted in each picture was divided by the volume in 
mm3 of the field analysed. The mean of the counting of all the sections per each 
animal was calculated. 
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2.7. Morphometric analysis 
Chapter 5 
 
S100β-, GFAP- and GS-immunopositive astrocytes from the entorhinal cortex of 
both 3xTg-AD and non-transgenic animals were imaged using a  Leica TCS 
STED CW SP8  microscope and a Leica 63X oil-immersion objective. Thirty to 
thirty-five astrocytes were acquired from 3 different slices from each animal. In 
relation to Aβ plaques, all cells with somata within 50 µm of distance from the 
plaque border were considered as plaque-associated astrocytes, while cells with 
somata positioned more far than 50 µm from the plaques were considered as not 
associated. 
Each astrocyte was sectioned along the vertical axis (z) into a uniformly spaced 
(0.3 µm) set of two-dimensional parallel confocal planes, resulting in a stack of 
70-90 consecutive images, each of which of 1024 x 1024 pixels in size. 
Image processing and morphometric measurements were performed with the 
program CellAnalyst (Chvátal et al., 2007; Kulijewicz-Nawrot et al., 2012; 
Rodríguez et al., 2014). To improve the images, a series of digital filters based on 
convolution kernels were used: average 3 X 3, convolution and gauss 5 X 5; the 
filtering was then completed through the steps of despeckle and simple objects 
removal. Finally, to remove the background a threshold of 50, in a greyscale of 0-
255, was applied. To perform the morphometric measurements, the related xyz 
values for each z-stack were given to the software. Cell volumes and somata 
volumes were calculated from a marked region of interest (ROI) using the 
Cavalieri method. The unit areas of each confocal plane represented by pixels 
were recalculated to real values in square micrometres, summed up and multiplied 
by the distance between two consecutive plans according to this equation: 
 
where V is the cell volume, T is the distance between sections, U is the unit area, 
and n is the number of sections. 
Cell surfaces were determined by using the isocontouring or isointensity 
contouring method with this equation: 
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where S is the cell surface area, K is the length of the isovalue edge, T is the 
distance between sections, U is the unit area, and n is the number of sections. 
Changes in the complexity of the cells were determined by calculating the 
surface/volume ratio using this equation: 
  
A sphere is the object with the lowest complexity and lowest S/V ratio, the more 
protrusions a cell has, the higher is the complexity. 
2.8. Statistics 
All chapters 
 
The statistical analysis was performed using the software GraphPad Prism 
(GraphPad, La Jolla, CA, USA). 
To examine the differences in CaSR expression between the 3xTg-AD and non-
transgenic animals considering the ageing of the mice from 9 months to 18 
months of age a one-way Analysis Of Variance (ANOVA) with a post-hoc Tukey 
test was performed. The changes in CaSR expression at single time points were 
analysed using an unpaired t-test. 
Calcium binding proteins changes of expression and Nv in 3xTg-AD respect to 
control animals were analysed with an unpaired t-test or Mann-Whitney test. 
The morphological and numerical changes of S100β-positive astrocytes in 3xTg-
AD mice compared to non-transgenic mice, as well as the differences in 
relationship with β-amyloid plaques were analysed through ANOVA or unpaired 
t-test. Difference among genotype and age groups were further analysed with a 
post hoc Bonferroni test. 
Significance of results was accepted at p<0.05. 
All data are expressed as means ± standard error of the mean (S.E.M.). 
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Chapter 3 
 
Calcium-Sensing Receptor Immunoreactivity is increased 
in the Hippocampus of the 3xTg-AD mouse model 
Gardenal E, Chiarini A, Armato U, Dal Prà I, Verkhratsky A and Rodríguez JJ (2017) Increased 
Calcium-Sensing Receptor Immunoreactivity in the Hippocampus of a Triple Transgenic Mouse 
Model of Alzheimer’s Disease Front. Neurosci. 11:81.  
 
CaSR expression was analysed in all hippocampal layers of the 3xTg-AD mice 
and the respective non Tg animals at 9, 12 and 18 months of age. 
The immunohistochemical labelling demonstrated that CaSR is present in the 
hippocampus of both 3xTg-AD and non Tg control animals at all ages with a 
rather homogeneous distribution throughout all hippocampal areas (Fig. 3.1 A and 
B). Punctate CaSR labelling is mainly present in pyramidal neurones of the 
different CA subfields and in granule cells of the DG as well as in the 
pleomorphic cells of the hilus, being more evident in the soma, nucleus excluded, 
although it is also detectable in the neuropil, including both dendrites and axons 
(Fig. 3.1 C-F). CaSR expression in astrocytes was rather rare and when detected 
was of very low intensity respect to neurons; appearing as puncta mainly 
restricted to the astrocytic soma (Fig. 3.1 K-P). 
3.1 CaSR expression is increased in 3xTg-AD animals  
Optical density analysis of CaSR staining in the hippocampus of the 3xTg-AD 
mice showed a significant increase in its expression in CA1 and DG subfields 
(F7,166=11.32, p < 0,0001 and F7,166=7.994, p < 0,0001, respectively) at all ages (9, 
12 and 18 months; Fig.  3.1, 3.2 and 3.3; Table 3.1). An increase in CaSR optical 
density of 23.44%, 17.62% and 20.09% at 9, 12 and 18 months of age 
respectively when compared to control non Tg animals was detected in CA1 area 
(Fig. 3.1 C and D; Fig. 3.2 A; Table 3.1). Similar increase in CaSR optical density 
was observed in DG: 17.82%, 14.74% and 20.74%, at 9, 12 and 18 months 
respectively in 3xTg-AD animals compared to non Tg (Fig. 3.1 E and F; Fig. 3.3A 
and Table 3.1).    
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Figure 3.1 CaSR expression and localization in mouse hippocampus. Brightfield micrographs 
showing the distribution of CaSR-IR within the dorsal hippocampus of 18 months old Non Tg 
controls (A, C, G, E and I) and 3xTg-AD mice (B, D, F, H and J; arrowheads show neuropil 
elements, whilst full arrows indicate interneurons). Confocal micrographs showing the rare 
expression of CaSR (red) in GFAP-positive astrocytes (green), in both Non Tg (K, L, M) and 
3xTg-AD mice (N, O, P). High magnification inserts are shown in the K, L and M panels. Scale 
bars: 250 µm (A and B); 100 µm (C-F); 20 µm (G-J and K-P). CA1, Cornu Ammonis 1; DG, 
Dentate Gyrus; St Rad, Stratum Radiatum; St Lac, Stratum Lacunosum-Moleculare; Mol L, 
Molecular Layer; GCL, Granular Cell Layer. 
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Figure 3.2 Changes of CaSR 
expression in hippocampal CA1. 
Bar graphs illustrating CaSR-IR 
IOD within CA1 subfield of 
hippocampus between Non Tg 
controls and 3xTg-AD mice at 9, 12 
and 18 months of age (Ns for non Tg 
= 5, 5, 4; ns for 3xTg-AD = 4, 5, 3, 
respectively; 3 slices have been 
analysed per each animal). (A) Total 
CA1, (B) CA1 Pyramidal Cell 
Layer, (C) CA1 Stratum Radiatum, 
(D) CA1 Stratum Lacunosum-
Moleculare. Bars represent means ± 
SEM (* p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
No significant alterations in the optical density of CaSR were identified in the 
CA2 and in CA3 sub-fields. 
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Hipp area Age CaSR IOD p-value t
CA1 9 months non Tg 82.71 ± 2.98
9 month 3xTg-AD 102.1 ± 2.72 < 0.0001 *** 4.474
12 months non Tg 83.92 ± 2.51
12 months 3xTg-AD 98.71 ± 2.56 0.0002 *** 4.117
18 months non Tg 93.51 ± 3.39
18 months 3xTg-AD 112.30 ± 4.68 0.0022 ** 3.342
DG 9 months non Tg 82.68 ± 3.11
9 month 3xTg-AD 97.41 ± 3.56 0.0039 ** 3.051
12 months non Tg 81.35 ± 3.33
12 months 3xTg-AD 93.34 ± 2.80  0.0079 ** 2.773
18 months non Tg 89.78 ± 4.75
18 months 3xTg-AD 108.40 ± 4.96 0.0119 * 2.676  
Table 3.1 CaSR IOD values of the hippocampal CA1 and DG subfields in both non Tg and 
3xTg-AD mice at 9, 12 and 18 months of age. Values are expressed as means ± SEM (* p ≤ 0.05, 
** p ≤ 0.01, *** p ≤ 0.001). 
3.2 The increase of CaSR expression in CA1 and DG is layer-specific 
The increase of CaSR expression in the CA1 area of 3xTg-AD animals mainly 
occurred in the pyramidal cell layer (PCL) (10.68% at 9 months, 2.28% at 12 
months and 20.17% at 18 months; Fig. 3.2 B; Table 3.2), in the stratum radiatum 
(St Rad) (12.93% at 9 months, 27.71% at 12 months, 14.55% at 18 months; Fig. 
3.2 C; Table 3.2) and in the stratum lacunosum moleculare (St Lac Mol) (93.19% 
at 9 months, 39.58% at 12 months, 56.08% at 18 months; Fig. 3.1 G and H; Fig. 
3.2 D; Table 3.2).  
CaSR expression increase in the DG was most prominent in the molecular layer 
(Mol L) of 3xTg-AD animals in respect to their controls (15.90% at 9 months, 
12.32% at 12 months, 20.98%, at 18 months; Fig. 3.3 B; Table 3.3) and in the 
granular cell layer (GCL) (19.33% at 9 months, 10.68% at 12 months, 37.38% at 
18 months; Fig. 3.1 I and J; Fig. 3.3 C; Table 3.3). The increase in the molecular 
layer was similar in all subdivisions; the inner, middle and outer molecular layers 
(data not shown).  
CaSR hyperexpression in the projections layers above described doesn’t appear to 
derive from neuronal somata, despite its presence in some interneurons cell 
bodies, but mainly from the neuropil comprising both dendrites and axons (Fig. 
3.1 D and F). 
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CA1 Layer Age CaSR IOD p-value t
PCL 9 months non Tg 115.20 ± 3.78
9 month 3xTg-AD 127.50 ± 3.80 0.0351 * 2.177
12 months non Tg 114.00 ± 2.49
12 months 3xTg-AD 116.60 ± 2.39 ns 0.7488
18 months non Tg 108.60 ± 4.57
18 months 3xTg-AD 130.50 ± 3.40 0.001 ** 3.659
St Rad 9 months non Tg 74.23 ± 2.91
9 month 3xTg-AD 83.83 ± 3.60 0.0451 * 2.066
12 months non Tg 75.08 ± 2.85
12 months 3xTg-AD 91.38 ± 2.75 0.0002 *** 4.112
18 months non Tg 91.23 ± 3.31
18 months 3xTg-AD 104.5 ± 5.99 0.0489 * 2.053
St Lac Mol 9 months non Tg 53.78 ± 2.60
9 month 3xTg-AD 103.9 ± 3.33 < 0.0001 *** 11.92
12 months non Tg 59.53 ± 2.71
12 months 3xTg-AD 83.09 ± 4.41 < 0.0001 *** 4.46
18 months non Tg 66.25 ± 5.31
18 months 3xTg-AD 103.4 ± 6.25 < 0.0001 *** 4.552  
 
Table 3.2 CaSR IOD values of the hippocampal CA1 layers with statistical significance 
between non Tg and 3xTg-AD mice at 9, 12 and 18 months of age. Values are expressed as 
means ± SEM (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). 
 
DG Layer Age CaSR IOD p-value t
Mol L 9 months non Tg 73.06 ± 3.16
9 month 3xTg-AD 84.68 ± 4.88 0.0424 * 2.094
12 months non Tg 80.58 ± 4.18
12 months 3xTg-AD 90.51 ± 3.01 0.0547 * 1.953
18 months non Tg 90.00 ± 4.11
18 months 3xTg-AD 108.8 ± 6.91 0.0203 * 2.45
GCL 9 months non Tg 98.30 ± 3.55
9 month 3xTg-AD 117.30 ± 4.27 0.0016 ** 3.379
12 months non Tg 87.76 ± 3.15
12 months 3xTg-AD 97.13 ± 2.78 0.0298 * 2.239
18 months non Tg 82.18 ± 6.16
18 months 3xTg-AD 112.90 ± 3.54 0.0004 *** 4.001  
Table 3.3 CaSR IOD values of the hippocampal DG layers with statistical significance 
between non Tg and 3xTg-AD mice at 9, 12 and 18 months of age. Values are expressed as 
means ± SEM (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). 
 
 
 
 
84 
 
 
Figure 3.3 Modification of CaSR 
expression in hippocampal DG. Bar 
graphs illustrating CaSR-IR IOD 
within DG subfield between Non Tg 
controls and 3xTg-AD mice at 9, 12 
and 18 months of age (Ns for non Tg 
= 5, 5, 4; ns for 3xTg-AD = 4, 5, 3, 
respectively; 3 slices have been 
analysed per each animal). (A) Total 
DG; (B) Molecular Layer; (C) 
Granular Cell Layer. Bars represent 
means ± SEM (* p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 CaSR increase in hippocampus occurs in the same areas affected by β-
amyloid accumulation 
The increase of CaSR immunoreactivity in the CA1 region follows the same 
spatio-temporal pattern as that of β-amyloid deposition (Fig. 3.4 A-F), while in 
the DG it starts even before the accumulation of A becomes evident. Indeed, 
intracellular Aβ appears in hippocampal neurones of 3xTg-AD mice between 4 
and 6 months of age and reaches its maximum at 9 months of age (Fig. 3.4 G and 
H); extracellular Aβ depositions start to mount from 9-12 months, being maximal 
at 18 months. At 18 months the Aβ plaques are big and expanded through the 
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hippocampus mainly concentrating in the CA1 subfield (Fig. 3.4 E, F, I and J); 
with later appearance in the DG (Noristani et al., 2012; Rodríguez et al., 2013). In 
a similar way hyper-phosphorylated tau protein begins to be detectable in 3xTg-
AD mice at 12 months causing the formation of tangles by 18 months, and it is 
also concentrated in CA1 region affecting all the layers (Fig. 3.4 K and L).  
 
Figure 3.4 CaSR and β-amyloid relationship in hippocampus during AD progression. 
Confocal micrographs showing the overlapping expression of CaSR (red) with the accumulation of 
intraneuronal Aβ (green, anti-Aβ 488) and the formation of plaques in hippocampal pyramidal 
neurons of 3xTg-AD mice of 12 and 18 months of age respectively. (A and D) CaSR-IR; (B and 
E) Aβ-IR; (C and F) merge. St Or Stratum Oriens; CA1 PcL CA1 Pyramidal Cell Layer; St Rad 
Stratum Radiatum. Bar graphs illustrating the number of Aβ positive cells within CA1 subfield of 
hippocampus between Non Tg controls (G) and 3xTg-AD mice (H) at 9 months of age (*** p ≤ 
0.001). Brightfield micrographs of CA1 areas of hippocampus of Non Tg and 3xTg-AD mice 
immunolabelled with anti-Aβ (I and J) and anti-tau antibody (K and L) at 12 months of age. St Or, 
Stratum Oriens; CA1 PcL, CA1 Pyramidal Cell Layer; St Rad, Stratum Radiatum; St Lac Mol, 
Stratum Lacunosum Moleculare. 
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3.4 Discussion 
This study in the 3xTg-AD mouse model conceptually complements the results 
previously obtained in vitro by Armato and colleagues (Armato et al., 2013). 
In vitro exposure of human cortical astrocytes and neurons to a truncated form of 
β-amyloid, the Aβ25-35 peptide, which binds and activates the CaSR (Dal Prà et al., 
2014), stimulated the intracellular production and secretion of β-amyloid by both 
cell types with the subsequent death of a fraction of neurons (Armato et al., 2013). 
While neurons were vulnerable to toxic β-amyloid, the cultured astrocytes 
survived and they showed a transient increase of CaSR expression. These 
cytotoxic effects were fully inhibited following addition of CaSR antagonist NPS 
2143 to the incubation media. Indeed, the NPS prevented the death of neurons and 
it deeply and steadily downregulated the receptor in the Aβ-treated astrocytes, and 
besides blocked the Aβ self-induction mechanism completely (Armato et al., 
2013). 
The results described in the present work further corroborate links existing 
between increases in CaSR expression and β-amyloid accumulation. In the 3xTg-
AD mice, intraneuronal β-amyloid starts to accumulate in the CA1 pyramidal 
neurones at 4 to 6 months of age and extracellular β-amyloid deposits emerge 
from 12 months of age, in parallel with a clear and specific astrogliosis around the 
plaques despite the generalized hippocampal astrocytic atrophy and with an 
increase in the density of activated microglia and recruitment of new ramified 
microglial cells (Rodríguez et al., 2009a, 2010, 2013; Olabarria et al., 2010). 
Accumulation of tau that occurs later follows similar pattern. The 3xTg-AD 
mouse model not only develops the typical histopathological hallmarks of 
Alzheimer’s disease, but also manifests synaptic dysfunction with impaired LTP 
(Oddo et al., 2003b; Rodríguez et al., 2008). 
Interestingly, a study of acute hypoxia/ischemia in rats revealed that Aβ 
overproduction due to hypoxic injury is mediated by CaSR hyperexpression (Bai 
et al., 2015). Experiments on rat hippocampal neurons demonstrated that hypoxia 
induces an up-regulation of CaSR which in turn promotes the elevation of 
cytosolic [Ca2+] thereby producing an increase of BACE1 expression that results 
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in the rise of Aβ40 and Aβ42 generation. In addition, specific block of CaSR with 
Calhex 231, an allosteric antagonist of CaSR, induced a decrease of BACE1 and 
Aβ both in vitro and in vivo in hypoxic conditions (Bai et al., 2015). The dramatic 
effect of the increased expression and activity of CaSR in hippocampus is 
confirmed also by another work on a mouse model of acute ischemic injury where 
a transient global cerebral ischemia (TGI) was induced. In this model CaSR was 
overexpressed in parallel with GABABR1 downregulation and was followed by 
neuronal death. The administration of the calcilytic compound NPS89636 through 
intracerebroventricular injections after the TGI specifically blocked the activity of 
CaSR, restored GABABR1 expression and protected hippocampal neurons from 
cell death. Furthermore, the treatment of TGI mice with calcilytics significantly 
improved learning and memory (Kim et al., 2014).  
Altogether these findings reveal the importance and the impact which CaSR’s 
altered expression has on maintaining the normal brain function, supporting the 
idea that its changes could contribute to the development and progression of 
pathologies such as Alzheimer’s disease and stroke. Our present data in an AD 
mouse model show that expression of CaSR is increasing while neuropathology 
progresses. Previous works demonstrated that the administration of A42 
oligomers to neuronal and astrocytic human cell cultures increases the 
endogenous A42 production and secretion resulting in a progressive death of 
neurons. This mechanism of A self-induction, which determine the advance of 
AD, was demonstrated to be completely suppressed by adding a specific calcilytic 
like NPS 2143 to the cell culture (Armato et al., 2013; Dal Prà et al., 2015; 
Chiarini et al., 2016). It needs to be emphasized that the CaSR could be a 
promising target of investigation for not only further understanding AD pathology 
onset and spread but also for evaluating new therapeutic solutions.  
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Chapter 4 
 
Parvalbumin and Calretinin regional changes in the 
hippocampus of the 3xTg-AD mouse model 
Zallo F, Gardenal E, Verkhratsky A, Rodríguez JJ. (2017) Manuscript in preparation  
 
4.1 Parvalbumin optical density and cell numerical density in hippocampal 
CA1 and DG  
Parvalbumin (PV) is homogeneously expressed throughout the hippocampal 
Cornu Ammonis of the non-transgenic 18 months old mice. In this area a strong 
positivity is present in the soma of interneurons as well as in their processes; the 
positive interneurons appear highly ramified and with numerous axonal 
varicosities. The entire stratum pyramidale shows a high labelling, even though 
pyramidal cells are slightly less positive than interneurons present in this layer. 
The stratum lacunosum moleculare is completely devoid of labelling, a weak PV-
immunoreactivity is visible only in the axon terminals. The dentate gyrus shows a 
similar labelling pattern with a strong reactivity in the soma and processes of 
some interneurons of the granular cell layer and hilus. Granular neurons are 
weakly labelled and the majority of the positivity is present in projections 
terminating in the outer part of the GCL and in the inner molecular layer, while 
the medium and outer molecular layers are completely devoid of labelling (Fig. 
4.1 A, C, E and G). 
In general, the 3xTg-AD 18 months old mice exhibit an interneurons’ arborisation 
less clear than in the normal mice, the immunoreactivity appear to be more diffuse 
and cellular structures are more difficult to identify (Fig 4.1 B, D, F and I). 
These mice show a decrease in the numerical density (Nv) of PV-positive 
interneurons (52%; Table 4.1; Fig. 4.1 C, D and I) as well as a lower PV optical 
density (13.8%; Table 4.2; Fig 4.1 C, D and J) in the CA1 hippocampal subfield. 
The decrease in the numerical density of PV-positive interneurons is specific of 
stratum oriens (46%) and stratum pyramidale (57%; Table 4.1; Fig. 4.1 E-H and 
I).  
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Hipp area
PV Nv in Non-Tg 
(cells/mm
3
)
PV Nv in 3xTg-AD 
(cells/mm
3
)
p-value t
Total CA1 2962 ± 375.8 1423 ± 274.4 p < 0.05 3.307
CA1 stratum oriens 3245 ± 506.2 1754 ± 329.9 p < 0.05 2.467
CA1 stratum piramidale 7742 ± 898.4 3316 ± 944.8 p < 0.05 3.235
 
Table 4.1 Values of PV-positive cells Nv in the CA1 and the sublayers which show significant 
reduction in the 3xTg-AD mice respect to the non Tg mice. Values are expressed as means ± 
SEM. 
Also PV optical density reduction is layer specific and follows the same pattern of 
Nv, thus the two layers that result statistically affected are the stratum oriens 
(16%) and the stratum pyramidale (23%; Table 4.2; Fig. 4.1 E-H and J). 
 
Hipp area PV IOD in Non-Tg PV IOD in 3xTg-AD p-value t
Total CA1 84.49 ± 4.546 68.48 ± 4.9 p < 0.05 2.398
CA1 stratum oriens 88.2 ± 4.245 74.1 ± 4.399 p < 0.05 2.307
CA1 stratum pyramidale 145.7 ± 3.816 112.1 ± 3.125 p < 0.0001 6.787
 
Table 4.2 Values of PV inverted optical density (IOD) in the CA1 and the sublayers which 
significant reduction in the 3xTg-AD mice respect to the non Tg mice. Values are expressed as 
means ± SEM. 
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Figure 4.1: Parvalbumin expression changes in mouse hippocampus with AD. 
(A-H) Brightfield micrographs illustrating the distribution of PV-immunoreactive cells and its 
expression within the CA1 of 18 months old Non Tg controls (A, C, E and G) and 3xTg-AD mice 
(B, D, F and H). (I-J) Bar graphs showing the Nv (#cells/mm3; I) and the inverse optical density 
(IOD; J) of PV-IR cells in the hippocampal CA1 subfields between 18 months old Non Tg controls 
and 3xTg-AD mice. Data represent mean ± SEM (* p≤0.05, ** p≤0.01, *** p≤0.001). CA, Cornu 
Ammonis; DG, Dentate Gyrus; St Or, Stratum Oriens; PCL, Pyramidal Cell Layer; St Rad, 
Stratum Radiatum; St Lac, Stratum Lacunosum-Moleculare.  
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4.2 Calretinin optical density and cell numerical density in the hippocampus 
of the 3xTg-AD mice 
Calretinin (CR) immunohistochemistry in the non-transgenic 18 months old mice 
shows a homogeneous expression of this protein among all the hippocampal 
subfields CA1, CA2 and CA3. A strong immunoreactivity is visible in the soma 
and varicose processes of a subpopulation of interneurons, whereas pyramidal 
cells are devoid of labelling. A high immunolabelling is also evident in 
projections at the border within the stratum radiatum and the stratum lacunosum 
moleculare. In the DG very few interneurons somas are positive for CR and they 
are mostly distributed in the hilus; the granular cells show no CR 
immunoreactivity, but positive projections are visible in the Subgranular Zone 
(SGZ). The inner part of the molecular layer is highly positive, however any 
neuronal soma result immunolabelled in this sublayer (Fig. 4.2 A, C, E and G). 
The hippocampus of the 3xTg-AD 18 months old mice shows a general staining 
similar to its non-transgenic counterpart (Fig. 4.2 A and B). The measurement of 
CR optical density in all the hippocampal subfields has revealed no differences in 
the total protein expression (Fig. 4.2 I). In contrast, a significant decrease of CR 
positive interneurons has been identified in the CA1 area (33.7%; Table 4.3; Fig. 
4.2 C, D and J). The loss of immunoreactive neuronal somas in the 3xTg-AD 
mouse model respect to the normal control is statistically significant in specific 
sublayers: the stratum radiatum (63.5%) and the stratum lacunosum moleculare 
(64.3%; Table 4.3; Fig. 4.2 E-H and J). 
Hipp area
CR Nv in Non-Tg 
(cells/mm
3
) 
CR Nv in 3xTg-AD 
(cells/mm
3
)
p-value t
Total CA1 3390 ± 246.6 2248 ± 352.6 p < 0.05 2.656
CA1 stratum radiatum 1990 ± 399.4 726 ± 139 p < 0.05 2.989
CA1 lacunosum moleculare 2107 ± 157.1 751.6 ± 40.45 p < 0.0001 8.358
 
Table 4.3 Values of CR-positive cells Nv in the CA1 and the sublayers which show significant 
reduction in the 3xTg-AD mice respect to the non Tg mice. Values are expressed as means ± 
SEM. 
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Figure 4.2: Calretinin expression changes in mouse hippocampus with AD. (A-H) Brightfield 
micrographs illustrating the distribution of CR-immunoreactive cells and its expression within the 
CA1 of 18 months old Non Tg controls (A, C, E and G) and 3xTg-AD mice (B, D, F and H). (I-J) 
Bar graphs showing the numerical density (Nv; #cells/mm3; I) and the inverse optical density 
(IOD; J) of CR-IR cells in the hippocampal CA1 subfields between 18 months old Non Tg 
controls and 3xTg-AD mice. Data represent mean ± SEM (* p≤0.05, ** p≤0.01, *** p≤0.001). 
CA, Cornu Ammonis; DG, Dentate Gyrus; St Or, Stratum Oriens; PCL, Pyramidal Cell Layer; St 
Rad, Stratum Radiatum; St Lac, Stratum Lacunosum Moleculare. 
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4.3 Discussion 
In this work and for the first time, we have carried out an in depth analysis of 
parvalbumin and calretinin expression in the hippocampus of the 3xTg-AD mouse 
model. So far, calcium-binding proteins have been characterized in several mouse 
models of AD but all the models previously used bear mutations generating only 
Aβ hyperexpression and amyloid plaques deposition, without any tau tangles 
presence. The 3xTg-AD mouse model is the unique animal model that closely 
mimics AD pathogenesis, since both Aβ plaques and NFTs are present in the brain 
of these mice. The animals chosen for this work were 18 months old because this 
age resemble a late-stage of Alzheimer’s disease comparable to human brains. In 
these animals PV and CR-positive interneurons showed a specific hippocampal 
regional vulnerability, since their numerical density was found significantly 
reduced, mainly in the CA1 subfield. Moreover, PV showed also a decrease of its 
optical density in the same hippocampal area. The alterations of the calcium 
binding proteins found in the 3xTg-AD animals are likely pathogenically related 
to AD, since CA1 hippocampal area is among the first regions to show 
intracellular and extracellular Aβ depositions and neurofibrillary tangles 
formation in these mice.  
In general, all the studies conducted on human AD hippocampal tissue 
demonstrated a reduced expression of PV and CR and/or a decrease in the number 
of interneurons positive for these calcium binding proteins (Tab. 4.4). The same 
vulnerability was demonstrated also in several AD mouse models which 
hyperproduce Aβ. Only one mouse model, the APPSwe/PSEN1dE9 exhibited an 
increase in PV expression in hippocampus (Verdaguer et al., 2015), but the mice 
used in this work were only 12 months old, thus they were at an earlier stage of 
the pathogenesis respect to our animals that were 18 months old. However, the 
same mouse model (APPSwe/PSEN1dE9) was studied by other research groups 
revealing a decrease of both CR and PV in the olfactory system areas, where PV 
seemed to be affected at an older age than CR. On the basis of this, it may be 
hypothesized that at early AD stages GABAergic interneurons are more resistant 
to toxicity and the expression of some calcium binding proteins like PV might 
show an increase in the attempt to compensate an initial brain dysfunction which 
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subsequently determine the significant decrease I have just described at later 
stages. In addition, these alterations, which have specific regional and temporal 
pattern, might be slightly different depending on the animal model used.  
It should be noted that the analysis of PV and CR in human brains demonstrated a 
reduction in calcium binding proteins immunoreactivity in the areas early affected 
by AD, like EC, hippocampus and parahippocampal gyrus, while the regions 
affected at later stages showed lesser alterations of these proteins (Table 4.4). This 
observation supports the hypothesis mentioned above about a PV and CR 
vulnerability apparent only at late stages of AD. 
The studies demonstrating a resistance of calcium binding proteins-positive 
interneurons to AD pathology sustain that the presence of calcium-buffering 
proteins including CR and PV, may offer neuroprotection by maintaining calcium 
homeostasis and more importantly, the lack of NFTs presence in PV interneurons 
seem to suggest that these neurons have distinct features that confer them 
resistance to AD pathological markers (Sampson et al., 1997). Indeed, it has been 
demonstrated that neurofilament triplet proteins are almost absent in the CBPs-
positive interneurons which don’t develop NFTs, suggesting that neurofibrillary 
pathology may arise only if axons contain neurofilament proteins (Vickers et al., 
1994, 1996; Sampson et al., 1997). 
However, GABAergic interneurons are also somehow vulnerable to AD 
pathology, indeed an interesting work has demonstrated that PV interneurons 
vulnerability is not associated to neurofibrillary tangle formation but to the loss of 
neuronal projections with which they are associated (Solodkin et al., 1996). 
Since it is clear that different neuronal populations show distinct vulnerability to 
pathogenic factors and that they are involved in neuronal networks in different 
ways, it is extremely important to have a deep characterization of the neuronal 
loss or alteration during the pathology progression. 
Spine-free CR-positive GABAergic interneurons (the most abundant CR cells in 
the hippocampal CA1) have been demonstrated to form synapses with other non-
principal neurons and for this reason they are supposed to be disinhibitory cells 
participating in synchronizing the inhibition of principal cells (Gulyás et al., 1996; 
Del Rio and DeFelipe, 1997). PV-positive interneurons innervate principal cells 
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forming inhibitory synapses (Andressen et al., 1993). The dysfunction or loss of 
these inhibitory neurons might cause hyperexcitability of the target neurons with 
detrimental consequences on their viability. 
To sum up, our results in the 3xTg-AD mice 18 months old demonstrate that the 
aggravation of symptoms during AD might be related to the loss of PV- and CR-
positive interneurons, hence to the alteration of specific neuronal circuits, which 
might be important for the brain functionality. Indeed, this could be also an 
explanation of why severe symptoms appear only after many years of the onset of 
AD pathogenesis. In conclusion, the identification of all the neuronal populations 
that might be responsible of pathogenesis onset and progression during the entire 
development of the disease could be useful for a better understanding of the 
complexity of AD and for the investigation of therapies that are able to recover 
brain functionality by targeting specific cellular subsets.  
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Reference Region Markers Outcome 
(Hof and Morrison, 1991) FC CB Preserved, reduced in layer III 
(Ferrer et al., 1993) FC PV Preserved 
(Satoh et al., 1991) FC, PC, OC PV Reduced (parahipp gyrus) 
(Inaguma et al., 1992) FC, PC, OC PV Reduced (parahipp gyrus) 
(Arai et al., 1987) FC, TC PV Reduced numbers and size 
(Hof et al., 1991) PFC, ITC PV Preserved 
(Hof et al., 1993) PFC, ITC CR Preserved 
(Fonseca et al., 1993) TC PV 
PV cells modified, dystrophic 
neurites and sprouting 
(Ferrer et al., 1991) TC PV Preserved 
(Fonseca and Soriano, 
1995) 
TC CR Preserved 
(Leuba et al., 1998) VC PV, CR, CB Preserved 
(Mikkonen et al., 1999) EC PV, CR, CB PV and CB reduced 
(Solodkin et al., 1996) EC PV Reduced 
(Brady and Mufson, 1997) Hi PV Reduced 
(Brion and Résibois, 1994) Hi CR 
Dystrophic neurites (parahipp 
gyrus and subiculum) 
(Popovi et al., 2008) Hi PV, CR, CB Reduced 
(Takahashi et al., 2010) Hi PV, CR Reduced 
(Albuquerque et al., 2015) Hi SOM, NPY, PV SOM, NPY reduced, PV preserved 
(Verdaguer et al., 2015) Hi PV, CR, CB 
PV increased, CR preserved, CB 
reduced 
(Lemmens et al., 2011) FC PV, CR Preserved 
(Saiz-Sanchez et al., 2012) Olf C SOM, CR, PV, CB 
Reduced first SOM and CR, then 
PV and CB 
(Saiz-Sanchez et al., 2013) Olf System SOM, CR, PV 
Reduced first SOM and CR, then 
PV 
 
Table 4.4 Summary of published reports on PV- and CR-expressing neuronal 
subpopulations in AD, adapted from Takahashi et al., 2010. 
FC frontal cortex, PC parietal cortex, OC occipital cortex, TC temporal cortex, PFC prefrontal 
cortex, ITC inferior temporal cortex, VC visual cortex, EC entorhinal cortex, Hi hippocampus, Olf 
C olfactory cortex, PV parvalbumin, CR calretinin, CB calbindin, SOM somatostatin, NPY 
neuropeptide Y. 
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Chapter 5 
 
Characterization of S100β-positive astrocytes compared 
to GFAP and GS astrocytic markers in the entorhinal 
cortex during ageing and progression of Alzheimer´s 
disease.  
Gardenal E, Zallo F, Terzieva S, Yeh CY, Verkhratsky A, Rodríguez JJ. (2017) Manuscript in 
preparation  
 
5.1 S100β-positive astrocytes Nv does not change during ageing and AD 
pathology, but GFAP and GS astrocytic populations show slightly alterations  
 
S100β-positive cells showed that they are equally distributed throughout the entire 
EC in non Tg and 3xTg-AD animals of different ages (Fig. 5.1 B, C, F, G and Fig. 
1 D, E, H, I respectively) and neither Nv (number of cells/mm3) of S100β-positive 
astrocytes nor their distribution demonstrated significant changes in the EC of the 
aged or transgenic animal tissues (Fig. 5.1 A-I). The S100β positive astrocytes in 
the EC showed typical morphology of protoplasmic astrocytes, characterized with 
small and rounded somata, radially extending proximal processes and several 
distal processes branching in random fashion and forming the extended 
"spongiform" arborisation (Fig. 5.3).  
The dual labelling of astrocytes in the EC of 18 months old mice with different 
astroglial markers has permitted to identify different astrocytic populations. S100β 
is expressed in the majority of astrocytes, if not almost all of them, while GS is 
slightly less expressed and GFAP is the marker less present in the EC (Fig. 5.2 A, 
B) of both aged and 3xTg-AD mice. The double labelling S100β/GFAP showed 
that most of S100β-positive astrocytes are negative for GFAP (77% in non Tg 
mice and 69% in 3xTg-AD mice), while all GFAP-positive astrocytes express also 
S100β (Fig. 5.2 A, C). The numerical density of total S100β and single S100β-
positive astrocytes was not altered between non Tg and 3xTg-AD mice, but 
GFAP-positive astrocytes were found significantly increased in the 3xTg-AD 
animals 18 months old compared to the non Tg (Fig. 5.2 A, C).  
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Fig. 5.1: Nv of S100β-positive astrocytes in the EC is not altered during ageing between the 2 
genotypes. (A) Histogram showing the numerical density of S100β-positive astrocytes in the EC 
of 3xTg-AD mice compared with non Tg animals. Bars represent mean ± SEM.  (B-I) Confocal 
images depicting cell density of S100β-IR cells in the deeper (D, H) and superficial (E, I) layers of 
EC of 3xTg-AD mice compared with deeper (B, F) and superficial (C, G) layers of EC of non Tg 
animals, at age of 1 and 18 months, respectively. 
 
The analysis of S100β/GS astrocytes demonstrated that the majority of S100β-
positive astrocytes express also GS (50% in non Tg mice and 65% in 3xTg-AD 
mice; Fig. 5.2 B, D), however a big population of single S100β astrocytes is 
present (38% in non Tg and 31% in 3xTg-AD mice), whereas the single GS are 
the smallest population and they showed a significant decrease in 3xTg-AD 
animals respect to the non Tg mice (12% and 4% in non Tg and 3xTg-AD mice 
respectively; Fig. 5.2 B, D). Since the total numerical density of astrocytes is 
unchanged between non Tg and 3xTg-AD mice, the alteration found in GFAP- 
and GS- positive astrocytes suggest that during the pathogenesis astrocytes can 
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alter the expression of these proteins which probably are related with their specific 
function and reaction to brain damage.  
 
 
 
Fig. 5.2 GS and GFAP positive astrocytes are less numerous and show alterations in their Nv 
in the EC of 3xTg-AD mice compared to the non Tg. Bar graphs showing the Nv of double 
labelled S100β and GFAP astrocytes (A) as well as S100β and GS (B) in 18 months old 3xTg-AD 
mice compared to control mice. Data represent mean ± SEM (* p ≤ 0.5). Bar graphs showing the 
estimated percentage of different astrocytic populations that are S100β and GFAP positive (C) and 
S100β and GS positive (D) in 3xTg-AD mice and their respective controls. 
 
5.2 Age-dependent increase in S100β-positive profiles 
 
S100β-positive astrocytes in the EC of the non-transgenic animals in ageing 
showed a statistically significant steady and continuous increase of their surface 
area and of their volume at 9 months of age. Compared to 1 month old mice, 
S100β profiles showed an increment of the surface area by 50.07% (p = 0.01) at 9 
months of age, by 42.77% at 12 months (p = 0.05) and by 116,38% (~2 fold) at 18 
months (p=0.005; Fig. 5.3 and 5.4 A and Table 5.1). However, the volume was 
significantly larger only at 18 months of age with a 117.98% increase (p=0.006) 
when compared with 1 month-old animals (Fig. 5.3 and 5.4 B and Table 5.1).   
Surface area and volume of the cell bodies showed no significant change at any 
age, whereas the S100β-positive processes were significantly increased; therefore, 
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Fig. 5.3: Changes in the 
S100β-positive profiles of 
astrocytes with age in 
non Tg and 3xTg-AD 
mice. Representative 
confocal images of 
S100β-positive astrocytes 
in the EC of 3xTg-AD 
mice at age of 1, 3, 6, 9, 
12 and 18 months (A, B, 
C, D, E and F, 
respectively) and their 
age-matched non Tg 
controls (G, H, I, J, K and 
L, respectively). 
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the general morphometric changes result exclusively from the enlargement of the 
processes and not the cell body (Fig. 5.3 and 5.4 C, D and Table 5.1). At 9 months 
of age, the surface area and the volume of astrocytic processes in the EC were 
increased by 164.49% (p = 0.004) and 165.41% (p = 0.008) when compared to 1 
months old mice.  At 12 months, the surface area was increased by 131.39% 
(p=0.04), and the volume by 148.24% (p=0.05), whereas at 18 months, the 
processes surface area was 375.46% larger (p=0.002) and volume 417.57% larger 
(p=0.002) (Fig. 5.4 E, F and Table 5.1). 
 
S100β profiles 1 month 9 months 12 months 18 months
Cell surface in µm
2 507.25 ± 50.81 764.31 ± 28.23 724.22 ± 36.98 1097.58 ± 98.76 
Cell volume µm
3 132.41 ± 31.36 177.12 ± 12.50 199.78 ± 7.51 288.63 ± 31.36
Processes surface in µm
2 147.48 ± 34.42 390.07 ± 21.72 341.25 ± 44.17 701.21 ± 77.18
Processes volume in µm
3 27.32 ± 7.48 72.51 ± 5.15 64.82 ± 8.61 141.40 ± 16.11
Somata surface in  µm
2 359.77 ± 21.41 341.87 ± 31.02 464.88 ± 33.86 419.81 ± 46.58
Somata volume in µm
3
105.09 ± 21.70 97.93 ± 10.99 161.73 ± 11.04 156.10 ± 17.12  
Table 5.1 S100β morphometric values in the non Tg mice at 1, 9, 12 and 18 months of age. 
Values are expressed as means ± SEM. 
5.3 S100β-positive astroglial profiles in 3xTg-AD 
The morphological changes in S100β-positive astrocytes in the EC among the age 
groups of 3xTg-AD mice were less pronounced than the aged non transgenic mice 
and they reached statistical significance at 18 months of age. S100β positive 
profiles in 18 months old 3xTg-AD mice showed an increase of 150.71% (p= 
0.003; Fig. 5.3 and 5.4 A) and 166.73% (p=0.006; Fig 5.3 and 5.4 B and Table 
5.2), in the surface area and volume, respectively, when compared to 1 month old 
3xTg-AD mice. Similarly, the morphometric parameters of the cell compartments 
showed alterations only at age of 18 months. The surface area of the cell 
processes was increased by 281.16% (p=0.003; Fig. 5.3 and 5.4 E and Table 5.2), 
and the volume by 343.16% (p=0.006; Fig. 5.3 and 5.4 F and Table 5.2) when 
compared to their 1 month old 3xTg-AD mice. Moreover, the somata volume was 
increased by 54.06% (p=0.02; and Table 5.2) whereas no significant alterations 
were found in the surface area, in the same age group.  
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Fig. 5.4: Increase of the s100β-positive astrocytes’ surface area and volume in the EC of 
3xTg-AD mice and the non Tg controls between the age of 1 and 18 months.  (A, C, E) 
Histograms showing surface area differences in the entire S100β-IR cells (A), their cell bodies (C) 
and processes (E) in the EC of 3xTg-AD and non Tg mice in the age between 1 and 18 months.  
(B, D, F) Histograms showing differences in the volume of the entire s100β-IR cells (B), their cell 
bodies (D) and processes (F) in the EC of 3xTg-AD and non Tg mice of age between 1 and 18 
months. Bars represent mean ± SEM (* p≤0.05, ** p<0.01, comparing with 1 month animals from 
the same genotype; # p≤ 0.05, ## p<0.01 comparing 3xTg-AD mice with their aged-matched non 
Tg control). 
When comparing 3xTg-AD animals with their age-matched non Tg controls, an 
increment of the surface area and volume in 3xTg-AD mice was already evident 
at 1 month, but statistical significant differences were observed only at 18 months 
of age, when an increase of 69.74% in the surface area (p=0.01; Fig. 5.4 A) and 
76.73% in the volume (p=0.01; Fig. 5.4 B) was detected (Fig. 5.3 and Table 5.2). 
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S100β profiles 1 month 9 months 12 months 18 months
Cell surface in µm
2 743.08 ± 110.32 919.84 ± 48.13 949.26 ± 94.05 1862.98 ± 208.83
Cell volume µm
3 191.24 ± 29.39 219.82 ± 17.69 253.46 ± 29.36 510.09 ± 67.59
Processes surface in µm
2 356.14 ± 72.23 532.68 ± 39.28 495.99 ± 89.11 1357.55 ± 193.35
Processes volume in µm
3 68.27 ± 15.19 104.22 ± 7.75 112.89 ± 19.54 302.28 ± 51.20
Somata surface in µm
2 421.00 ± 49.32 387.16 ± 13.02 374.21 ± 20.97 508.63 ± 21.08
Somata volume in µm
3 137.62 ± 17.67 154.71 ± 42.77 138.84 ± 14.26 212.02 ± 16.06
 
Table 5.2 S100β morphometric values in the 3xTg-AD mice at 1, 9, 12 and 18 months of age. 
Values are expressed as means ± SEM. 
The same animals were also characterised by enlarged somata with an increase in 
the volume of the cell body of 35.82% (p=0.04; Fig. 5.4 D), whereas no 
significant alterations were detected in the surface area (Fig. 5.4 C and Table 5.2).  
In addition, differences in the morphometric parameters of the astrocytic 
processes in the 3xTg-AD mice were detected at 9 months of age when the 
surface area and the volume were increased by 36.56% (p=0.05; Fig. 5.4E) and 
43.73% (p=0.039; Fig. 5.4F and Table 5.2), respectively, when compared with 
non Tg animals.  
S100β profiles 18 months non-Tg 18 months 3xTg-AD
Cell surface in µm
2 1097.58 ± 98.76 1862.98 ± 208.83
Cell volume µm
3 288.63 ± 31.36 510.09 ± 67.59
Processes surface in µm
2 701.21 ± 77.18 1357.55 ± 193.35
Processes volume in µm
3 141.40 ± 16.11 302.28 ± 51.20
Somata surface in µm
2 419.81 ± 46.58 508.63 ± 21.08
Somata volume in µm
3 156.10 ± 17.12 212.02 ± 16.06
 
Table 5.3 S100β morphometric values in the 3xTg-AD mice compared to the non Tg at 18 
months of age. Values are expressed as means ± SEM. 
No differences were found in the astrocytic processes at 12 months of age, while a 
maximal increase of 2 folds was detected in 3xTg-AD animals at age of 18 
months both in the surface area (93.6%; p=0.013) and volume (113.78%; 
p=0.017; Fig. 5.4 E, F and Table 5.2, 5.3). 
104 
 
5.4 Hypertrophy of S100β-positive astrocytes is associated with the presence 
of Aβ plaques 
 
Finally, an important analysis compared the S100β-positive profiles of astrocytes 
associated with -amyloid plaques (with somatas placed within 50 µm range from 
the plaque border) with astrocytes located further away from the plaques (Fig. 5.5 
A-C and Table 5.4). Although the accumulation of Aβ plaques in the EC starts at 
12 months of age, the measurements were performed in 18 months old animals 
where the astroglial hypertrophy is maximal. The S100β-positive astroglial 
profiles associated with plaques were much larger than astrocytes distant to them: 
the surface area was 136.00% larger (p=0.05; Fig. 5.5 D) and the volume 140.20% 
larger (p=0.06; Fig. 5.5 E and Table 5.4).  Surface area of somata of astrocytes 
associated with plaques was 54.90% larger (p=0.006; Fig. 5.5 D), and their 
volume 66.34% larger (66.34%; p=0.004; Fig. 5.5 E and Table 5.4). Processes of 
astrocytes associated with plaques were similarly larger when compared to distal 
astrocytes. The surface area and the volume of processes of cells located near 
plaques were 195.70% (p=0.06; Fig. 5.5 D) and 231.57% larger (p=0.07; Fig. 5.5 
E and Table 5.4). 
 
S100β profiles
18 months 3xTg-AD close 
to Aβ plaques
18 months 3xTg-AD far 
from Aβ plaques
Cell surface in µm
2 2891.19 ± 683.88 1225.10 ± 107.76
Cell volume µm
3 807.99 ± 206.73 336.38 ± 37.15
Processes surface in µm
2 2319.71 ± 662.92 784.48 ± 92.14
Processes volume in µm
3 545.57 ± 173.07 164.54 ± 21.43
Somata surface in µm
2 688.50 ± 53.62 444.47 ± 22.55
Somata volume in µm
3 292.04 ± 17.81 175.57 ± 17.87
 
 
Table 5.4 S100β morphometric values in the astrocytes close to Aβ plaques and far from Aβ 
plaques in the 3xTg-AD mice at 18 months of age. Values are expressed as means ± SEM. 
  
Astrocytes in the EC of 3xTg-AD mice located far from amyloid plaques showed 
no statistical significant differences in their morphometric values when compared 
with the astrocytes in the non-transgenic mice (Fig. 5.5 D, E).  
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Fig. 5.5: Increment in the surface area and volume of s100β-IR astrocytes in close vicinity to 
senile plaques in EC of 3xTg-AD mice at age of 18 months. (A-C) Representative confocal 
images of Aβ (A, green) and S100β-positive astrocytes (B, red) dual labelling (C) showing the 
morphometric difference in the astrocytes distant from the plaques (indicated with arrowhead) and 
associated with the Aβ plaques (indicated with arrows).  (D and E) Histograms showing the 
difference in surface area (D) and volume (E) between the S100β expressing astrocytes located 
around the senile plaques and those placed distant to the plaques in the EC of the 3xTg-AD, 
compared to S100β expressing astrocytes in the EC of the non Tg animals. Morphometric analysis 
was performed on the entire astrocyte, but also cells counterparts, the processes and the somata. 
Bars represent mean ± SEM (* p≤0.05; ** p <0.01 compared with astrocytes from non Tg mice; # 
p≤0.05, ## p<0.01 comparing with the astrocytes away from the plaques).  
 
5.5 Distinct astrocytic populations show different morphological alterations 
during AD progression 
 
A preliminary morphological characterization was conducted on S100β/GFAP 
and S100β/GS astrocytes of non-transgenic and 3xTg-AD mice 18 months old. In 
general, S100β/GFAP positive astrocytes showed a decrease in the surface and 
volume of both S100β and GFAP profiles, even if this reduction was not 
significant (Fig. 5.6).  
The analysis of S100β/GS positive astrocytes showed that both S100β and GS 
profiles are increased in 3xTg-AD mice 18 months old compared to the non-
transgenic mice. The increase of GS profiles seem to be in discordance with 
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previous work (Yeh, 2013) that demonstrated GS is not altered in 3xTg-AD mice 
compared to non Tg, but we should bear in mind that this study was conducted on 
mice maximum 12 months old, thus a more aggravated stage of the disease might 
be the cause of an increase in the GS-profiles that we preliminary found in the 
present work. Indeed, S100β-positive profiles show an increase in 3xTg-AD mice 
only at 18 months of age when compared to non-transgenic animals. However, 
further experiments are necessary to better characterize these astrocytic sub-
populations. 
 
Fig. 5.6: S100β, GFAP and GS differently label astrocytes. Confocal micrographs showing in 
red the astrocytic labelling with GFAP (A, C, D, F) and GS (G, I, J, L) and in green the astrocytic 
labelling with S100β (B, C, E, F, H, I, K, L) in the EC of 18 months old non-transgenic mice 
compared with the 3xTg-AD mice. Scale bars: 25 µm. 
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5.6 Discussion  
 
The present study provides an astrocytic numerical analysis and morphological 
characterization of the entorhinal cortex of 3xTg-AD mice and their non-
transgenic counterpart based on the trophic astroglial marker S100β. Different 
brain areas and regional subfields present astrocytes with distinct morphology and 
functional specialisation and their features and distribution can show a 
considerable divergence depending on the astrocytic marker utilised. Moreover, 
astrocytic heterogeneity is even more visible during pathogenesis, where different 
subsets of astrocytes respond with a different behaviour to CNS insults depending 
on the specific vulnerability or resistance of each brain region (Emsley and 
Macklis, 2006; Matyash and Kettenmann, 2010; Oberheim et al., 2012; 
Verkhratsky et al., 2013).  
The S100β immunolabelling of astroglia in the entorhinal cortex reported in this 
study has displayed a highly numerous astrocytic population when compared to 
astrocytes labelled with other markers. Indeed, S100β-positive astrocytes occupy 
the entire extent of this cortical region and they are much more abundant than GS- 
and GFAP-positive astrocytes. Analogously, Savchenko et al. demonstrated a 
different distribution of S100β- and GFAP-positive astrocytes in the normal adult 
brain, in fact, GFAP stained more astrocytes in white matter than in grey matter 
and GFAP-positive astrocytes were approximately one-third that of S100β-
positive astrocytes (Savchenko et al., 2000). Despite being S100β expressed also 
in some rat and mouse neurons and oligodendrocytes, its expression in these cells 
is very rare and concerns only some brain areas, thus the non-astrocytic cells 
S100β-positive can be considered negligible in quantitative studies. Therefore, 
since almost the entire cellular extent labelled with S100β is formed by astrocytes, 
S100β can be recognized as the chemical marker that label the largest population 
of astrocytes (Rickmann and Wolff, 1995; Ogata and Kosaka, 2002). 
The counting of S100β-positive astrocytes in this work demonstrated that their 
numerical density was not altered in the 3xTg-AD mice, but the morphological 
analysis of their profiles showed a significant increase of volume and surface of 
the S100β-positive astrocytes at 18 months of age compared to the non Tg mice. 
An increased astrocytic expression of S100β was already associated with AD 
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pathogenesis and with cerebral amyloidosis and gliosis (Griffin et al., 1998; Mori 
et al., 2010), as well as its secretion in the CSF was related with AD severity 
(Whitaker-Azmitia et al., 1997; Jesse et al., 2009). Indeed, here we have also 
demonstrated that this increase is exclusive of Aβ plaques-related astrocytes, 
while S100β astrocytic profiles of distant astrocytes were unchanged comparing to 
non Tg mice. It is noteworthy the observation that S100β-positive profiles are 
significantly higher at 18 months of age also in the non Tg mice compared to the 
younger animals, this means that there is also a component of age in the increase 
of S100β-positive profiles. Astrocytic relevance in AD is usually contemplated 
considering only astrogliotic reaction and production of inflammatory cytokines.  
However, what we have observed in the 3xTg-AD mice is that astrocytes become 
gliotic only at late stages of the pathogenesis and this reactivity is circumscribed 
to specific regions and in the vicinity of Aβ plaques. The role that astrocytes 
might have in AD early stages, prior to Aβ deposition, is almost unknown and 
underestimated. At these stages, we have observed a very small and non-
significant increase in S100β-positive profiles in 3xTg-AD mice entorhinal cortex 
compared to the non Tg animals. In previous studies it was demonstrated an early 
astrocytic atrophy (already evident at 1 month of age and sustained, even if with a 
lesser extent, until 12 months of age) in the EC of the 3xTg-AD animal model by 
means of GFAP labelling, while GS-positive profiles showed no alteration in the 
same area (Yeh et al., 2011, 2013). An original work that analysed the S100β 
level in serum reported a positive correlation between S100β concentration in the 
serum and severity of the disease, but interestingly, the total AD group showed a 
lower serum level of S100β compared to the controls (Chaves et al., 2010). This 
finding suggest that initial astrocytic dysfunction might be characterized by an 
incapability to protect neurons, whilst their inflammatory activation is a late event 
that only favour the progression of the pathology. 
In this study a significant increase of the S100β/GFAP positive astrocytes was 
found in the 3xTg-AD mice at 18 months of age comparing with the non Tg mice, 
but the profiles of these astrocytes were decreased. This finding is in line with our 
previous study which demonstrated GFAP atrophy in the entorhinal cortex (Yeh 
et al., 2011). The numerical density increase of S100β/GFAP positive astrocytes is 
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associated to a decrease in single GS astrocytes. We hypothesize that GS single 
astrocyte at late stages of AD might start to express S100β protein as a reaction to 
the amyloid pathology, but further experiments must be conducted to elucidate 
these preliminary data. 
Altogether these findings demonstrate that distinct astrocytic populations in the 
EC probably have different functional properties and might respond in a diverse 
way during AD progression. We sustain that further studies should be conducted 
to better characterize astrocytic diversity and role in the different brain regions 
and a deep characterization of their role in AD should be studied at early stages 
when their behaviour doesn’t resemble to be reactive and inflammatory but rather 
atrophic and insufficient to support and defend neurons from pathological 
conditions. 
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Chapter 6 
 
Conclusions 
 
This research work has had the aim to characterize three distinct aspects of AD 
pathogenesis in the 3xTg-AD mouse model: 1. The expression changes (increase) 
in the Calcium Sensing Receptor within the hippocampus during the progression 
of AD pathology; 2. The decreased expression of two calcium binding proteins, 
parvalbumin and calretinin, in the hippocampus at late stages of the pathology and 
3. The determination and characterization of the numerical density, the 
distribution and the morphological profiles of astrocytes positive for the astrocytic 
marker S100β in the entorhinal cortex in relation with AD progression and 
comparing also to other astrocytic markers such as GFAP and GS. 
In Chapter 3, the immunohistochemical analysis of the expression of the CaSR in 
3xTg-AD animals compared to non-transgenic animals has revealed an increase of 
the expression of the CaSR in specific hippocampal subfields which are 
characterized by accumulation of intracellular and extracellular Aβ and amyloid 
plaques depositions. This study has been performed on the basis of a new original 
hypothesis of pathological Aβ hyperproduction and diffusion in the brain. 
Experiments conducted on human primary cortical astrocytes have demonstrated 
that there is a direct interaction between Aβ42 toxic oligomers and the CaSR, 
which can activate this receptor and induce an increased production and secretion 
of Aβ42 peptides. This mechanism has been demonstrated through the concomitant 
administration of exogenous Aβ and a specific antagonist of CaSR, the compound 
NPS 2143, which is able to totally block Aβ self-induction caused by the Aβ and 
CaSR interaction (Armato et al., 2013). Therefore, this new pathological pathway 
has been proposed as a fundamental process of spread of the deleterious Aβ 
peptides. After in vitro Aβ stimulation, CaSR resulted also hyperexpressed. The 
finding here reported that CaSR has increased expression also in the 3xTg-AD 
mouse model compared to the non-transgenic mice is an interesting evidence 
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which permit to sustain the need to further investigate this pathological 
mechanism of increased amyloidogenesis due to CaSR direct activation. Future 
studies will aim to treat these animals with a calcilytic compound as NPS 2143 to 
test its possible therapeutical use in the treatment of AD. 
In Chapter 4, PV- and CR-positive interneurons were analysed in the 
hippocampus of the 3xTg-AD mice to measure their numerical density alteration 
and the changes in the total expression of these two calcium-binding proteins. 
GABAergic interneurons immunoreactive for both PV and CR resulted 
numerically reduced in the CA1 area, which is strongly affected by Aβ plaques 
deposition and NFTs formation and is strictly connected with entorhinal cortex 
and subiculum in the hippocampal-entorhinal circuit involved in memory 
formation. The labelling of these calcium-binding proteins showed a deterioration 
of the neurons that are still immunoreactive, and in addition also a decrease in the 
expression of PV, which was significantly evident in the CA1 area of the 
hippocampus. The dysfunction of inhibitory interneurons is believed to be 
extremely detrimental for the functionality of brain since it can alter the general 
function of entire complex networks and might be crucial for the appearance of 
symptoms. This was the first characterization of calcium binding proteins in the 
3xTg-AD mouse model, the possible alterations of other subpopulations of 
inhibitory interneurons should be investigated in this mouse model in the future, 
as well as the age-related onset of these changes, in order to establish the exact 
relation with the progression of the disease. 
In chapter 5, an extensive analysis of S100β-positive profiles confirmed our 
previous results, which showed an increase in their surface and volume on the 
entorhinal cortex of normal aged mice (Rodríguez et al., 2014). Moreover, in the 
present work the same analysis was conducted also in the 3xTg-AD animals and 
demonstrated that S100β-positive profiles are even more expanded than in the 
normal mice, with significant increase evident at 9 months of age, but massive 
difference only at 18 months of age. A deeper characterization showed that this 
significant increase is specific of astrocytes that localize close to Aβ-plaques, 
while the more distant astrocytes have S100β-profiles similar to the non-
transgenic animals. This evidence supports our hypothesis that astrocytic 
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hypertrophy is associated only to Aβ plaques and become manifest only at late 
stages, whereas astrocytes that are not in close contact with neuritic plaques are 
not reactive and might be incapable to defend neurons from toxic agents such as 
the diffusible Aβ oligomers. 
Altogether these different works demonstrate that many pathways and cellular 
populations are affected with a different temporal and regional pattern during AD 
and they should be all clarified in a way to better understand the mechanism of 
onset and progression of AD. However, all the alterations that we have 
investigated are clearly related with amyloid and tau pathology, since the protein 
changes found appear in the areas where the AD hallmarks first accumulate. 
These alterations, even if in the 3xTg-AD mouse model are a consequence of Aβ 
hyperproduction, concur to the progression of AD pathology and/or to the onset of 
symptoms and if considered in early stages of the disease they might be an 
efficient target to stop the progression of the pathology. Hence, a multi target 
approach might be more useful to the final purpose of preventing and treating AD. 
Furthermore, all the proteins that we have investigated in this research work are 
somehow related to calcium signalling and/or homeostasis; and since calcium is 
extremely important for neuronal excitability and brain homeostasis, strong 
attention should be paid to these proteins whose alterations might have severe 
consequences and can reveal new disease progression mechanisms and potential 
treatment strategies.  
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The Calcium-Sensing Receptor (CaSR) is a G-protein coupled, 7-transmembrane
domain receptor ubiquitously expressed throughout the body, brain including. The role of
CaSR in the CNS is not well understood; its expression is increasing during development,
which has been implicated inmemory formation and consolidation, and CaSR localization
in nerve terminals has been related to synaptic plasticity and neurotransmission.
There is an emerging evidence of CaSR involvement in neurodegenerative disorders
and Alzheimer’s disease (AD) in particular, where the over-production of β-amyloid
peptides was reported to activate CaSR. In the present study, we performed CaSR
immunohistochemical and densitometry analysis in the triple transgenic mouse model
of AD (3xTg-AD). We found an increase in the expression of CaSR in hippocampal CA1
area and in dentate gyrus in the 3xTg-ADmice when compared to non-transgenic control
animals. This increase was significant at 9 months of age and further increased at 12
and 18 months of age. This increase paralleled the accumulation of β-amyloid plaques
with age. Increased expression of CaSR favors β-amyloidogenic pathway following direct
interactions between β-amyloid and CaSR and hence may contribute to the pathological
evolution of the AD. In the framework of this paradigm CaSR may represent a novel
therapeutic target.
Keywords: Alzheimer’s disease, β-amyloid, tau, calcium sensing receptor (CaSR), hippocampus
INTRODUCTION
The calcium sensing receptor (CaSR) belongs to the extended family of plasmalemmal G protein-
coupled heptahelical receptors (GPCRs); it shares the C subfamily of GPCRs with metabotropic
glutamate receptors (mGluR) and γ-aminobutyric acid GABAB receptors (Brown and MacLeod,
2001). CaSRs are widely distributed throughout the brain, with highest expression in the
Abbreviations: AD, Alzheimer’s disease; ANOVA, One-way Analysis of Variance; CaSR, Calcium-Sensing Receptor; DG,
Dentate Gyrus; GCL, Granular Cell Layer; IOD, Inverted Optical Density; mGluR, metabotrobic Glutamate Receptors;
ML, Molecular Layer; OD, Optical Density; PB, Phosphate Buffer; PCL, Pyramidal Cell Layer; S.Mol, Stratum Lacunosum-
Moleculare; SO, Stratum Oriens; S.Rad, Stratum Radiatum; TS, Trizma-base Saline; VEGF, Vascular Endothelial Growth
Factor; 3xTg-AD, triple Transgenic mouse model of AD.
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subfornical organ, hippocampus, striatum, cingulate cortex,
cerebellum, ependymal zones of the cerebral ventricles and
perivascular nerves around cerebral arteries, some CaSR
expressing cells were found also in rat dorsal root ganglia (Ruat
et al., 1995; Yano et al., 2004). The CaSR has been found
abundantly expressed in vivo in neurons and in oligodendrocytes;
in vitro studies demonstrated its expression in human primary
astrocytes and in rat microglia (Ruat et al., 1995; Chattopadhyay
et al., 1998, 1999a; Ferry et al., 2000; Dal Prà et al., 2005).
Numerous functions have been assigned to CaSR in the
CNS from regulation of neuronal growth and migration, to
the role in neurotransmission and synaptic plasticity (Ruat and
Traiffort, 2013); CaSR can also contribute to astroglial functions,
microglial reactivity and oligodendroglial development (Ruat
and Traiffort, 2013). The level of extracellular ionized Ca2+
([Ca2+]o) is usually considered to be stable in the brain, which
is not really the case, since [Ca2+]o undergoes rapid fluctuations
in normal physiological processes such as development, synaptic
transmission and aging as well as in pathological processes
including neurodegeneration and Alzheimer’s disease (AD;
Small, 2009; Ruat and Traiffort, 2013).
Expression of CaSR markedly increases during development,
specifically in perinatal and early post-natal periods just before
and after birth (Chattopadhyay et al., 1997; Vizard et al., 2008).
In the hippocampus CaSR was reported to regulate neuronal
growth, as well as extension and branching of neurites (Vizard
et al., 2008). In addition, CaSR has been identified in neocortical
nerve terminals where it senses the [Ca2+]o and activates voltage
dependent non-selective cation channels (NSCCs) (Chen et al.,
2010). It has been proposed that the decrease in [Ca2+]o in
the synaptic cleft may act as feedback to presynaptic CaSR and
the associated increased activity of NSCCs may prolong action
potentias; in this way CaSR may influence synaptic transmission
through a homeostatic pathway to prevent synaptic failure when
[Ca2+]o falls (Ye et al., 1996). Studies in vitro conducted in the
human astrocytoma cell line U87, and in primary cultures of
rat microglia and oligodendroglia showed that CaSR stimulates
Ca2+-activated K+ channels, thus contributing to local ionic
homeostasis following the lowering of [Ca2+]o due to increased
neuronal activity; there are also indications that CaSR could also
play a role in microglia activation (Chattopadhyay et al., 1998,
1999a,b). CaSR can form heterodimers with others GPCRs, like
GABAB receptors and mGluRs, which might be important for
their trafficking to the membrane, their ligand binding sensitivity
and thus the regulation of signaling responses (Gama et al., 2001;
Chang et al., 2007). Activation of CaSR was also demonstrated to
induce a distinct form of glutamate release independent on Ca2+
influx (Vyleta and Smith, 2011).
In the context of AD, CaSR has been reported to be directly
activated by β-amyloid as well as by apoE (isoforms 3 and 4)
(Conley et al., 2009). In rat hippocampal neurons exposure to β-
amyloid stimulated openings of NSCCs linked to CaSR activation
(Ye et al., 1997). How β-amyloid interacts with CaSR remains
unclear, although it is possible that either β-amyloid fibrils or
variously sized oligomers, having regular positive charges, mimic
CaSR agonists, or hydrophobic interactions between β-amyloid
and CaSR may take place (Ye et al., 1997). Thus, extracellular
accumulation of β-amyloid can activate CaSRwhich, in turn, may
contribute to Ca2+ dyshomeostasis observed in AD (Lim et al.,
2014, 2015).
Previous studies on human cultured primary adult astrocytes
showed that their exposure to exogenous β-amyloid25–35, a
surrogate of β-amyloid42, triggers CaSR-dependent signaling
cascade that stimulates the expression of nitric oxide synthase-
2 (NOS-2) followed by an excessive release of nitric oxide
(Chiarini et al., 2005), and increased expression of vascular
endothelial growth factor (VEGF)-A (Chiarini et al., 2010). Most
importantly, cultured human cortical astrocytes and neurons
exposed to β-amyloid25–35, which binds and activates CaSR (Dal
Prà et al., 2014), begin to excessively produce and secrete β-
amyloid42 oligomers, contributing in this way to the β-amyloid
load (Dal Prà et al., 2011; Armato et al., 2013).
In the present study, for the first time we aimed to determine
in vivo CaSR expression in the 3xTg-AD mouse model and
correlate its changes with β-amyloid load.
MATERIALS AND METHODS
All animal procedures were carried out in accordance with the
United Kingdom Animals (Scientific Procedures) Act of 1986
under the license from the Home Office. All efforts were made to
reduce the number of animals by following the 3R’s (reduction,
refinement and replacement).
Mice
Experiments were performed on male 3xTg-AD mice generated
on 129/C57BL6 background (the wild type of which was
employed as a non-Tg control). The 3xTG-AD mice harbor
the mutant genes for amyloid precursor protein (APPSwe),
presenilin 1 PS1M146V and tauP301L (Oddo et al., 2003a,b;
Rodríguez et al., 2008). All 3xTg-AD and non-Tg control mice
were obtained by crossing homozygous breeders. Animals were
housed in groups of the same genotype and in the same cage
according to their age, kept in 12 h light-dark cycles with ad
libitum access to food and water.
The experimental groups chosen were of 9, 12, and 18 months
of age, since it is at these ages that the amyloid and tau
pathologies emerge resembling the human Alzheimer’s disease
progression. Indeed, the 3xTg-AD mice exhibit the highest
intracellular β-amyloid deposition at 9 months of age, they start
showing extracellular β-amyloid plaques followed by intracellular
tau deposition at 12 months of age and they present massive
Aβ plaques and neurofibrillary tangles at 18 months of age
(Rodríguez et al., 2008; Olabarria et al., 2010).
Fixation and Tissue Processing
As described previously (Olabarria et al., 2010; Kulijewicz-
Nawrot et al., 2012) 3xTg-AD and non-Tg control mice at 9,
12, 18 months of age (Ns for non-Tg = 5, 5, 4; ns for 3xTg-
AD = 4, 5, 3, respectively) were intraperitoneally anesthetized
with sodium pentobarbital (50 mg/kg). Mice were trans-cardially
perfused with 4% paraformaldehyde (PFA, Sigma, UK) and
0.1 M phosphate buffer (PB) at pH 7.4. Brains were removed
and post-fixed in 4% paraformaldehyde overnight, then cut
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FIGURE 1 | CaSR expression and localization in hippocampus. Brightfield micrographs showing the distribution of CaSR-IR within the dorsal hippocampus of
18 months old non-Tg controls (A,C,E,G,I) and 3xTg-AD mice (B,D,F,H,J; arrowheads show neuropil elements, whilst full arrows indicate interneurons). Confocal
micrographs showing the immunoreactivity for CaSR (red) and for GFAP (green), in Non-Tg (K–M) and 3xTg-AD mice (N–P). Inserts in (N–P) show an astrocyte
bearing CaSR at higher magnification (scale bar 20 µm). CA1, Cornu Ammonis 1; DG, Dentate Gyrus; St Rad, Stratum Radiatum; St Lac, Stratum
Lacunosum-Moleculare; Mol L, Molecular Layer; GCL, Granular Cell Layer.
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into 4–5 mm coronal slabs of tissue containing the entire
rostrocaudal extent of the hippocampus, as previously described
(Olabarria et al., 2011). The tissue was further sectioned in 40–
50 µm-thick slices with a vibrating microtome (VT1000S, Leica,
Milton Keynes, UK). Free floating sections were collected in
0.1 M PB and stored in a cryoprotectant solution containing
25% sucrose and 3.5% glycerol in 0.05 M PB at pH 7.4.
Three coronal sections at levels −1.58 mm/−2.46 mm (dorsal
hippocampus) posterior to Bregma, were selected from each
animal for immunohistochemistry according to the mouse brain
atlas of Paxinos and Franklin (2012).
Antibodies
A mouse monoclonal anti-Calcium Sensing Receptor antibody
(anti-CaSR; Sigma-Aldrich, UK; C0493) was used for the
determination of CaSR expression throughout the dorsal
hippocampus. For the identification of intracellular β-amyloid
deposits and plaques a monoclonal mouse antibody that reacts
with abnormally processed isoforms, as well as precursor forms
of Aβ, recognizing an epitope within amino acids 3–8 (EFRHDS;
anti-Aβ 6E10 [SIG-39320] Signet Laboratories, Dedham, MA)
was used, for hyperphosphorylated Tau we employed the mouse
monoclonal antibody anti-PHF Tau AT8 (Innogenetics, Gent,
Belgium). For double immunostaining of CaSR with GFAP and
Aβ, a rabbit anti-GFAP (Sigma-Aldrich, UK; G9269) and a
mouse anti-Aβ Alexa 488 6E10 conjugated antibody (Covance,
USA) were used. To assess for non-specific background labeling
or cross reactivity between antibodies derived from different
host species, a series of control experiments were performed,
including the omission of primary (Supplementary Figure 1C)
and/or secondary antibodies from the incubation solutions;
resulting all of them in a total absence of target labeling.
Immunohistochemistry
All the sections were processed at the same time using the same
experimental conditions to minimize methodological variability
(Noristani et al., 2010; Olabarria et al., 2011; Kulijewicz-Nawrot
et al., 2012). Then sections were incubated for 30 min in 30%
methanol in 0.1 M PB and 30% hydrogen peroxide (H2O2;
Sigma, UK). Sections were then rinsed with 0.1 M PB for 5
min and placed in 1% sodium borohydride (Sigma, UK) for
30 min. The sections were then washed with PB profusely
before rinsing in 0.1 M Trizma base saline (TS) for 10 min.
Brain sections were then incubated in 0.5% bovine serum
albumin (Sigma, UK) in 0.1 M TS and 0.25% Triton X-100
(Sigma, UK) for 30 min. Sections were incubated for 72 h
at room temperature in primary antibody (mouse anti-CaSR,
1:250, Sigma, UK). The sections were rinsed in 0.1 M TS for
30 min and incubated in 1:400 dilutions of biotinylated horse
anti-mouse IgG (Vector Laboratories, Peterborough, UK) for 1
h at room temperature. Sections were rinsed with 0.1 M TS
for 30 min followed by incubation for 30 min in avidin-biotin
peroxidase complex (Vector Laboratories, Peterborough, UK).
The peroxidase reaction product was visualized by incubation
in a solution containing 0.022% of 3,3’ diaminobenzidine (DAB,
Aldrich, Gilligham, UK) and 0.003% H2O2 for 7 min. The
reaction was stopped by rinsing the sections in 0.1 M TS
FIGURE 2 | Changes of CaSR expression in hippocampal CA1. Bar
graphs illustrating CaSR-IR IOD within CA1 subfield of hippocampus between
non-Tg controls and 3xTg-AD mice at 9, 12 and 18 months of age (Ns for
non-Tg = 5, 5, 4; ns for 3xTg-AD = 4, 5, 3, respectively; 3 slices have been
analyzed per each animal). (A) Total CA1, (B) CA1 Pyramidal Cell Layer,
(C) CA1 Stratum Radiatum, (D) CA1 Stratum Lacunosum-Moleculare. Bars
represent means ± SEM (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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TABLE 1 | Summary of CaSR IOD values in the hippocampal CA1 and DG subfields and their respective layers in both non-Tg and 3xTg-AD.
CaSR IOD 9 months NTG 9 months 3xTG-AD 12 months NTG 12 months 3xTG-AD 18 months NTG 18 months 3xTG-AD
Total CA1 82.71 ± 2.98 102.1 ± 2.72*** 83.92 ± 2.51 98.71 ± 2.56*** 93.51 ± 3.39 112.30 ± 4.68**
PCL CA1 115.20 ± 3.78 127.50 ± 3.80* 114.00 ± 2.49 116.60 ± 2.39ns 108.60 ± 4.57 130.50 ± 3.40**
St Rad CA1 74.23 ± 2.91 83.83 ± 3.60* 75.08 ± 2.85 91.38 ± 2.75*** 91.23 ± 3.31 104.5 ± 5.99*
St Lac CA1 53.78 ± 2.60 103.9 ± 3.33*** 59.53 ± 2.71 83.09 ± 4.41*** 66.25 ± 5.31 103.4 ± 6.25***
Total DG 82.68 ± 3.11 97.41 ± 3.56** 81.35 ± 3.33 93.34 ± 2.80** 89.78 ± 4.75 108.40 ± 4.96*
ML 73.06 ± 3.16 84.68 ± 4.88* 80.58 ± 4.18 90.51 ± 3.01* 90.00 ± 4.11 108.8 ± 6.91*
GCL 98.30 ± 3.55 117.30 ± 4.27** 87.76 ± 3.15 97.13 ± 2.78* 82.18 ± 6.16 112.90 ± 3.54***
Values are expressed as means ± SEM (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
for 5 min followed by 0.1 M PB for 15 min. Brain sections
were permanently mounted onto gelatinized slides and allowed
to dry overnight. Sections were then dehydrated in ascending
concentration of ethanol (50, 70, 80, 90, 95, and 100%)
and, finally, xylene. Sections were then permanently mounted
and coverslipped using Entellan (Merck KGaA, Darmstadt,
Germany) and slides were left to dry overnight.
For the dual immunofluorescence labeling with CaSR and
GFAP the sections were simultaneously incubated with both
antibodies (mouse anti-CaSR, 1:250; rabbit anti-GFAP, 1:20,000)
for 48 h at room temperature. Then CaSR and GFAP were
detected in a sequential manner on the same sections by
incubation of 2 h with Alexa Fluor 594-conjugated goat anti-
mouse and Alexa Fluor 488-conjugated goat anti-rabbit (1:400,
Invitrogen, Paisley, UK), respectively.
For the dual immunofluorescence labeling with CaSR and Aβ
the sections were first incubated for 48 h at room temperature
in CaSR antibody solution then in the Alexa 594 conjugated
goat anti-mouse for 2 h, finally for 24 h in Alexa 488-conjugated
mouse anti-Aβ antibody (1:1,000, Covance, USA).
Sections were rinsed with 0.1 M TS for 30 min and
permanently mounted in an aqueous medium (Vectashield;
Vector laboratories, Peterborough, UK).
Optical Density (OD) Measurement
Using computer-assisted imaging analysis (ImageJ 2.0.0-rc-
39/1.50b; NIH, USA) we analyzed the expression of CaSR by
measuring its OD, as described previously (Cordero et al., 2005;
Noristani et al., 2010, 2012). Briefly, to exclude any experimental
errors and/or bias, all images were taken at constant light
intensity with a Nikon Eclipse 80i microscope coupled with an
8001 MicroFIRE camera. Optical filters were used to ensure
the specificity of the signal recorded by the camera. The OD
was calculated from a relative scale of intensity ranking from
0 to 250, with a measurement of 250 corresponding to the
area with very low CaSR expression and 0 corresponding to
the area with highest labeling. The calibration density was
kept constant for measuring all sections to avoid experimental
variances. Non-specific OD in sections was measured from
the corpus callosum (CC). CaSR density of the complete CA
subfields of the hippocampus and their different layers (stratum
pyramidale, PCL; stratum oriens, SO; stratum radiatum, S.Rad
and stratum lacunosum-moleculare, S.Mol), except CA3 where
we also studied stratum lucidum, were measured independently.
Similarly, CaSR density of the dentate gyrus (DG) and its
different layers (granular cell layer, GCL, molecular layer,
ML and hilus) were measured individually. The OD of the
region of interest is determined by outlining each layer and
obtaining the mean value of the intensities in the selected area
(Supplementary Figures 1A,B). The changes in CaSR density
were analyzed against a constant control region (CC): 250 was
divided by control region and the obtained factor was multiplied
by the region of interest in every given section. Inverse OD (IOD)
was obtained by subtracting the OD (after the control region
normalization) from 250. Values of IODwere taken and averaged
in both the left and right hemisphere of each slice. The results are
shown as inverse optical CaSR density (IOD/pixel).
Counting of Aβ-Positive Cells
β-amyloid containing neurons were counted in the entire extent
of the CA1 region of the hippocampus, since this field shows the
earliest and strongest accumulation of Aβ intracellular deposits.
This quantification was carried out on six non-consecutive
sections from dorsal hippocampus of three non-Tg and 3xTg-AD
animals of 9 months of age immunolabeled with anti-Aβ 6E10
antibody.
Statistical Analysis
One-way analysis of variance (ANOVA) was used to determine
changes in CaSR density between 3xTg-AD animals and their
non-transgenic controls at different ages, followed by unpaired
t-test comparisons at the different time points. Significance was
accepted at P ≤ 0.05. The data were analyzed using GraphPad
Prism software (La Jolla, CA, USA). Results are expressed as
mean± SEM.
RESULTS
Immunohistochemical labeling demonstrated that CaSR is
present in the hippocampus of both 3xTg-AD and non-Tg
control animals at all ages (9, 12, and 18 months) with a rather
homogeneous distribution throughout all hippocampal areas
(Figures 1A,B). Punctate CaSR labeling is mainly present in
pyramidal neurons of the different CA subfields and in granule
cells of the DG as well as in the pleomorphic cells of the hilus,
being more evident in the soma, nucleus excluded, although it
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is also detectable in the neuropil, including both dendrites and
axons (Figures 1C–F). Astroglial occurrence of CaSR was rather
rare and when detected was of very low intensity as compared to
neurons; appearing as puncta mainly restricted to the astrocytic
soma (Figures 1K–P).
Increase of CaSR Expression in 3xTg-AD
Animals
Optical density analysis of CaSR staining in the hippocampus
of the 3xTg-AD mouse showed a significant increase in its
expression in CA1 and DG subfields [F(7, 166) = 11.32, p< 0.0001
and F(7, 166) = 7.994, p < 0.0001, respectively] at all ages (9,
12, and 18 months; Figures 1, 2). An increase in CaSR optical
density of 23.44, 17.62, and 20.09% at 9, 12, and 18 months
of age respectively when compared to control non-Tg animals
was detected in CA1 area (Figures 1C,D, 2A; Table 1). Similar
increase in CaSR optical density was observed in DG: 17.82,
14.74, and 20.74%, at 9, 12, and 18 months respectively in 3xTg-
AD animals compared to non-Tg (Figures 1E,F, 3A; Table 1).
No significant alterations in the optical density of CaSR were
identified in the CA2 and in CA3 sub-fields.
CaSR Expression Increase in CA1 and DG
Is Layer-Specific
In CA1 we found that the increase in CaSR expression in 3xTg-
AD animals mainly occurred in the pyramidal cell layer (PCL,
10.68% at 9 months, 2.28% at 12 months, 20.17% at 18 months;
Figure 2B), in the stratum radiatum (SR, 12.93% at 9 months,
27.71% at 12 months, 14.55% at 18 months; Figure 2C) and in
the stratum lacunosum moleculare (SLM, 93.19% at 9 months,
39.58% at 12 months, 56.08% at 18 months; Figures 1G,H, 2D;
Table 1).
In theDG an increase in CaSR expressionwasmost prominent
in the molecular layer (ML) of 3xTg-AD animals respect to their
controls (15.90% at 9 months, 12.32% at 12 months, 20.98%
at 18 months; Figure 3B) and in the granular cell layer (GCL,
19.33% at 9 months, 10.68% at 12 months, 37.38% at 18 months;
Figures 1I,J, 3C; Table 1). The increase in the molecular layer
was similar in all subdivisions; the inner, middle and outer ML
(data not shown).
Increased level of CaSR labeling in the projections layers
described above doesn’t appear to derive from neuronal somata,
despite its presence in some interneurons cell bodies, but
mainly from the neuropil comprising both dendrites and axons
(Figures 1D,F).
CaSR Increase in Hippocampus Occurs in
the Areas Affected by β-Amyloid
Accumulation
In 3xTg-AD mice intracellular β-amyloid in hippocampal
neurons appears between 4 and 6 months of age and reaches
its maximum at 9 months of age (Figures 4G,H); extracellular
β-amyloid depositions start to mount from 9 to 12 months,
being maximal at 18 months. At 18 months the β-amyloid
plaques are big and expanded through the hippocampus mainly
concentrating in the CA1 subfield (Figures 4E,F,I,J); with later
FIGURE 3 | Modification of CaSR expression in hippocampal DG. Bar
graphs illustrating CaSR-IR IOD within DG subfield between non-Tg controls
and 3xTg-AD mice at 9, 12, and 18 months of age (Ns for non-Tg = 5, 5, 4;
ns for 3xTg-AD = 4, 5, 3, respectively; 3 slices have been analyzed per each
animal). (A) Total DG; (B) Molecular Layer; (C) Granular Cell Layer. Bars
represent means ± SEM (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
appearance in the DG (Noristani et al., 2012; Rodríguez et al.,
2013). In a similar way hyper-phosphorylated Tau protein begins
to be detectable in 3xTg-AD mice at 12 months causing the
formation of tangles by 18 months, and it is also concentrated in
CA1 region affecting all the layers (Figures 4K,L). The increase
of CaSR intensity in the CA1 region follows the same spatio-
temporal pattern as that of β-amyloid deposition (Figures 4A–F),
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FIGURE 4 | CaSR and β-amyloid relationship in hippocampus during AD progression. Confocal micrographs showing the overlapping expression of CaSR
(red) with the accumulation of intraneuronal Aβ (green, anti-Aβ 488) and the formation of plaques in hippocampal pyramidal neurons of 3xTg-AD mice of 12 and 18
months of age respectively. (A,D) CaSR-IR; (B,E) Aβ-IR; (C,F) merge. St Or Stratum Oriens; CA1 PcL CA1 Pyramidal Cell Layer; St Rad Stratum Radiatum. Bar graphs
illustrating the number of Aβ positive cells (G) and the IOD of CaSR (H) within CA1 subfield of hippocampus between non-Tg controls and 3xTg-AD mice at 9 months
of age (***p ≤ 0.001). Brightfield micrographs of CA1 areas of hippocampus of non-Tg and 3xTg-AD mice immunolabeled with anti-Aβ (I,J) and anti-Tau antibody
(K,L) at 12 months of age. St Or, Stratum Oriens; CA1 PcL, CA1 Pyramidal Cell Layer; St Rad, Stratum Radiatum; St Lac Mol, Stratum Lacunosum Moleculare.
while in the DG it appears even before the accumulation of Aβ
becomes evident.
DISCUSSION
In vitro exposure of human cortical astrocytes and neurons to a
truncated form of β-amyloid, the Aβ25–35 peptide, which binds
and activates the CaSR (Dal Prà et al., 2014), stimulated the
intracellular production and secretion of β-amyloid by both cell
types with the subsequent death of a fraction of neurons (Armato
et al., 2013). While neurons were vulnerable to β-amyloid
toxicity, cultured astrocytes survived and they showed a transient
increase of CaSR expression. The cytotoxic effects on neurons
were fully inhibited following addition of CaSR antagonist NPS
2143 to the incubation media. Indeed, the NPS prevented the
death of neurons and it deeply and steadily downregulated the
receptor in the Aβ-treated astrocytes, and completely blocked the
Aβ self-induction mechanism (Armato et al., 2013).
This in vitro study conceptually complements results we
obtained in the 3xTg-AD mice model described in the present
paper; these results further corroborate links existing between
increases in CaSR expression and β-amyloid accumulation. In
the 3xTg-ADmice, intraneuronal β-amyloid starts to accumulate
in the CA1 pyramidal neurons at 4–6 months of age reaching
maximum at 9 months of age, while extracellular β-amyloid
deposits emerge from 12 months of age. Appearance of senile
plaques is associated with specific astrogliosis around the plaques
despite the generalized hippocampal astrocytic atrophy and with
an increase in the density of activated microglia and recruitment
of new ramified microglial cells (Rodríguez et al., 2009, 2010,
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2013; Olabarria et al., 2010). Accumulation of Tau that occurs
later follows similar pattern with maximum presence from 18
months. The 3xTg-AD mouse model not only develops the
typical histopathological hallmarks of Alzheimer’s disease, but
also manifests synaptic dysfunction with impaired long-term-
potentiation (LTP) (Oddo et al., 2003b; Rodríguez et al., 2008).
Analysis of an acute hypoxia/ischemia in rats revealed that
Aβ overproduction due to hypoxic injury is mediated by
CaSR hyperexpression (Bai et al., 2015). Experiments on rat
hippocampal neurons demonstrated that hypoxia induces an
up-regulation of CaSR which in turn promotes the elevation
of cytosolic [Ca2+] thereby producing an increase of BACE1
expression that results in the rise of Aβ40 and Aβ42 generation.
In addition, specific inhibition of CaSR with Calhex 231, an
allosteric antagonist of CaSR, induced a decrease of BACE1 and
Aβ both in vitro and in vivo in hypoxic conditions (Bai et al.,
2015). The prominent effect of the increased expression and
activity of CaSR in hippocampus is confirmed also by analysing
a mouse model of acute ischemic injury where a transient global
cerebral ischemia (TGI) was induced. In this model CaSR was
overexpressed in parallel with GABAB receptor 1 downregulation
and was followed by neuronal death. The administration of the
calcilytic compound NPS89636 through intracerebroventricular
injections after the TGI specifically blocked the activity of
CaSR, restoredGABABR1 expression and protected hippocampal
neurons from cell death. Furthermore, the treatment of TGI
mice with calcilytics significantly improved learning andmemory
(Kim et al., 2014).
Altogether these findings reveal the importance and the
impact which altered expression of CaSR has on maintaining the
normal brain function, supporting the idea that its changes could
contribute to the development and progression of pathologies
such as Alzheimer’s disease and stroke. Our present data in an
AD mouse model show that expression of CaSR is increasing
while neuropathology progresses. Previous works demonstrated
that the administration of Aβ42 oligomers to neuronal and
astrocytic human cell cultures increases the endogenous Aβ42
production and secretion resulting in a progressive death of
neurons. This mechanism of Aβ self-induction, which contribute
to the advance of AD, was demonstrated to be completely
suppressed by adding a specific calcilytic like NPS 2143 to the
cell culture (Armato et al., 2013; Dal Prà et al., 2015; Chiarini
et al., 2016). It needs to be emphasized that the CaSR could
be a promising target of investigation for not only further
understanding AD pathology onset and spread but also for
evaluating new therapeutic solutions.
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